<SEC-DOCUMENT>0001434265-25-000014.txt : 20250508
<SEC-HEADER>0001434265-25-000014.hdr.sgml : 20250508
<ACCEPTANCE-DATETIME>20250508111936
ACCESSION NUMBER:		0001434265-25-000014
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20250508
FILED AS OF DATE:		20250508
DATE AS OF CHANGE:		20250508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GENMAB A/S
		CENTRAL INDEX KEY:			0001434265
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38976
		FILM NUMBER:		25924753

	BUSINESS ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000

	MAIL ADDRESS:	
		STREET 1:		TOLDBODGADE 33
		CITY:			1253 COPENHAGEN K
		STATE:			G7
		ZIP:			00000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>gmab_20250508x6k.htm
<DESCRIPTION>6-K
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i47dc33b5f3314515855dfcb93c2abcbf_1"></div><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:3pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</font></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.936%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:100%"><br>FORM&#160;6-K<br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.936%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE&#160;13a-16 OR&#160;15d-16</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FOR THE&#160;MONTH OF MAY 2025<br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.936%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMMISSION FILE NUMBER 001-38976  </font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Genmab A&#47;S<br></font><font style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Exact name of Registrant as specified in its charter)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Carl Jacobsens Vej 30</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2500 Valby</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Denmark</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">+45 70 20 27 28<br></font><font style="background-color:#ffffff;color:#333333;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(Address of principal executive offices)<br></font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:19.936%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F or&#160;Form&#160;40-F.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form&#160;20-F&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      Form&#160;40-F&#160;</font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font></div><div><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report on Form&#160;6-K&#160;shall be deemed to be&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incorporated by reference</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in Genmab A&#47;S&#8217;s registration statements on&#160;Form&#160;S-8&#160;(File&#160;No. 333-232693, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">333-253519, 333-262970, 333-277273 and 333-284876</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)&#160;and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:3pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.305%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Description of Exhibit</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a href="genmabinterimreport.htm" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interim Report Dated May 8, 2025</a></font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:63.36pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURE</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.825%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.272%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GENMAB A&#47;S</font></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Anthony Pagano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58; Anthony Pagano</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58; Executive Vice President &#38; Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DATE&#58; May 8, 2025</font></div><div><font><br></font></div><div style="height:63.36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>genmabinterimreport.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5bf39db2728b4c8fa0a2052d4956f209_695"></div><div style="min-height:108pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">99.1</font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:112%">Genmab Announces Financial Results for the First Quarter of 2025</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">May 8, 2025 Copenhagen, Denmark&#59; </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Interim Report for the First Quarter Ended March 31, 2025</font></div><div><font><br></font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Highlights</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">EPKINLY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> (epcoritamab) approved by the Japan Ministry of Health, Labour and Welfare (MHLW) for additional indication as a treatment for relapsed or refractory follicular lymphoma (FL)</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Rinatabart sesutecan (Rina-S</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">) continues to show encouraging antitumor activity in patients with advanced ovarian cancer in data presented at the 2025 Society of Gynecologic Oncology Annual Meeting on Women&#8217;s Cancer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> (SGO) </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Tivdak</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> (tisotumab vedotin) approved by the Japan MHLW and by the European Commission (EC) as the first and only antibody-drug conjugate (ADC) approved in both Japan and the European Union (EU) for the treatment of recurrent or metastatic cervical cancer after prior therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%;padding-left:14.5pt">Genmab revenue increased 19% compared to the first quarter of 2024, to $715 million</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;Our commitment to advancing our late-stage programs was reflected in the progress we made in the first quarter of the year. Both EPKINLY and Tivdak expanded their reach with approvals in additional territories and the updated Rina-S data presented at SGO reinforces its potential as a treatment option for patients with advanced ovarian cancer,&#8221;  said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Financial Performance First Quarter of 2025</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Revenue was $715 million for the first three months of 2025 compared to $603 million for the first three months of 2024. The increase of $112 million, or 19%, was primarily driven by higher DARZALEX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and Kesimpta</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> royalties achieved under our collaborations with Johnson &#38; Johnson (J&#38;J) and Novartis Pharma AG (Novartis), respectively, and EPKINLY net product sales.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Royalty revenue was $589 million in the first three months of 2025 compared to $452 million in the first three months of 2024, an increase of $137 million, or 30%. The increase in royalties was driven by higher net sales of DARZALEX and Kesimpta.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Net sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in the U.S.) by J&#38;J were $3,237 million in the first three months of 2025 compared to $2,692 million in the first three months of 2024, an increase of $545 million or 20%.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Total costs and operating expenses were $527 million in the first three months of 2025 compared to $487 million in the first three months of 2024. The increase of $40 million, or 8%, was driven by the expansion of our product pipeline, including Rina-S, the continued development of Genmab&#8217;s broader organizational capabilities as well as profit-sharing amounts payable to AbbVie Inc. (AbbVie) related to EPKINLY sales.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Operating profit was $188 million in the first three months of 2025 compared to $116 million in the first three months of 2024. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Net financial items resulted in income of $56 million for the first three months of 2025 compared to $133 million in the first three months of 2024. The decrease was primarily due to a decrease in foreign exchange impacts driven by the change in functional currency of Genmab A&#47;S on January 1, 2025.</font></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br>Outlook<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab is maintaining its 2025 financial guidance published on February 12, 2025.</font></div><div><font><br></font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Matters</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Both the functional currency of the Genmab A&#47;S legal entity and the presentation currency of the condensed consolidated financials statements have been changed from DKK to USD effective January 1, 2025. The change in functional currency has been implemented with prospective effect. The change in presentation currency has been implemented with retrospective effect. Comparative figures for prior periods have been restated accordingly.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.909%"><tr><td style="width:1.0%"></td><td style="width:41.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.901%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.063%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.020%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.167%"></td><td style="width:0.1%"></td></tr><tr style="height:0pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 1&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="margin-bottom:6pt;text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:112%">Genmab Announces Financial Results for the First Quarter of 2024</font></div></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conference Call</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Genmab will hold a conference call to discuss the results for the first quarter of 2025 today, Thursday, May 8, at 6&#58;00 pm CEST, 5&#58;00 pm BST or 12&#58;00 pm EDT. To join the call please use the below registration link. Registered participants will receive an email with a link to access dial-in information as well as a unique personal PIN&#58; </font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">https&#58;&#47;&#47;register.vevent.com&#47;register&#47;BI2b36f53f97c64ad190f5eaa552875059</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. A live and archived webcast of the call and relevant slides will be available at </font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">www.genmab.com&#47;investor-relations</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div><font><br></font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contact</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Marisol Peron, Senior Vice President, Global Communications &#38; Corporate Affairs</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">T&#58; +1 609 524 0065&#59; E&#58; </font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">mmp&#64;genmab.com</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Andrew Carlsen, Vice President, Head of Investor Relations</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">T&#58; +45 3377 9558&#59; E&#58; </font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">acn&#64;genmab.com</font></div><div><font><br></font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 2&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_4"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTENTS</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REVIEW</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_7" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">CONSOLIDATED KEY FIGURES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_7" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">4</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_10" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">OUTLOOK</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_10" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">5</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_16" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">PRODUCT PIPELINE</a>&#160;<a href="#i5bf39db2728b4c8fa0a2052d4956f209_16" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">AND TECHNOLOGY PROGRESS FIRST QUARTER OF 2025</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_16" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">6</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_19" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">SIGNIFICANT RISKS AND UNCERTAINTIES</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_19" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">15</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_22" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">FINANCIAL REVIEW</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_22" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">16</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_25" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_25" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">22</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_40" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">NOTES&#160;TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_40" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">28</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_76" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">ABOUT GENMAB</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_76" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">37</a></font></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_79" style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:none">DIRECTORS&#8217; AND MANAGEMENT&#8217;S STATEMENT ON THE INTERIM REPORT</a></font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><a href="#i5bf39db2728b4c8fa0a2052d4956f209_79" style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none">38</a></font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 3&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_7"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONSOLIDATED KEY FIGURES</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:1.0%"></td><td style="width:59.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(USD million, unless otherwise indicated)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Full Year</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Income Statement</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="6" style="background-color:#E6E6E6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</font></td><td colspan="6" style="background-color:#E6E6E6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2024</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Revenue</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">715&#160;</font></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">603&#160;</font></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3,121&#160;</font></td><td style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cost of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(42)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(143)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Research and Development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(359)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(335)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1,414)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(126)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(125)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(560)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Acquisition and integration related charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(32)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total costs and operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(527)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(487)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(2,149)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Operating profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">188&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">116&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">972&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net financial items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">56&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">133&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">354&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">195&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,133&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance Sheet</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,607&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,163&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,574&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,619&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,127&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,380&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total non-current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,549&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">335&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,514&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,586&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,319&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">6,414&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shareholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,296&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4,713&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">5,137&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Cash Flow Statement</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash provided by operating activities</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">287&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">219&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,126&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash (used in) investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(43)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(210)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(1,447)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net cash (used in) financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(13)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(85)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(566)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investment in intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(18)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(17)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Investment in tangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(12)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">(27)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Financial Ratios and Other Information</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Basic net profit per share</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.06&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.96&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17.74&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Diluted net profit per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">3.05&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">17.61&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Period-end share market price (DKK per share)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,340&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,084&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">1,493&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Price &#47; book value</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.53&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">4.42&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2.91&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shareholders' equity per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">529.60&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">471.30&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">513.70&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Equity ratio</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">80&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">89&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">80&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Shares outstanding</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66,197,244</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66,122,964</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">66,187,186</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Average number of employees (FTE*)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,669</font></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,266</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,535</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Number of employees (FTE) at the end of the period</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,638</font></td><td colspan="3" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,286</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">2,682</font></td><td colspan="3" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%;padding-left:1.78pt">Full-time equivalent or team members </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 4&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_10"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 FULL YEAR OUTLOOK</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.113%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(USD million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025 Guidance</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025 Guidance    Mid-Point</font></div></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3,340 - $3,660</font></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3,500</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalties</font></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2,785 - 3,015</font></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2,900</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net product sales&#47;Collaboration revenue*</font></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">415 - 460</font></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">438</font></td></tr><tr><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Milestones&#47;Reimbursement revenue</font></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">140 - 185</font></td><td colspan="3" style="background-color:#f2f2f2;padding:0 1pt"></td><td colspan="3" style="background-color:#f2f2f2;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">162</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit**</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,120 - 3,420</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,270</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses**</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,055) - (2,225)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2,140)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$895 - $1,365</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,130</font></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.39pt">Net Product Sales and Collaboration Revenue consists of EPKINLY Net Product Sales in the U.S. and Japan and Tivdak (Genmab&#8217;s share of net profits) in the U.S.</font></div><div style="margin-bottom:12pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">**</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.78pt">Operating Expenses Range excludes Cost of Product Sales Range, which is included in Gross Profit Range</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab is maintaining its 2025 financial guidance published February 12, 2025.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab expects its 2025 revenue to be in the range of $3.3 - 3.7 billion. Genmab&#8217;s projected revenue growth for 2025 is driven by higher royalties, net product sales and collaboration revenue. Royalty growth relates mainly to DARZALEX and Kesimpta net sales growth. Net product sales and collaboration revenue growth is driven by strong performance for both EPKINLY and Tivdak. Net product sales and collaboration revenue consists of EPKINLY net product sales in the U.S. and Japan, and Tivdak (50% gross profit share).</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#8217;s projected revenue for 2025 primarily consists of DARZALEX royalties of approximately $2.2 billion at the midpoint. Such royalties are based on estimated DARZALEX 2025 net sales of $12.6&#8211;13.4 billion. DARZALEX royalties are partly offset by Genmab&#8217;s share of J&#38;J&#8217;s royalty payments to Halozyme Therapeutics, Inc. (Halozyme) in connection with SC net sales as well as royalty reduction in countries and territories where there is no Genmab patent coverage. The remainder of Genmab&#8217;s revenue consists of royalties from Kesimpta, TEPEZZA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RYBREVANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TECVAYLI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, TALVEY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and TEPKINLY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, net product sales and collaboration revenue from EPKINLY and Tivdak, reimbursement revenue and milestones</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Expenses<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab anticipates its 2025 operating expenses to be in the range of $2.1 - 2.2 billion. </font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Profit<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab expects its 2025 operating profit to be in the range of $0.9 - 1.4 billion.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outlook&#58; Risks and Assumptions<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to factors already mentioned, the estimates above are subject to change due to numerous reasons, including but not limited to, the achievement of certain milestones associated with Genmab&#8217;s collaboration agreements&#59; the timing and variation of development activities (including activities carried out by Genmab&#8217;s collaboration partners) and related income and costs&#59; DARZALEX, DARZALEX&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kesimpta, TEPEZZA, RYBREVANT, TECVAYLI, TALVEY&#160;and TEPKINLY net sales and royalties paid to Genmab&#59; changing rates of inflation&#59; and currency exchange rates The financial guidance assumes that no significant new agreements are entered into during the remainder of&#160;2025 that could materially affect the results. Refer to the section &#8220;Significant Risks and Uncertainties&#8221; in this interim report for matters that may cause Genmab&#8217;s actual results to differ materially from 2025 Guidance.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors discussed above, as well as other factors that are currently unforeseeable, may result in further and other unforeseen material adverse impacts on Genmab&#8217;s business and financial performance, including on the sales of Tivdak&#160;and EPKINLY&#47;TEPKINLY, and on the net sales of DARZALEX, Kesimpta, TEPEZZA, </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 5&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RYBREVANT, TECVAYLI and TALVEY by Genmab&#8217;s collaboration partners and on Genmab&#8217;s royalties, collaboration revenue and milestone revenue therefrom.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_16"></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRODUCT PIPELINE&#160;AND TECHNOLOGY PROGRESS FIRST QUARTER OF 2025</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the first three months of 2025, Genmab&#8217;s proprietary pipeline of investigational medicines, where we are responsible for at least 50% of development, consisted of over 10 antibody products in clinical development. These include Genmab&#8217;s approved medicines, Tivdak, which Genmab is co-developing globally and co-promoting in the U.S. in collaboration with Pfizer Inc. (Pfizer), and EPKINLY&#47;TEPKINLY, which Genmab is co-developing and co-commercializing in the U.S. and Japan in collaboration with AbbVie. In addition to our own pipeline, there are multiple investigational medicines in development by global pharmaceutical and biotechnology companies, including six approved medicines powered by Genmab&#8217;s technology and innovations. Beyond the investigational medicines in clinical development, our pipeline includes multiple preclinical programs. An overview of the development status of our approved medicines and each of our investigational medicines is provided in the following section, including updates for the first quarter of 2025. Detailed descriptions of dosing, efficacy and safety data from certain clinical trials have been disclosed in company announcements and media releases published via the Nasdaq Copenhagen A&#47;S (Nasdaq Copenhagen) stock exchange and may also be found in Genmab&#8217;s filings with the U.S. Securities and Exchange Commission (U.S. SEC). Additional information is available on Genmab&#8217;s website,&#160;www.genmab.com. The information accessible through our website is not part of this report and is not incorporated by reference herein.</font></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genmab Proprietary Products</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:700;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Approved Medicines</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.296%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approved Product</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Target</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Developed By</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disease Indication</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EPKINLY</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epcoritamab-bysp, epcoritamab)</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TEPKINLY</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epcoritamab)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CD3xCD20</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-development</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#47;AbbVie Inc. (AbbVie)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved in multiple territories including in the U.S. and Europe for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy and in Japan for adult patients with certain types of relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved in multiple territories including the U.S., Europe and Japan for adult patients with relapsed or refractory FL after two or more lines of systemic therapy</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tivdak</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(tisotumab vedotin-tftv, tisotumab vedotin)</font></div></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tissue factor (TF)</font></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Co-development Genmab&#47;Pfizer</font></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approved in the U.S., Europe and Japan for adult patients with recurrent&#47;metastatic cervical cancer with disease progression on or after chemotherapy</font></div></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.61pt">Approved and investigational medicines where Genmab has &#8805;50% ownership, in co-development with partners as indicated.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.61pt">Refer to relevant local prescribing information for precise indication and safety information.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 6&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pipeline, Including Further Development for Approved Medicines</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.424%"><tr><td style="width:1.0%"></td><td style="width:8.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.858%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.493%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.350%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.085%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.585%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Product</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Developed By</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Target(s)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Technology</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Disease Indications</font></td><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Most Advanced Development Phase</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Preclinical</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">1</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">2</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Epcoritamab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Co-development<br>Genmab &#47; AbbVie</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">CD3, CD20</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody&#174;</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Relapsed&#47;refractory DLBCL</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Relapsed&#47;refractory FL</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">First line DLBCL</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">First line FL</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">B-cell non-Hodgkin lymphoma (NHL)</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Relapsed&#47;refractory chronic lymphocytic leukemia (CLL) &#38; Richter's Syndrome</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Aggressive mature B-cell neoplasms in pediatric patients</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Tisotumab vedotin</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Co-development<br>Genmab &#47; Pfizer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">TF</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Antibody-drug<br>conjugate (ADC)</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Acasunlimab</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(GEN1046)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">programmed death ligand 1 (PD-L1), 4-1BB</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">non-small cell lung cancer (NSCLC)</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Rinatabart Sesutecan</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(Rina-S, PRO1184)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Folate receptor alpha<br>(FR&#945;)</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">ADC</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Platinum resistant ovarian cancer (PROC)</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="background-color:#b6fffa;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt dotted #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1042</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(BNT312)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Co-development<br>Genmab &#47; BioNTech SE (BioNTech)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">CD40, 4-1BB</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#72fff7;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1059</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(BNT314)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Co-development<br>Genmab &#47; BioNTech</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Epithelial cell adhesion <br>molecule (EpCAM), 4-1BB</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1055</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(BNT315)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Co-development<br>Genmab &#47; BioNTech</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">OX40</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">HexaBody</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1160</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(PRO1160)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">CD70</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">ADC</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Advanced solid and liquid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1107</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(PRO1107)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Protein tyrosine kinase 7 (PTK7)</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">ADC</font></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Advanced solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1057</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Fibroblast activation protein alpha (FAP&#945;), death receptor 4 (DR4)</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Malignant solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:38pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">GEN1286</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(PRO1286)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Genmab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">epidermal growth factor receptor (EGFR), cellular-mesenchymal epithelial transition factor receptor tyrosine kinase (cMET)</font></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">ADC</font></div></td><td colspan="3" rowspan="2" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Advanced solid tumors</font></td><td colspan="3" style="background-color:#004d49;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#004d49;border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#02756e;border-bottom:1pt solid #029c93;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EPKINLY&#47;TEPKINLY (epcoritamab) &#8211; the only bispecific antibody approved with a dual indication for the treatment of certain B-cell malignancies in the U.S., Europe and Japan</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Epcoritamab (approved as EPKINLY and TEPKINLY) has received regulatory approvals in multiple territories including in the U.S. and Europe for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy, and in Japan for adult patients with certain types of relapsed or refractory LBCL after two or more lines of systemic therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">EPKINLY&#47;TEPKINLY has also been approved in multiple territories including the U.S., Japan and Europe for the treatment of adults with relapsed or refractory FL after two or more lines of systemic therapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple clinical trials are ongoing across different settings and histologies, including five Phase 3 trials, with more trials in planning</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SC bispecific antibody targeting CD3 and CD20, created using Genmab&#8217;s DuoBody technology platform</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Co-developed and co-commercialized in collaboration with AbbVie</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Epcoritamab is a proprietary bispecific antibody created using Genmab&#8217;s DuoBody technology platform. Epcoritamab targets CD3, which is expressed on T-cells, and CD20, a clinically validated target on malignant B-</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 7&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cells. Genmab used technology licensed from Medarex Inc. (Medarex) to generate the CD20 antibody forming part of epcoritamab. Epcoritamab is marketed as EPKINLY in the U.S., Japan, and other regions, and as TEPKINLY in Europe and other regions. See local prescribing information for specific indications and safety information. In 2020, Genmab entered into a collaboration agreement with AbbVie to jointly develop and commercialize epcoritamab. The companies share commercialization responsibilities in the U.S. and Japan, with AbbVie responsible for further global commercialization.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab records sales in the U.S. and Japan and receives tiered royalties between 22% and 26% on remaining global sales outside of these territories, subject to certain royalty reductions. The companies have a broad clinical development program for epcoritamab including five ongoing Phase 3 trials and additional trials in planning. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for EPKINLY and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for TEPKINLY for the labeled indication and safety information.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2025 Updates</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">January&#58; The Japan MHLW approved EPKINLY (epcoritamab) for the treatment of patients with relapsed or refractory FL who have received two or more lines of therapy. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">February&#58; Epcoritamab-bysp in combination with gemcitabine and oxaliplatin (GemOx) was added to the National Comprehensive Cancer Network</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(NCCN</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Clinical Practice Guidelines in Oncology (NCCN Guidelines</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) for &#8220;B-cell Lymphomas&#8221; (Version 2.2025) for second-line patients with DLBCL who are ineligible for transplant as a Category 2A, preferred regimen.</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Tivdak (tisotumab vedotin) &#8211; First and only ADC for recurrent or metastatic cervical cancer in the U.S., Europe and Japan</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An ADC directed to TF, a protein highly prevalent in solid tumors, including cervical cancer, which is associated with poor prognosis</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tisotumab vedotin, approved as&#160;Tivdak, is the first and only ADC approved in the U.S., Europe and Japan for the treatment of recurrent or metastatic cervical cancer after prior therapy. </font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">It is the only ADC with demonstrated overall survival data in this setting compared to chemotherapy</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Co-developed globally and co-promoted in the U.S. in collaboration with Pfizer</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Tisotumab vedotin is an ADC composed of Genmab&#8217;s human monoclonal antibody directed to TF and Pfizer&#8217;s ADC technology that utilizes a protease-cleavable linker that covalently attaches the microtubule-disrupting agent monomethyl auristatin E to the antibody. Genmab used technology licensed from Medarex to generate the TF antibody forming part of tisotumab vedotin. Tisotumab vedotin, marketed as Tivdak, is the first and only ADC approved for the treatment of adult patients with recurrent or metastatic cervical cancer after prior therapy in the U.S., Europe and Japan. Tisotumab vedotin is being co-developed by Genmab and Pfizer. Under a joint commercialization agreement, Genmab is co-promoting Tivdak in the U.S. and will lead commercial operational activities in Japan. Pfizer is leading commercial operational activities in the U.S. and will lead commercial operational activities in China once approved in connection with the sublicense of its rights to develop and commercialize tisotumab vedotin in China to Zai Lab. In the U.S. market there is a 50&#58;50 profit split. Effective January 1, 2025, Genmab and Pfizer agreed to amend the License and Collaboration Agreement and the Joint Commercialization Agreement for Tivdak, assigning Genmab sole responsibility for the development and commercialization of Tivdak for second line plus recurrent or metastatic cervical cancer in Europe and all other regions globally, excluding the United States and the China region. Genmab will record sales for Europe, Japan and rest of world markets (excluding the United States and the China region), and will provide royalties to Pfizer on net sales in the low teens. The companies have joint decision-making power on the worldwide development and commercialization strategy for Tivdak. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the labeled indication and safety information for Tivdak.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2025 Updates</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">January&#58; Genmab and Pfizer agreed to amend the License and Collaboration Agreement and the Joint Commercialization Agreement for Tivdak, assigning Genmab sole responsibility for the development </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 8&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and commercialization of Tivdak for second line plus recurrent or metastatic cervical cancer in Europe and all other regions globally, excluding the United States and the China region.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">March&#58; The Japan MHLW approved Tivdak (tisotumab vedotin) for the treatment of advanced or recurrent cervical cancer that has progressed on or after cancer chemotherapy. Tivdak is the first and only ADC to be approved for people living with cervical cancer in Japan.</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">March&#58; The EC granted marketing authorization for Tivdak (tisotumab vedotin) as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy. Tivdak is the first and only ADC to be granted EU marketing authorization for people living with recurrent or metastatic cervical cancer.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acasunlimab (GEN1046) &#8211; Bispecific next-generation immunotherapy</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bispecific antibody targeting PD-L1 and 4-1BB, created using Genmab&#8217;s DuoBody technology platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Phase 3 trial (NCT06635824, ABBIL1TY NSCLC-06) in NSCLC is recruiting</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Acasunlimab (GEN1046, DuoBody-PD-L1x4-1BB) is a proprietary bispecific antibody, created using Genmab&#8217;s DuoBody technology platform. Originally developed in collaboration with BioNTech, in 2024 Genmab assumed sole responsibility for the continued development and potential commercialization of acasunlimab. The program will be subject to payment of certain milestones and a tiered single-digit royalty on net sales by Genmab to BioNTech. Acasunlimab is designed to induce an antitumor immune response by simultaneous and complementary PD-L1 blockade and conditional 4-1BB stimulation using an inert DuoBody format. A Phase 3 trial of acasunlimab in combination with pembrolizumab compared to docetaxel in CPI-experienced, PD-L1 positive metastatic NSCLC is recruiting.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rinatabart Sesutecan (Rina-S, GEN1184) &#8211; Potential best-in-class FR&#945;-targeted topoisomerase I (TOPO1) ADC</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FR&#945;-targeted TOPO1 ADC being evaluated for potential treatment of FR&#945;-expressing cancers</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 3 clinical trial&#160;(NCT06619236)&#160;in PROC is recruiting</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rina-S is a novel FR&#945;-targeted TOPO1 ADC being evaluated for the potential treatment of ovarian cancer and other FR&#945;-expressing cancers. Dose escalation data suggests that Rina-S has robust single agent activity in various cancers across a broad range of FR&#945; expression levels. In January 2024, Rina-S was granted Fast Track Designation by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of FR&#945;-expressing high-grade serous or endometrioid PROC. A Phase 3 trial in second line plus platinum PROC is recruiting.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">First Quarter 2025 Update</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">March&#58; Data from the Phase 2 RAINFOL&#8482;-01 trial (NCT05579366, B1 cohort) was presented during an oral presentation at the 2025 Society of Gynecologic Oncology Annual Meeting on Women&#8217;s Cancer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Results showed that Rina-S 120 mg&#47;m</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> every 3 weeks resulted in a confirmed objective response rate of 55.6% (95% CI&#58; 30.8-78.5) in heavily pre-treated ovarian cancer patients regardless of FR&#945; expression levels. With a median on-study follow-up of 48 weeks, 1 out of 10 patients experienced disease progression and the median duration of response was not reached (95% CI&#58; 40.14-NR). </font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1042 (BNT312) &#8211; Potential first-in-class bispecific agonistic antibody</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bispecific antibody targeting CD40 and 4-1BB, created using Genmab&#8217;s DuoBody technology platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple clinical trials in solid tumors ongoing</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Co-developed in collaboration with BioNTech</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1042 (DuoBody-CD40x4-1BB, BNT312) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab&#8217;s DuoBody technology platform. It is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1042 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 9&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a 50&#58;50 basis. CD40 and 4-1BB were selected as targets to enhance activation of both dendritic cells and antigen-dependent T-cells. Three clinical trials of GEN1042 in solid tumors are ongoing.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1059 (BNT314) &#8211; Bispecific antibody with potential in solid tumors</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bispecific antibody targeting EpCAM and 4-1BB, created using Genmab&#8217;s DuoBody technology platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial (NCT06150183) in solid tumors is recruiting</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Co-developed in collaboration with BioNTech</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1059 (DuoBody-EpCAMx4-1BB, BNT314), jointly owned by Genmab and BioNTech and created using Genmab&#8217;s DuoBody technology platform, is a bispecific antibody aimed at boosting antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity. GEN1059 is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1059 on a 50&#58;50 basis. A Phase 1&#47;2 clinical trial of GEN1059 in solid tumors is recruiting.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1055 (BNT315) &#8211; HexaBody-based antibody with potential in solid tumors</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody targeting OX40, created using Genmab&#8217;s HexaBody technology platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial (NCT06391775) in malignant solid tumors </font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Co-developed in collaboration with BioNTech</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1055 (HexaBody-OX40, BNT315), jointly owned by Genmab and BioNTech and created using Genmab&#8217;s HexaBody technology platform, is an immune-modulating OX40 agonist antibody designed to promote immunity by enhancing T-cell responses through Fc&#947;R-independent OX40 clustering on T cells. GEN1055 is being co-developed by Genmab and BioNTech under an agreement in which the companies share all costs and future potential profits for GEN1055 on a 50&#58;50 basis. </font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br>GEN1160 &#8211; ADC with potential in both solid tumors and hematological malignancies</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CD70-targeted ADC being evaluated in advanced solid and liquid tumors</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial&#160;(NCT05721222)&#160;in advanced solid and liquid tumors is recruiting</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1160 is a CD70-targeted ADC. CD70 is a protein expressed on both solid tumors and hematological malignancies. A Phase 1&#47;2 clinical study of GEN1160 in advanced renal cell carcinoma, nasopharyngeal carcinoma and NHL is recruiting.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1107 &#8211; ADC with potential in solid tumors</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PTK7-targeted ADC being evaluated in advanced solid tumors</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial (NCT06171789) in advanced solid tumors is recruiting</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1107 is a PTK7-targeted ADC. PTK7 is a clinically validated ADC target with broad solid tumor expression, particularly in tumor-initiating cells. A Phase 1&#47;2 clinical study of GEN1107 in advanced solid tumors is recruiting.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1057 &#8211; Bispecific antibody with potential in solid tumors</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Bispecific antibody targeting FAP&#945; and DR4, created using Genmab&#8217;s DuoBody technology platform</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial&#160;(NCT06573294)&#160;in malignant solid tumors is recruiting </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN1057 (DuoBody-FAP&#945;xDR4) is a bispecific antibody-based investigational medicine created using Genmab&#8217;s DuoBody technology platform. GEN1057 is designed for the conditional DR4 transactivation-mediated tumor cell killing by crosslinking FAP&#945; expression on cancer-associated fibroplasts with DR4 expressed on tumor cells. A Phase 1&#47;2 clinical trial of GEN1057 in malignant solid tumors is recruiting.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 10&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN1286 &#8211; ADC with potential in solid tumors</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ADC that targets EGFR and cMet being evaluated in advanced solid tumors</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Phase 1&#47;2 clinical trial&#160;(NCT06685068)&#160;in advanced solid tumors is recruiting </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">GEN1286 is an ADC targeting EGFR and cMet, two validated cancer targets. A Phase 1&#47;2 clinical study of GEN1286 in advanced solid tumors is recruiting.</font></div><div><font><br></font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GEN3014 &#8211; HexaBody-based investigational medicine with potential in hematological malignancies</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Antibody targeting CD38, created using Genmab&#8217;s HexaBody technology platform</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed in an exclusive worldwide license and option agreement with J&#38;J</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2025 J&#38;J decided that it would not exercise its option to receive a worldwide license to develop, manufacture and commercialize GEN3014</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Genmab will not pursue further clinical development of GEN3014</font></div><div><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GEN3014 (HexaBody-CD38) is a human CD38 monoclonal antibody-based investigational medicine created using Genmab&#8217;s HexaBody technology platform. GEN3014 is a second generation CD38-targeting lgG1 antibody with a hexamerization-enhancing modification. In June 2019, Genmab entered into an exclusive worldwide license and option agreement with J&#38;J to develop and commercialize GEN3014. In March 2025 J&#38;J decided that it would not exercise its option to receive a worldwide license to develop, manufacture and commercialize GEN3014. While the initial GEN3014 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab&#8217;s rigorous portfolio prioritization, Genmab will not pursue further clinical development of GEN3014.</font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Preclinical Programs</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Broad preclinical pipeline that includes both partnered products and in-house programs based on our proprietary technologies and&#47;or antibodies</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple new Investigational New Drug (IND) applications expected to be submitted over the coming years</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Genmab has entered multiple strategic collaborations to support the expansion of our innovative pipeline<br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical pipeline includes immune effector function enhanced antibodies developed with our HexaBody technology platform, bispecific antibodies created with our DuoBody technology platform and ADCs created with our ADC technology platforms. We are also collaborating with our partners to generate additional new antibody-based product concepts. A number of the preclinical programs are conducted in cooperation with our collaboration partners.</font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Programs Incorporating Genmab&#8217;s Innovation and Technology</font><font style="color:#02756e;font-family:'Arial',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">1</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to Genmab&#8217;s own pipeline of investigational medicines and preclinical pipeline candidates, our innovations and proprietary technology platforms are applied in the pipelines of global pharmaceutical and biotechnology companies. These companies are running clinical development programs with antibodies created by Genmab or created using Genmab&#8217;s proprietary DuoBody bispecific antibody technology platform. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this section includes those therapies that have been approved by regulatory agencies in certain territories. Under the agreements for these medicines Genmab is entitled to certain potential milestones and royalties.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 11&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Approved Medicines</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Approved Product</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Discovered and&#47;or Developed &#38; Marketed By</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Disease Indication(s)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.17pt;font-weight:700;line-height:120%;position:relative;top:-3.32pt;vertical-align:baseline">2</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">DARZALEX</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(daratumumab)&#47; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">DARZALEX&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(daratumumab and hyaluronidase-fihj)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">J&#38;J (Royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Multiple myeloma</font></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Light-chain (AL) Amyloidosis</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Kesimpta</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(ofatumumab)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Novartis (Royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Relapsing multiple sclerosis (RMS)</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TEPEZZA</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(teprotumumab-trbw)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Amgen Inc. (Amgen) (under sublicense from Roche, royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Thyroid Eye Disease (TED)</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">RYBREVANT</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(amivantamab&#47;amivantamab-vmjw)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">J&#38;J (Royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Advanced NSCLC with certain </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">epidermal growth factor receptor (</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">EGFR) mutations</font></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TECVAYLI</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(teclistamab&#47;teclistamab-cqyv)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">J&#38;J (Royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Relapsed and refractory multiple myeloma</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">TALVEY</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">(talquetamab&#47;talquetamab-tgvs)</font></div></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">J&#38;J (Royalties to Genmab on global net sales)</font></div></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Relapsed and refractory multiple myeloma</font></div></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">1</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.61pt">Approved and investigational medicines created by Genmab or created by collaboration partners leveraging Genmab&#8217;s DuoBody technology platform, under development, and where relevant, commercialized by a third party.</font></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">2</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.61pt">See local prescribing information for precise indication and safety information.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Pipeline, Including Further Development for Approved Medicines, &#8805; Phase 2 Development</font></div><div style="margin-bottom:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:81.818%"><tr><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.096%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.905%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Product</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Technology</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Discovered and&#47;or<br>Developed By</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Disease Indications</font></td><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Most Advanced Development Phase</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Preclinical</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">2</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">3</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Daratumumab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">UltiMAb*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">J&#38;J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Multiple myeloma</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#691a6b;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">AL Amyloidosis</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Teprotumumab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">UltiMAb</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Amgen</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">TED</font></td><td colspan="3" style="background-color:#691a6b;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#691a6b;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Amivantamab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">J&#38;J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">NSCLC</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#691a6b;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Advanced or metastatic colorectal cancer </font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Recurrent&#47;metastatic head and neck cancer</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt dotted #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Teclistamab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">J&#38;J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Multiple myeloma</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#691a6b;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Talquetamab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">J&#38;J</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Multiple myeloma</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Amlenetug</font></div><div style="padding-left:2.34pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">(Lu AF82422)</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">UltiMAb</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Lundbeck</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Multiple system atrophy</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Inclacumab</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">UltiMAb</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Pfizer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Vaso-occlusive crises in sickle cell disease</font></td><td colspan="3" style="background-color:#691a6b;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #029c93;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:700;line-height:120%">Mim8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">DuoBody</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Novo Nordisk</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:2px 1pt 2px 3.34pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5pt;font-weight:400;line-height:120%">Hemophilia A</font></td><td colspan="3" style="background-color:#691a6b;border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#d149d3;border-bottom:1pt solid #029c93;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#df86e2;border-bottom:1pt solid #029c93;border-left:1pt solid #ffffff;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="background-color:#edc4f0;border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #029c93;border-top:1pt solid #029c93;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:1.39pt">UltiMAb&#160;transgenic mouse technology licensed from Medarex, a wholly owned subsidiary of Bristol-Myers Squibb.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DARZALEX (daratumumab) &#8211; Redefining the treatment of multiple myeloma</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First-in-class human CD38 monoclonal antibody</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed and commercialized by J&#38;J under an exclusive worldwide license from Genmab</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Intravenous (IV) formulation approved in combination with other therapies and as monotherapy for certain multiple myeloma indications</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First and only SC CD38-directed antibody approved for the treatment of certain multiple myeloma indications, known as DARZALEX&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S., and DARZALEX SC in Europe</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 12&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SC daratumumab is the first and only approved therapy for AL amyloidosis in the U.S., Europe, and Japan</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net sales of DARZALEX by J&#38;J were $3,237 million in the first three months of 2025</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Daratumumab is a human monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells and is also expressed by AL amyloidosis plasma cells. Genmab used technology licensed from Medarex to generate the CD38 antibody. Daratumumab is being developed and commercialized by J&#38;J under an exclusive worldwide license from Genmab. Under the terms of the agreement, Genmab receives royalties between 12% and 20% with J&#38;J reducing such royalty payments for Genmab&#8217;s share of J&#38;J&#8217;s royalty payments made to Halozyme&#59; payments are further reduced in countries and territories where there are no relevant patents. Daratumumab (marketed as DARZALEX for IV administration and as DARZALEX&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;in the U.S. and as DARZALEX SC in Europe for SC administration) is approved in a large number of territories for the treatment of adult patients with certain multiple myeloma indications and is the only&#160;approved therapy in the U.S., Europe and Japan for the treatment of adult patients with AL amyloidosis. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristic</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s&#160;for DARZALEX and DARZALEX SC and the U.S. Prescribing Information for&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARZALEX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARZALEX&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the labeled indication and safety information.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Kesimpta (ofatumumab) &#8211; Approved for the treatment of RMS</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Human CD20 monoclonal antibody developed and commercialized by Novartis under a license agreement with Genmab</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Approved in multiple territories including the U.S., Europe and Japan for the treatment of RMS in adults</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First B-cell therapy that can be self-administered by patients using the Sensoready</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;autoinjector pen</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ofatumumab is a human monoclonal antibody that targets an epitope on the CD20 molecule encompassing parts of the small and large extracellular loops. Genmab used technology licensed from Medarex to generate the CD20 antibody. Ofatumumab, marketed as Kesimpta, is approved in territories including the U.S., Europe, and Japan for the treatment of certain adult patients with RMS. Kesimpta is the first B-cell therapy that can be self-administered by patients using the Sensoready autoinjector pen, once monthly after starting therapy. Ofatumumab is being developed and marketed worldwide by Novartis under a license agreement between Genmab and Novartis. Under the terms of the agreement, Genmab receives a 10% royalty on net sales of Kesimpta, and Genmab pays a low-single digit royalty to Medarex based on Kesimpta sales. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the labeled indication and safety information for Kesimpta.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TEPEZZA (teprotumumab) &#8211; First U.S. FDA-approved medicine for the treatment of TED</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developed and commercialized by Amgen for the treatment of TED</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First and only approved medicine for the treatment of TED in the U.S. and Japan</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory approval pending in Europe</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teprotumumab, approved by the U.S. FDA and by Japan&#8217;s MHLW under the trade name TEPEZZA, is a human monoclonal antibody that targets the Insulin-like Growth Factor 1 Receptor (IGF-1R), a validated target. It is the first and only medicine approved in the U.S. and in Japan for the treatment of TED. Genmab used technology licensed from Medarex to generate the IGF-1R antibody. The antibody was created by Genmab under a collaboration with Roche. Development and commercialization of the product was subsequently conducted by Horizon Therapeutics plc (Horizon) under a sublicense from Roche. In October 2023, Amgen completed its acquisition of Horizon, including the rights to all commercialization and development of teprotumumab. Under the terms of Genmab&#8217;s agreement with Roche, Genmab receives a mid-single digit royalty on net sales (as defined) of TEPEZZA. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for the labeled indication and safety information for TEPEZZA.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 13&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RYBREVANT (amivantamab) &#8211; First regulatory approvals for a DuoBody-based medicine</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Part of Genmab and J&#38;J DuoBody research and license agreement</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First approved medicine created using Genmab&#8217;s proprietary DuoBody technology</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the agreement with J&#38;J, Genmab is eligible to receive milestones and receives royalties on net sales of RYBREVANT</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&#38;J to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of these, J&#38;J&#8217;s amivantamab, is a fully human bispecific antibody that targets EGFR and cMet, two validated cancer targets. The two antibody libraries used to produce amivantamab were both generated by Genmab. In collaboration with J&#38;J, the antibody pair used to create amivantamab was co-discovered. Amivantamab, marketed as RYBREVANT, is approved in certain territories for the treatment of certain adult patients with NSCLC. J&#38;J is responsible for the development and commercialization of amivantamab. Under the agreement with J&#38;J, Genmab is eligible to receive milestones and receives royalties between 8% and 10% on net sales of RYBREVANT subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions. Genmab pays a royalty to Medarex based on RYBREVANT net sales. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for RYBREVANT for the labeled indication and safety information.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TECVAYLI (teclistamab) &#8211; Bispecific antibody approved for the treatment of relapsed and refractory multiple myeloma</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Part of Genmab and J&#38;J DuoBody research and license agreement</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Second approved medicine created using Genmab&#8217;s proprietary DuoBody technology</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the agreement with J&#38;J, Genmab is eligible to receive milestones and receives royalties on net sales of TECVAYLI</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&#38;J to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of the products subsequently discovered and developed by J&#38;J is teclistamab, a bispecific antibody that targets CD3, which is expressed on T-cells, and B-cell maturation antigen (BCMA), which is expressed in mature B lymphocytes. Teclistamab, marketed as TECVAYLI, is approved in certain territories for the treatment of certain adult patients with relapsed or refractory multiple myeloma. J&#38;J is responsible for the development and commercialization of TECVAYLI. Under our agreement with J&#38;J, Genmab is eligible to receive milestones and receives a mid-single digit royalty on net sales of TECVAYLI subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for TECVAYLI for the labeled indication and safety information.</font></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TALVEY (talquetamab) &#8211; Bispecific antibody approved for the treatment of relapsed and refractory multiple myeloma</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Part of Genmab and J&#38;J DuoBody research and license agreement</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fourth approved medicine created using Genmab&#8217;s proprietary DuoBody technology</font></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Under the agreement with J&#38;J, Genmab is eligible to receive milestones and royalties on net sales of TALVEY</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2012, and as amended in December 2013, Genmab entered into a collaboration with J&#38;J to create and develop bispecific antibodies using Genmab&#8217;s DuoBody technology platform. One of the products subsequently discovered and developed by J&#38;J is talquetamab, a bispecific antibody that targets CD3, which is expressed on T-cells, and G protein-coupled receptor, family C, group 5, member D (GPRC5D), an orphan receptor expressed in malignant plasma cells. Talquetamab, marketed as TALVEY, is approved in certain territories for the treatment of certain adult patients with relapsed or refractory multiple myeloma. J&#38;J is responsible for the </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 14&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and commercialization of TALVEY. Under our agreement with J&#38;J, Genmab is eligible to receive milestones and receives a mid-single digit royalty on net sales of TALVEY subject to a reduction of such royalty payments in countries and territories where there are no relevant patents, among other reductions. Please consult the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Prescribing Information</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;and the&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">European Summary of Product Characteristics</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;for TALVEY for the labeled indication and safety information.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_19"></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SIGNIFICANT RISKS AND UNCERTAINTIES</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a biotech company, Genmab faces a number of risks and uncertainties. These are common for the industry and relate to operations, intellectual property, research and development, commercialization, and financial activities.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab is exposed to increasing risks related to evolving trade policies, including tariffs and other trade restrictions, which may increase costs or create regulatory uncertainty in key markets. In addition, changes made at the U.S. FDA may lead to delays in regulatory reviews, which could impact the timing of clinical milestones and product launches.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information about risks and uncertainties that Genmab faces, refer to the 2024 Annual Report filed with the Nasdaq Copenhagen and the Form 20-F filed with the U.S. SEC, both of which were filed in February 2025. At the date of this interim report, there have been no significant changes to Genmab&#8217;s overall risk profile since the publication of these reports. See Genmab&#8217;s Form 20-F for a detailed summary of risks related to our collaborations.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 15&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_22"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FINANCIAL REVIEW</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim report is prepared on a consolidated basis for Genmab A&#47;S (parent company) and its subsidiaries. Management has determined it is appropriate to change both the functional currency of the Genmab A&#47;S legal entity and the presentation currency of the condensed consolidated financial statements from DKK to USD effective January 1, 2025. The change in functional currency was triggered by the commercialization of EPKINLY and was made to reflect that USD has become the predominant currency of the Genmab A&#47;S legal entity. The change has been implemented with prospective effect. The change in presentation currency is applied retrospectively and was made to better reflect the Company&#8217;s financial position. Comparative figures for prior periods have been restated accordingly. The symbol &#8220;$&#8221; is used throughout this interim report to refer to the U.S. dollar. The Genmab consolidated Group is referenced herein as &#8220;Genmab&#8221; or the &#8220;Company.&#8221;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In all accompanying tables, amounts of dollars are expressed in millions, except per share amounts, unless otherwise noted)</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_535"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#8217;s revenue was $715 million for the first three months of 2025 compared to $603 million for the first three months of 2024. The increase of $112 million, or 19%, was primarily&#160;driven by higher DARZALEX and Kesimpta royalties achieved under our collaborations with J&#38;J and Novartis, respectively, and increased EPKINLY net product sales, partly offset by milestones achieved under our collaboration with AbbVie in the first three months of 2024.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">589&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">452&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenue</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">715</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">603</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Royalties</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue amounted to $589 million in the first three months of 2025 compared to $452 million in the first three months of 2024. The increase of $137 million, or 30%, was&#160;primarily driven by higher DARZALEX and Kesimpta royalties achieved under our daratumumab collaboration with J&#38;J and ofatumumab collaboration with Novartis. The table below summarizes Genmab&#8217;s royalty revenue by product.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.401%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended<br>March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DARZALEX</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">450&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">347&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kesimpta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TEPEZZA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total royalties</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">589</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">452</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">J&#38;J&#8217;s next sales of DARZALEX were $3,237 million in the first three months of 2025 compared to $2,692 million in the first three months of 2024. The increase of $545 million, or 20%, was driven by market share gains in all regions. Royalty revenue on net sales of DARZALEX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $450 million in the first three months of 2025 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 16&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $347 million in the first three months of 2024, an increase of $103 million. The percentage increase in royalties of 30% is higher than the percentage increase in the underlying net sales primarily due to a higher effective royalty rate.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis&#8217; net sales of Kesimpta were $899 million in the first three months of 2025 compared to $637 million in the first three months of 2024. The increase of $262 million, or 41%, was primarily driven by increased demand and strong access. Royalty revenue on net sales of Kesimpta was $90 million in the first three months of 2025 compared to $64 million in the first three months of 2024, an increase of $26 million, or 41%.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amgen&#8217;s net sales of TEPEZZA were $381 million in the first three months of 2025 compared to $424 million in the first three months of 2024. Royalty revenue on net sales of TEPEZZA was $25 million in the first three months of 2025 compared to $26 million in the first three months of 2024, a decrease of $1 million, or 4%. Other royalties consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY. These royalties were not material for the first three months of 2025 or 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue fluctuations from period to period are driven by the level of product net sales, foreign currency exchange rate movements and more specifically to DARZALEX, the contractual arrangement related to annual Currency Hedge Rate, Genmab&#8217;s share of J&#38;J&#8217;s royalty payments to Halozyme in connection with SC product net sales and the level of royalty deductions on net sales in countries and territories where there is no patent protection.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reimbursement Revenue</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement revenue amounted to $23 million in the three months of 2025 compared to $40 million in the first three months of 2024. The decrease of $17 million, or 43%, was&#160;primarily driven by Genmab assuming full control of development, as well as future commercialization, of the acasunlimab program and relevant patent protection, effective in the second half of 2024.  </font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Milestone Revenue</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenue was $12 million in the first three months of 2025 compared to $50 million in the first three months of 2024, a decrease of $38 million, or 76%, primarily driven by an AbbVie milestone achieved in the first three months of 2024 related to the U.S. FDA granting Priority Review for the sBLA for EPKINLY for the treatment of  adult patients with relapsed or refractory FL after two or more lines of systemic therapy.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenue may fluctuate significantly from period to period due to both the timing of achievements and the varying amount of each individual milestone under our license and collaboration agreements.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration Revenue</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue was $16 million in the first three months of 2025 compared to $14 million in the first three months of 2024, an increase of $2 million, or 14%, primarily driven by an increase in net sales of Tivdak.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Sales</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global net sales of EPKINLY&#47;TEPKINLY were $90 million in the first three months of 2025 compared to $52 million in the first three months of 2024, an increase of $38 million or 73%, driven by strong growth in 3L+ DLBCL and the expansion to address a second indication, 3L+ FL, which was approved in June 2024.&#160;Net product sales in the U.S. and Japan by Genmab were $75 million in the first three months of 2025 compared to $47 million in the first three months of 2024. EPKINLY was approved in the U.S. in May 2023 and in Japan in September 2023.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net sales of TEPKINLY in territories where Genmab receives royalty revenue were $15 million in the first three months of 2025 compared to $5 million in the first three months of 2024. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Statement Note 2 in this interim report for further details about revenue.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 17&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_554"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Product Sales<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab recognized cost of product sales of $42 million in the first three months of 2025 compared to $27 million in the first three months of 2024.&#160;Cost of product sales related to EPKINLY sales is primarily comprised of profit-sharing amounts payable to AbbVie of $35 million as well as product costs. </font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_791"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses amounted to $359 million in the first three months of 2025 compared to  $335 million in the first three months of 2024. The increase of $24 million, or 7%,&#160;was driven by the addition of ProfoundBio related research and development expenses, primarily Rina-S, and the increase in team members to support the continued expansion of our product portfolio. The acquisition of ProfoundBio occurred in the second quarter of 2024 and therefore there were no ProfoundBio related research and development expenses during the first three months of 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses accounted for 74% of total research and development expenses &#38; selling, general and administrative expenses in the first three months of 2025 compared to 73% in the first three months of 2024.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_830"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were $126 million in the first three months of 2025 compared to $125 million in the first three months of 2024. The increase of $1 million, or 1%, was&#160;driven by the expansion of Genmab&#8217;s commercialization capabilities. Selling, General and Administration expense growth has remained relatively consistent with prior year as a result of Genmab&#8217;s continuing focus on driving efficiency. We continue to increase team members and commercial support in a strategic manner.&#160;</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses accounted for 26% of total research and development expenses &#38; selling, general and administrative expenses in the first three months of 2025 compared to 27% for the first three months of 2024.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_866"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Profit<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit was $188 million in the first three months of 2025 compared to $116 million in the first three months of 2024.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_593"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Financial Items<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial income and expense was comprised of the following&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.538%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other financial income</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange rate gain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total financial income</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">101</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">168</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other financial expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss on other investments, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange rate loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(31)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total financial expenses</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(45)</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(35)</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net financial items</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">56</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">133</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 18&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $33 million in the first three months of 2025 compared to $46 million in the first three months of 2024. The decrease of $13 million was primarily driven by lower average cash and cash equivalents and marketable securities as a result of the ProfoundBio acquisition in the second quarter of 2024, as well as lower interest rates on USD denominated marketable securities in the first three months of 2025 compared to the first three months of 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Marketable Securities, net<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on marketable securities, net, which includes foreign exchange rate movements on marketable securities, was $19 million in the first three months of 2025 compared to $46 million in the first three months of 2024. The decrease in gain on marketable securities, net is primarily driven by the change in functional currency of Genmab A&#47;S on January 1, 2025. As the majority of the investment portfolio is denominated in USD, those securities are no longer impacted by foreign exchange rate fluctuations included in the gain on marketable securities, net.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Gain, net</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange rate gain, net, which excludes foreign exchange rate movements on marketable securities, was $11 million in the first three months of 2025 compared to foreign exchange rate gain, net of $46 million in the first three months of 2024. The decrease in foreign exchange rate gain, net is primarily driven by a lower foreign exchange rate impact due to the change in functional currency of Genmab A&#47;S from DKK to USD on January 1, 2025.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Statement Note 1 and Note 5 in this interim report for further details about the net financial items.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_612"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Tax<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate tax expense for the first three months of 2025 was $49 million compared to $57 million for the first three months of 2024. The decrease in corporate tax expense is primarily the result of Genmab&#8217;s lower net profit before tax and a decrease in the estimated annual effective tax rate in the first three months of 2025 to 20.3% from 22.8% in the first three months of 2024. </font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_926"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Profit<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net profit for the first three months of 2025 was $195 million compared to $192 million in the first three months of 2024. The increase was driven by the items described above.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_631"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable securities</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,607&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,574&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,619&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,380&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders' equity</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,296&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,137&#160;</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 19&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.424%"><tr><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:59.086%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.344%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Change</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">287&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">219&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(43)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(210)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">167&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash (used in) financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(85)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Increase (decrease) in cash and cash equivalents</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">231</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(76)</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">307</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exchange Rate adjustments</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash provided by operating activities is primarily related to our operating profit, changes in operating assets and liabilities, reversal of net financial items, and adjustments related to non-cash transactions. The $68 million increase in net cash provided by operating activities is primarily driven by an increase in operating profit of $72 million and an improvement in receivables which was largely attributable to higher royalty-related receivables as of year end 2024 compared to 2023, with the corresponding cash collections occurring during the first three months of 2025 and 2024. These increases were partly offset by a $75 million decrease in changes in other payables, in part due to the timing of share repurchases, and a $13 million reduction in interest received.<br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in investing activities primarily reflects differences between the proceeds received from the sale and maturity of our investments and amounts invested, and the cash paid for investments in tangible and intangible assets. The $167 million decrease in net cash used in investing activities is primarily driven by the purchases of marketable securities exceeding the sales and maturities to a greater extent in the first three months of 2024 compared to first three months of 2025.<br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Net cash used in financing activities is primarily related to the purchase of treasury shares, exercise of warrants, lease payments, and payment of withholding taxes on behalf of employees on net settled Restricted Stock Units (RSUs). The $72 million decrease in net cash used in financing activities between the periods is primarily driven by $79 million increased cash paid for the purchase of treasury shares during the first three months of 2024 compared to the first three months of 2025 due to the timing of share repurchases. This decrease was partly offset by lower proceeds from the exercise of warrants of $8 million, with $1 million received in the first three months of 2025 as compared to $9 million in the first three months of 2024.<br> </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#8217;s USD denominated marketable securities represented 77% of Genmab&#8217;s total marketable securities as of March 31, 2025, compared to 76% as of December 31, 2024. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents included short-term marketable securities of $80 million as of March 31, 2025, compared to $11 million as of December 31, 2024. In accordance with our accounting policy, securities purchased with a maturity of less than ninety days at the date of acquisition are classified as cash and cash equivalents. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4 -  Financial Instruments in this interim report for further details about our marketable securities.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_650"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheet<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, total assets were $6,586 million compared to $6,414 million on December 31, 2024. As of  March 31, 2025, assets were mainly comprised of $355 million of goodwill and $1,756 million of other intangible assets, primarily made up of  assets acquired in the ProfoundBio acquisition, marketable securities of $1,607 million, current receivables of $799 million, cash and cash equivalents of $1,619 million. The current receivables consist primarily of amounts related to royalties from our collaboration agreements.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, total liabilities were $1,290 million compared to $1,277 million on December 31, 2024. The increase in total liabilities of $13 million&#160;was primarily driven by an increase in current other payables of $18 </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 20&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million, primarily related to accruals related to the expansion of our product pipeline, partially offset by a decrease of $10 million in corporate taxes payable primarily due to Genmab&#8217;s net profit before tax.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shareholders&#8217; equity as of March 31, 2025, was $5,296 million compared to $5,137 million on December 31, 2024. The increase of $159 million, or 3%, was primarily driven by Genmab&#8217;s net profit for the period and share-based compensation expenses, partly offset by the purchase of treasury shares. Genmab&#8217;s equity ratio remained consistent at 80% as of both March 31, 2025 and December 31, 2024.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_669"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Team Members<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, the total number of team members was 2,638 compared to 2,286 as of March 31, 2024. The increase was primarily driven by the continued expansion of our product portfolio, as well as the investment in the expansion of Genmab&#8217;s commercialization capabilities, including continued support for EPKINLY in the U.S. and Japan post launch activities, and broader organizational capabilities and the acquisition of ProfoundBio, which occurred during the second quarter of 2024.</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.419%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Team Members</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development team members</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,837&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,601&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative team members</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">801&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">685&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total team members</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,638</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2,286</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Matters</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chugai Patent Infringement Complaint </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, Chugai filed a lawsuit in the Tokyo District Court, Japan against AbbVie&#8217;s and Genmab&#8217;s subsidiaries in Japan asserting that their activities with EPKINLY (epcoritamab) in Japan infringe two Japanese patents held by Chugai, JP6278598 and JP6773929. Chugai is claiming damages and injunctive relief. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab and AbbVie believe that the two Japanese patents are invalid and not infringed and are vigorously defending against the lawsuit, and thus no provision has been recorded related to this matter.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbbVie Rina-S Trade Secret Complaint</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025, AbbVie filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A&#47;S&#59; ProfoundBio US Co.&#59; ProfoundBio (Suzhou) Co., Ltd.&#59; and former AbbVie employees as defendants. AbbVie alleges that the defendants have misappropriated AbbVie&#8217;s alleged trade secrets relating to the use of disaccharides to improve the hydrophilicity of drug-linkers in ADCs in connection with Rina-S and other ADC pipeline products of ProfoundBio. AbbVie is seeking damages and broad injunctive reliefs. AbbVie is not asserting or enforcing any patent rights against the defendants, and to Genmab&#8217;s knowledge, AbbVie has not pursued any development of products incorporating their alleged trade secrets.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie&#8217;s claims, and thus no provision has been recorded related to this matter.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 21&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_25"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_28"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:59.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.061%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:1.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.054%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.521%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(USD million)</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024* Restated</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Revenue</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">715&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">603&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cost of product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(42)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(27)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(359)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(335)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Selling, general and administrative expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(126)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total costs and operating expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(527)</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(487)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Operating profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">188</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">116</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">168&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(45)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(35)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">244</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">249</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(49)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(57)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">195</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">192</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Other comprehensive income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amounts which may be re-classified to the income statement&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exchange differences on translation of foreign operations</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">208</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">199</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net profit per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.06&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.96&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net profit per share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.05&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2.94&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*Effective January 1, 2025, the Company changed its presentation currency from DKK to USD. Accordingly, prior year balances have been re-presented retrospectively. Refer to Note 1 for more information.</font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 22&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_31"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED&#160;CONSOLIDATED BALANCE SHEETS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#E6E6E6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024* Restated</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(USD million)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#E7E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,756&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,728&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other investments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E7E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E7E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,549</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2,514</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E7E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate tax receivable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">799&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">923&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,607&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,574&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,619&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,380&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">4,037</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">3,900</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,586</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,414</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SHAREHOLDERS&#8217; EQUITY AND LIABILITIES</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share premium</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,962&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other reserves</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213)</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(226)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,537&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,392&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total shareholders' equity</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,296</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5,137</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">330&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total non-current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">534</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">533</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 23&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.769%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.809%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate tax payable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">229&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">239&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#E7E6E6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507&#160;</font></td><td style="background-color:#E7E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">756</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">744</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,290</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1,277</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#E6E6E6;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total shareholders' equity and liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#E6E6E6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="background-color:#E6E6E6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,586</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="background-color:#E6E6E6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">6,414</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Related parties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingencies</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subsequent events to the balance sheet date</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*Effective January 1, 2025, the Company changed its presentation currency from DKK to USD. Accordingly, prior year balances have been re-presented retrospectively. Refer to Note 1 for more information.</font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 24&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_34"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:59.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(USD million)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024* Restated</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net profit before tax</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">244</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">249</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(101)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(168)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Financial expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments for non-cash transactions</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Share-based compensation expense</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment charges</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in operating assets and liabilities&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">39&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventories</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other payables</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(46)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash flows from operating activities before financial items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">305</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">223</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest received</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest elements of lease payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate taxes paid</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(47)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash provided by operating activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">287</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">219</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investment in intangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(18)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Investment in tangible assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities bought</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(271)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(660)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Marketable securities sold</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">259&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">457&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other investments bought</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) investing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(43)</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(210)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Warrants exercised</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Principal elements of lease payments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchase of treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(79)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Payment of withholding taxes on behalf of employees on net settled RSUs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net cash (used in) financing activities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(13)</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(85)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in cash and cash equivalents</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">231</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(76)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents at the beginning of the period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,380&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,204&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Exchange rate adjustments</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and cash equivalents at the end of the period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,619</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,127</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and cash equivalents include&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Bank deposits</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,539&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,997&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Short-term marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">80&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">130&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash and cash equivalents at the end of the period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,619</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,127</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 25&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.969%"><tr><td style="width:1.0%"></td><td style="width:59.368%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.243%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.497%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*Effective January 1, 2025, the Company changed its presentation currency from DKK to USD. Accordingly, prior year balances have been re-presented retrospectively. Refer to Note 1 for more information.</font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 26&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_37"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY*</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.995%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Share</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Translation</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Retained</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shareholders'</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(USD million)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Note</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">capital</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">premium</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">reserves</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">earnings</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">equity</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,942</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(2)</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,737</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,687</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">192&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(96)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(96)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(96)</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">192</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">96</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transactions with owners&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of warrants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(91)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(91)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Withholding taxes on behalf of employees on net settled RSUs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,951</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(98)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2,850</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">4,713</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,961</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(226)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,392</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,137</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Net profit</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">195&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">195&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total comprehensive income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">13</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">195</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">208</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Transactions with owners&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Exercise of warrants</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Purchase of treasury shares</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(63)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Share-based compensation expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">7</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Withholding taxes on behalf of employees on net settled RSUs</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(12)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Balance at March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">1,962</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(213)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">3,537</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">5,296</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="39" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*Effective January 1, 2025, the Company changed its presentation currency from DKK to USD. Accordingly, prior year balances have been re-presented retrospectively. Refer to Note 1 for more information.</font></div></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 27&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_40"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_43"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 1 -  Basis of Presentation</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounting Policies</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim statements of the Genmab Group (Genmab or the Company) have been prepared in accordance with IAS 34 (Interim Financial Reporting) as issued by the International Accounting Standards Board (IASB) and in accordance with IAS 34 as endorsed by the EU and additional Danish disclosure requirements for interim reports of listed companies. The interim report has not been audited by Genmab&#8217;s external auditors.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim report has been prepared using the same accounting policies as outlined in Section 1 &#8211; Basis of Presentation in the financial statements in the Genmab 2024 Annual Report (Annual Report), except as noted below. A number of amended standards became applicable for the current reporting period. There was no impact to Genmab&#8217;s financial statements as a result of adopting these amended standards. These interim financial statements should be read in conjunction with the Annual Report.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Functional and Presentation Currency Change</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has determined it is appropriate to change both the functional currency of the Genmab A&#47;S legal entity and the presentation currency of the condensed consolidated financial statements from DKK to USD effective January 1, 2025. The change in functional currency was triggered by the commercialization of EPKINLY and was made to reflect that USD has become the predominant currency of the Genmab A&#47;S legal entity. The change has been implemented with prospective effect. The change in presentation currency is applied retrospectively and was made to better reflect the Company&#8217;s financial position. Comparative figures for prior periods have been restated accordingly.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The condensed consolidated statements of comprehensive income and the condensed consolidated statements of cash flows have been translated into the presentation currency using the average exchange rates prevailing during each reporting period. In the condensed consolidated balance sheets, all assets and liabilities have been translated using the period-end exchange rates, and all resulting exchange differences have been recognized in accumulated other comprehensive income. Shareholders&#8217; equity balances have been translated using historical rates in effect on the date of the transactions. The DKK&#47;USD exchange rates used to reflect the change in presentation currency were as follows&#58; </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.696%"><tr><td style="width:1.0%"></td><td style="width:27.343%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.790%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q1 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q2 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q3 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Q4 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average rate</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1456</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1443</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1472</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1433</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Closing rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1450</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1435</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1502</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1400</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation currency resulted in the following impact on the December 31, 2024 condensed consolidated balance sheets&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously reported in DKK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported in USD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Presentation currency change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,811&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39,397)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,414&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,114&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,837)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total shareholders' equity</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,697&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31,560)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,137&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation currency resulted in the following impact on the three months ended March 31, 2024 condensed consolidated statements of comprehensive income&#58;</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 28&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:22.760%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.279%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously reported in DKK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported in USD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Presentation currency change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net profit</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,133)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,373&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation currency resulted in the following impact on the three months ended March 31, 2024 condensed consolidated statements of cash flows&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:25.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.327%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously reported in DKK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported in USD</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash provided by (used in)&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Presentation currency change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,513&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,294)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,231&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(595)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(85)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in presentation currency resulted in the following impact on the three months ended March 31, 2024 basic and diluted earnings per share&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.545%"><tr><td style="width:1.0%"></td><td style="width:25.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.187%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Previously reported in DKK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported in USD</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Presentation currency change</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - basic</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.29</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.33)</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per share - diluted</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.18</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.24)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.94</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Information about Geographical Areas</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab is managed and operated as one business unit, which is reflected in the organizational structure and internal reporting. No separate lines of business or separate business entities have been identified with respect to any licensed products, product candidates, product sales or geographical markets and no segment information is currently prepared for internal reporting. Refer to Note 2.2 in the Annual Report for further details.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to conform to the current period gross presentation for the first quarter of 2025, a reclassification of net $40 million has been made to the gross amounts presented for the first quarter of 2024 to move foreign exchange rate gains and losses related to marketable securities from gains and losses on foreign exchange rates to gains and losses on marketable securities. These reclassifications have no impact on the net amounts of financial items as presented in Note 5 - Financial Income and Expenses.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(In all accompanying tables, amounts of dollars expressed in millions, except per share amounts, unless otherwise noted)</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_49"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 2 -  Revenue</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes Genmab&#8217;s revenue by type and collaboration partner, and royalties by product, under Genmab&#8217;s agreements.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 29&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:49.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:23.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.182%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue by type&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Royalties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">589&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">452&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reimbursement revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Milestone revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">50&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Collaboration revenue</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net product sales</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">715</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">603</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Revenue by collaboration partner&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">J&#38;J</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">481&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">361&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Roche</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Novartis</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">91&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">BioNTech</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pfizer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">AbbVie</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total*</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">640</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">556</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Royalties by product&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DARZALEX</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">450&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Kesimpta</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">90&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">TEPEZZA</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other**</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">589</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">452</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:4.5pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">*</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:1.39pt">Excludes Genmab&#8217;s Net product sales</font></div><div style="margin-bottom:10pt;padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">**</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%;padding-left:2.78pt">Other consist of royalties from net sales of RYBREVANT, TECVAYLI, TALVEY and TEPKINLY.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Product Sales</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab recognized net product sales of $75 million during the first three months of 2025 compared to $47 million in the first three months of 2024. EPKINLY was approved in the U.S. in May 2023 and Japan in September 2023.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the continued evaluation of contract liabilities related to the AbbVie Agreement, during the first three months of 2025, Genmab&#8217;s classification of contract liabilities reflects the current estimate of co-development activities as of March 31, 2025. These co-development activities are related to a performance obligation in connection with the product concepts under a research option agreement.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 2.1 in the Annual Report for further details regarding revenue.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_52"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 3 -  Goodwill &#38; Other Intangible Assets</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Goodwill</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Licenses and Patents</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Technology Platform</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Acquired IPR&#38;D</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total Intangible Assets</font></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 30&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cost at the beginning of the period</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">355</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">149</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">180</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,532</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,216</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions during the period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of exchange rate adjustment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cost at the end of the period</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">355</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">181</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">180</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,532</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,248</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt;text-indent:4.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization and impairment losses at the beginning of the period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization for the period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment losses for the period</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization and impairment losses at the end of the period</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">128&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">137&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying amount at the end of the period</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">355</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">53</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">171</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,532</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,111</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cost at the beginning of the year</font></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">126</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8212;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">126</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Additions during the year</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">341&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">174&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,481&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,019&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate adjustment</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cost at the end of the year</font></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">355</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">149</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">180</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,532</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,216</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt;text-indent:4.5pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization and impairment losses at the beginning of the year</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">112&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization for the year</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Impairment losses for the year</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0</font></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amortization and impairment losses at the end of the year</font></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">126&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">133&#160;</font></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Carrying amount at the end of the year</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">355</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">23</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">173</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">1,532</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2,083</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of goodwill, which relates to the acquisition of ProfoundBio during the second quarter of 2024, was $355 million as of both March 31, 2025 and  December 31, 2024.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Intangible Assets</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the gross carrying value of other intangible assets during the first three months of 2025 was due to the addition of $32 million of licenses and patents. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense was $4 million and $2 million for the first three months of 2025 and 2024 respectively, which was recorded in Research and development expenses in the Condensed Consolidated Statements of Comprehensive Income.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 31&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_55"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 4 -  Financial Instruments</font></div><div style="margin-bottom:6pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#8217;s portfolio is spread over a number of different securities with a focus on liquidity and the preservation of capital. Genmab&#8217;s marketable securities in USD, DKK, EUR, and GBP as a percentage of total marketable securities were as follows&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:46.699%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.358%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.394%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</font></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Percent</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USD</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</font></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">DKK</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</font></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EUR</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GBP</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</font></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">100</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">%</font></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2025, 70% of Genmab&#8217;s marketable securities were long-term A rated or higher, or short-term A-1 &#47; P-1 rated compared to 71% as of December 31, 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below shows the fair value measurements by level for Genmab&#8217;s financial assets measured at fair value through profit or loss&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:36.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.765%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.962%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.604%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.447%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">March 31, 2025</font></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Assets Measured at Fair Value</font></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</font></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</font></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</font></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;1</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;2</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level&#160;3</font></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</font></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Marketable securities</font></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,607&#160;</font></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,574&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,574&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Other investments</font></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30&#160;</font></td><td style="background-color:#dbdbdb;border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32&#160;</font></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All fair values are determined by reference to external sources using unadjusted quoted prices in established markets for Genmab&#8217;s marketable securities (Level 1).</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Investments</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other investments primarily consist of investments in certain strategic investment funds. Genmab&#8217;s share of the fair value of these fund investments is determined based on the valuation of the underlying investments included in the fund. Investments in publicly traded equity securities included in these strategic investment funds are valued based at the most recent sale price or official closing price reported on the exchange or over-the-counter market on which they trade, while investments in non-publicly traded equity securities are based on other factors, including but not limited to, type of the security, the size of the holding, the initial cost of the security, the price and extent of public trading in similar securities of the comparable companies, an analysis of the company's or issuer's financial statements and with respect to debt securities, the maturity and creditworthiness. As such, these fund investments have been characterized as Level 3 investments as fair values are not entirely based on observable market data.</font></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4.3 and Note 4.4 in the Annual Report for further details regarding Genmab&#8217;s marketable securities and other investments.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 32&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_58"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 5 -  Financial Income and Expenses</font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:51.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial income&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and other financial income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Gain on marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">69&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange rate gain</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial income</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">101</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">168</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Financial expenses&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest and other financial expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e7e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on marketable securities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(23)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Loss on other investments, net</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Foreign exchange rate loss</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(31)</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(7)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial expenses</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(45)</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(35)</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Net financial items</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">56</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">133</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest Income</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest income was $33 million in the first three months of 2025 compared to $46 million in the first three months of 2024. The decrease of $13 million was primarily driven by lower average cash and cash equivalents and marketable securities as a result of the ProfoundBio acquisition in the second quarter of 2024, as well as lower interest rates on USD denominated marketable securities in the first three months of 2025 compared to the first three months of 2024.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Gain on Marketable Securities, net<br></font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain on marketable securities, net, which includes foreign exchange rate movements on marketable securities, was $19 million in the first three months of 2025 compared to $46 million in the first three months of 2024. The decrease in gain on marketable securities, net is primarily driven by the change in functional currency of Genmab A&#47;S on January 1, 2025. As the majority of the investment portfolio is denominated in USD, those securities are no longer impacted by foreign exchange rate fluctuations included in the gain on marketable securities, net.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign Exchange Rate Gain, net</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign exchange rate gain, net, which excludes foreign exchange rate movements on marketable securities,  was $11 million in the first three months of 2025 compared to foreign exchange rate gain, net of $46 million in the first three months of 2024. The decrease in foreign exchange rate gain, net is primarily driven by a lower foreign exchange rate impact due to the change in functional currency of Genmab A&#47;S from DKK to USD on January 1, 2025.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_61"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 6 -  Share-Based Payments</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock Unit Program</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab has established an RSU program (equity-settled share-based payment transactions)&#160;as an incentive for Genmab&#8217;s employees, members of the Executive Management, and members of the Board of Directors. RSUs granted to Executive Management are performance-based (PSUs).</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 33&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font><br></font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.324%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSUs granted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">633,505</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">436,774</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Weighted average fair value per RSU granted (DKK)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">1,602.57&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">2,015.91&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">RSUs vested</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">168,850</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">117,107</font></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4.6 in the Annual Report for details on the RSU program.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Warrant Program</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab has established a warrant program (equity-settled share-based payment transactions) as an incentive for all Genmab employees. </font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:71.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Warrants granted</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">526,694</font></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 7pt 0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">329,027</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Weighted average exercise price per warrant granted (DKK)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">1,605.64&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">2,014.28&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Weighted average Black-Scholes fair value per warrant granted (DKK)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">500.66&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">653.05&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Warrants exercised</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">10,058</font></td><td colspan="3" style="padding:0 7pt 0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">48,429</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">Weighted average exercise price on date of grant per warrant exercised (DKK)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">1,138.01&#160;</font></td><td style="background-color:#e7e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">1,211.78&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">% change in share capital - warrants exercised</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">0.02&#160;</font></td><td style="background-color:#e7e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">%</font></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">0.07&#160;</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-style:italic;font-weight:400;line-height:120%">%</font></td></tr></table></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4.6 in the Annual Report for details on the warrant program.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share-Based Compensation Expense</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expenses related to Genmab&#8217;s RSU and warrant programs for the first three months of 2025 were $25 million compared to $24 million for the first three months of 2024.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchases</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Genmab&#8217;s Annual General Meeting on March 12, 2025, the Board of Directors authorized Genmab to acquire treasury shares with a total nominal value of up to 10% of the share capital in the period until and including March 11, 2030. The purchase price for the relevant shares may not deviate by more than 10% from the price quoted on Nasdaq Copenhagen A&#47;S at the time of the acquisition. Such shares may only be acquired to the extent that the Company&#8217;s total holding of treasury shares does not at any time exceed a nominal value of 10% of the share capital. The authorization replaced existing previously provided authorizations to purchase treasury shares. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As announced on March 25, 2025, Genmab initiated a share buy-back program to reduce capital and to honor our commitments under the RSU program. During the first three months of 2025, Genmab acquired 316,630 of its own shares&#160;under the program, representing approximately 0.5% of share capital as of December 31, 2024. The total amount incurred to acquire the shares, including directly attributable costs, was $63 million and was recognized as a deduction to shareholders&#8217; equity. These shares are classified as treasury shares and are presented within retained earnings on the Condensed Consolidated Balance Sheets as of March 31, 2025. As </font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 34&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of March 31, 2025, 3,765,106 shares were available for repurchase, and 2,854,618 treasury shares were held by Genmab. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As announced on February 14, 2024, and March 15, 2024, Genmab initiated two share buy-back programs. The purpose of the share buy-back program announced on February 14, 2024, was to honor Genmab&#8217;s commitments under the RSU program. The share buy-back program announced on March 15, 2024, was in support of Genmab&#8217;s capital allocation strategy. During the first three months of 2024, Genmab acquired 311,123 of its own shares, under both programs, representing approximately 0.5% of share capital as of December 31, 2023. The total amount incurred to acquire the shares, including directly attributable costs, was $91 million and was recognized as a deduction to shareholders&#8217; equity.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_64"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 7 -  Related Parties</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab&#8217;s related parties are its Board of Directors, Executive Management, and close members of the family of these persons.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab has not granted any loans, guarantees or other commitments to or on behalf of any of the members of the Board of Directors or members of the Executive Management.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the similar remuneration relating to the Board of Directors and the Executive Management described in Note&#160;5.1 in the Annual Report, there were no material related party transactions during the first three months of 2025.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to the Executive Management and the Board of Directors</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following Genmab&#8217;s Annual General Meeting on March 12, 2025, the Board of Directors is comprised of five independent board members, one non-independent board member, and three employee-elected board members. Deirdre P. Connelly (Chair), Pernille Erenbjerg (Deputy Chair), Rolf Hoffmann, Elizabeth O&#8217;Farrell, Paolo Paoletti and Anders Gersel Pedersen were re-elected to the Board of Directors for a one-year period. Mijke Zachariasse, Martin Schultz and Michael Kavanagh were elected as employee-elected board members and will serve for a three-year period expiring in 2028.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_67"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 8 -  Leases</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts recognized in the Condensed Consolidated Balance Sheets</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Balance Sheets show the following amounts relating to leases&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.242%"><tr><td style="width:1.0%"></td><td style="width:32.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.252%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">March 31, 2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">December 31, 2024</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Properties</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">126</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">128</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-current</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total lease liabilities</font></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">143</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e6e6e6;border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">144</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-bottom:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 35&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first three months of 2025, there were no material additions to Genmab&#8217;s right-of-use assets and lease liabilities. During the first three months of 2024, there were additions to Genmab&#8217;s right-of-use assets and lease liabilities related to the commencement of a lease in the U.S. with respect to office and laboratory space.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amounts recognized in the Condensed Consolidated Statements of Comprehensive Income</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Condensed Consolidated Statements of Comprehensive Income show the following amounts relating to leases&#58;</font></div><div style="margin-bottom:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:51.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.598%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.601%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Depreciation charge of right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e6e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Properties</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e6e6e6;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="background-color:#e6e6e6;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4&#160;</font></td><td style="background-color:#e6e6e6;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</font></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3&#160;</font></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e7e6e6;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total depreciation charge of right-of-use assets</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="background-color:#e7e6e6;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"></td><td style="border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$</font></td><td style="border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></td><td style="border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments, short-term lease expense, lease interest expense and low-value leases are not material.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_70"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 9 -  Contingencies</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Chugai Patent Infringement Complaint </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, Chugai filed a lawsuit in the Tokyo District Court, Japan against AbbVie&#8217;s and Genmab&#8217;s subsidiaries in Japan asserting that their activities with EPKINLY (epcoritamab) in Japan infringe two Japanese patents held by Chugai, JP6278598 and JP6773929. Chugai is claiming damages and injunctive relief. </font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab and AbbVie believe that the two Japanese patents are invalid and not infringed and are vigorously defending against the lawsuit, and thus no provision has been recorded related to this matter.</font></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AbbVie Rina-S Trade Secret Complaint</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025, AbbVie filed a complaint in the U.S. District Court for the Western District of Washington (Seattle) naming Genmab A&#47;S&#59; ProfoundBio US Co.&#59; ProfoundBio (Suzhou) Co., Ltd.&#59; and former AbbVie employees as defendants. AbbVie alleges that the defendants have misappropriated AbbVie&#8217;s alleged trade secrets relating to the use of disaccharides to improve the hydrophilicity of drug-linkers in ADCs in connection with Rina-S and other ADC pipeline products of ProfoundBio. AbbVie is seeking damages and broad injunctive reliefs. AbbVie is not asserting or enforcing any patent rights against the defendants, and to Genmab&#8217;s knowledge, AbbVie has not pursued any development of products incorporating their alleged trade secrets.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genmab categorically refutes these allegations and will vigorously defend the company against AbbVie&#8217;s claims, and thus no provision has been recorded related to this matter.</font></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_73"></div><div style="margin-bottom:6pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note 10 -  Subsequent Events&#160;to the Balance Sheet Date</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No events have occurred subsequent to the balance sheet date that could significantly affect the financial statements as of March 31, 2025.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 36&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_76"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ABOUT GENMAB</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab&#8217;s vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines&#174;.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Genmab.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and follow us on&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">LinkedIn</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">X</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">This Interim Report contains forward looking statements. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;intend&#8221; and &#8220;plan&#8221; and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab&#8217;s most recent financial reports, which are available on&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.genmab.com</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and the risk factors included in Genmab&#8217;s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at&#160;</font><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">. Genmab does not undertake any obligation to update or revise forward looking statements in this Interim Report nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Genmab A&#47;S and&#47;or its subsidiaries own the following trademarks&#58; Genmab</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; the Y-shaped Genmab logo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; Genmab in combination with the&#160;Y-shaped Genmab logo</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; HuMax</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; DuoBody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; HexaBody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; DuoHexaBody</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; HexElect</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;&#160;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">and KYSO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#59; ProfoundBio&#8482; and Rina-S</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174; </font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">are trademarks of ProfoundBio, US, Co. and ProfoundBio (Suzhou) Co., Ltd. Tivdak</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;is a trademark of Seagen Inc.&#59;&#160;EPCORE</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, EPKINLY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, TEPKINLY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and their designs are trademarks of AbbVie Biotechnology Ltd.&#59; Kesimpta</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and Sensoready</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;are trademarks of Novartis AG or its affiliates&#59; DARZALEX</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, DARZALEX FASPRO</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, RYBREVANT</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">, TECVAYLI</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;and TALVEY</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;are trademarks of Johnson &#38; Johnson&#59; TEPEZZA</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">&#160;is a trademark of Horizon Therapeutics Ireland DAC.</font></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 37&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div><div id="i5bf39db2728b4c8fa0a2052d4956f209_79"></div><hr style="page-break-after:always"><div style="min-height:108pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><img alt="gmab_20250508xex99d1002a.jpg" src="gmab_20250508xex99d1002a.jpg" style="height:60px;margin-bottom:5pt;vertical-align:text-bottom;width:202px"></div><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:13pt;font-weight:700;line-height:120%">Interim Report for the First Three Months of 2025</font></div><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:10pt"><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">DIRECTORS&#8217; AND MANAGEMENT&#8217;S STATEMENT ON THE INTERIM REPORT</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors and the registered members of Executive Management have today considered and adopted the unaudited interim report of the Genmab Group for the three months ended March 31, 2025.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim report is prepared in accordance with IAS 34, &#8220;Interim Financial Reporting,&#8221; as issued by the IASB and in accordance with IAS 34 as endorsed by the EU, and additional Danish disclosure requirements for interim reports of listed companies.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the applied accounting policies to be appropriate and, in our opinion, the interim report gives a true and fair view of the assets and liabilities, financial position, results of operation and cash flows of the Group.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we consider the Management&#8217;s Review to give a true and fair account of the development in the Group&#8217;s activities and financial affairs, results of operations and the Group&#8217;s financial position as a whole as well as a description of the significant risks and uncertainties which the Group faces, as further described in this report, our 2024 Annual Report and the Form 20-F filed with the U.S. Securities and Exchange Commission in February 2025.</font></div><div style="margin-bottom:10pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Copenhagen, 8&#160;May 2025</font></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Registered Members of Executive Management</font></div><div style="margin-bottom:25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr style="height:45pt"><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1004.jpg" src="gmab_20250508xex99d1004.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:110px"></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1005.jpg" src="gmab_20250508xex99d1005.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:110px"></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jan van de Winkel<br>(President &#38; CEO)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anthony Pagano<br>(Executive Vice President &#38; CFO)</font></td></tr></table></div><div><font style="color:#029c93;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Board of Directors</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.900%"></td><td style="width:0.1%"></td></tr><tr style="height:40pt"><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1006.jpg" src="gmab_20250508xex99d1006.jpg" style="height:48px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1007.jpg" src="gmab_20250508xex99d1007.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:96px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1008.jpg" src="gmab_20250508xex99d1008.jpg" style="height:38px;margin-bottom:5pt;vertical-align:text-bottom;width:124px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deirdre P. Connelly<br>(Chair) </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pernille Erenbjerg<br>(Deputy Chair)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Anders Gersel Pedersen</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:42pt"><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1009.jpg" src="gmab_20250508xex99d1009.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:105px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1010.jpg" src="gmab_20250508xex99d1010.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1011.jpg" src="gmab_20250508xex99d1011.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:120px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rolf Hoffmann</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Paolo Paoletti</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elizabeth O&#8217;Farrell</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:53pt"><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1012.jpg" src="gmab_20250508xex99d1012.jpg" style="height:43px;margin-bottom:5pt;vertical-align:text-bottom;width:76px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1013.jpg" src="gmab_20250508xex99d1013.jpg" style="height:45px;margin-bottom:5pt;vertical-align:text-bottom;width:153px"></div></td><td colspan="3" style="padding:0 1pt"><div><img alt="gmab_20250508xex99d1014.jpg" src="gmab_20250508xex99d1014.jpg" style="height:57px;margin-bottom:5pt;vertical-align:text-bottom;width:48px"></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mijke Zachariasse<br>(Employee elected)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Michael Kavanagh<br>(Employee elected)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Martin Schultz<br>(Employee elected)</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:63pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genmab A&#47;S<br>Carl Jacobsens Vej 30<br>2500 Valby, Denmark</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Tel&#58; +45 7020 2728<br>www.genmab.com</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Company Announcement no. 25</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Page 38&#47;38</font></div><div style="padding-right:4.5pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">CVR no. 2102 3884</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>gmab_20250508xex99d1002a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1002a.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  \ ,H# 2(  A$! Q$!_\0
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M;')RHZ9S\[_L\ZYXCL?C+X7CT*[NS<7=]''<PK(S)- 3F7S!T(";CD]" >M
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4I5JU,PQ5N:I9)+5**\W:[?4__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>gmab_20250508xex99d1004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1004.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" &! S(# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MM8U*THXVGK6;OL7<F3&T8%+38SE:=60B.GIT_&@JIZBE QP* "BBB@ HHHH
M**** "BBB@ HHHH ***9.6"?+0 ^BH8)& _>=:E#!NE "T4UG5>]1[V)XIVN
M!-13!(!P3S2-(5Y)I 245$'8G(IYD4#DT .HJ-F9N5H5]OWZ )**;N8_=HR_
M^10 ZBBB@ HHHH **1C@<4T.WK0 ^BB@G S0 44U6).#3J "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F-U/
MUI],;J?K0 A?:.M0HA\[=4CJQ/%* JCGK0 VZN?+^6H(LA_,IUTC2-GL#S5>
MXU>RMH]KMR/>@"S(3+(&![U:CX0"J6F7UM>1[XSD8S5AIU;Y4ZBID 7$.07'
M:H;.;=*4/8U-OS&5/4U#;P.LA<]":B*U 2>,F<-FL[Q=XF3P_9F1G ^0]:U;
M@@=^:\<_:=\2W&B:3O23;F.NN$;F;/E#XG7%WXP_:*MK<-(T;E\@9Q]Y:^P?
MAYX&M? GAZ*["1H7M<GIW6O!?AGX#B\1^-[;Q)+!N9<_-CU(KVCX^>+SX-T"
MWA679_HZ#K[5NTDTB.9GB%Q837W[0<=RI8KST/'WA7V5H=I]GTV '_G@O\A7
MS/\ "KP\/$'BJ'Q$8]W^UBOIP+(EM"L7:-1^E8S;O8TB-?3M\WF G\ZL1VA4
M\G]:=$P5 TG6GI(K_=K)R>Q8JKM&*6BBI **** "BBB@ HHHH **** "BBBB
MX!1110 4444 5[@[6X_2E@;)YITTL*MAZ1P"N8Z=]+ ++&&/6HPWDG-,^TF-
MPCGJ:6\E18@Q/6K2MN X_.?,STIKS>8-H-8.I^-M+TD%;F3&.O-8DGQP\'6;
MD3W/0_WA5<J [I+E4^0D4KGS!P?UKS*;X]>$GNQY5SQ_O"MW0?BYX9U4A89\
MG_>%#BN@'8Q3[3L)IURN[D5DVNK17;">%OE^M:,<PG "5FU9@.2Z*?)C]*E2
M8L.E(L4>/FZTX>6O04@%,GM3#)N-/RA[4TA<\4@'J<@4M, ;'%.7..: !^GX
MTRGOT_&F4 24-T/THH;H?I0 U.OX4ZFIU_"G4 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,;J?K3Z8W4_6@
M!"^T5 TS%\8J9EW=Z:K0[MN.>] $=Q,8[1WQT4UX;\<?BS<^"+.2\&X 9[5[
MI=P^9$R)W%?.?[:W@O4;GP*\M@N'*OSM]J .R_9:^*R_$OP[]NFG&?)!Y/TK
MU>WC_>E@<BO@[]C_ .+8^&=I!H/B"ZQ+(H0#=CFON#PIXDL]:T2"_MSD2+D'
M.:F0&M(N&S2/,$4"@3(RGUJ&=)#T-*!,A-0E$-D]V3C:.M?,G[7OB\7^G&VB
MDW;4QA:^A?'6I?8/"-U+NP0GY5\?>*9KWQWKES9K)O"S%<=:ZJ=R'L>Q?L^:
M!#;^!1X@F"J4"\M]#7!?M8^,SXG6.RM)/,V%%PA]"/2NPMO%UGX-^#USIA;;
M.-N.?0&O'/@WIVK?%?Q).EP_G*+IMHQG@&MK]60?1G[-/A/'@Z"]ECPWR_>^
ME>QQ*-@7/08KGOAOX</ASPRM@4VD8X_"MV!9<\FN>4KF@^9 !@4EJNWJ:?C/
M!%)*-A^6N:4F6MB6BD3.T9I:M.Z&%%%%, HHHH **** "BBB@ HHHJ'N 444
M58!2,=HS2TC$ <T 59[;SCYI/3FHIM1%HN'/ [FIKF7RT:7/RJ,FO-_B]\8O
M#WA?3"99-K*IS\^*N-FP.RU/6M,AM'O9+^)609 ,@KPSXX?M8W/@:TD&G,TI
M13@1+NKR[Q9\7O%/C34!;^%]1VQRMC')_K4^B? 'X@>+2+G7_P!['+R/W1Z?
MG6B5@.)U']L#Q=XQOUMQI=YB0]1;M_A5B\U#Q)JUN+DV5V"XS]QJ^COAQ^RY
MX2TVW635-&RZ@<X _I7I%E\(?A\L*P_V3]T8ZC_"ANP'PM;S^)5OUMS8WF#W
MV-6Y=?$'Q-\/XEN8+"[?@-\L;&OLN3X1?#<2X&CC?V.1_A4=_P# WP'J4)6Z
MT?<-IQT_PI*28'RK\.?VX?$5QK\7AZ]L+F-&ZM) 0/SKZ?\  WQ2L-5@CE:^
MCRZ D%AU(KQKXJ?LMQQ74E[X3T[RY!G8VW->=:7H?Q7^'ET#K5_A%DX'ED<9
M^M*5F!]PV>J07<0D293GT-3[P_((_"OG[P%\>M.M;&.RU*YS*.OSUZ=X5^*6
MBZJHV29R/[U0UH!V8)!R*=YGM5>TUFSNXP\?0^]/GE5C\AJ0+*2*>":=D'H:
MI()B>#5J .%^8U"W <_3\:93WZ?C3*L"2ANA^E%#=#]* &IU_"G4U.OX4Z@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z&H
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M[M=5X ^)T?B)TB"]<=J .VN;Y(#B5L>M9FJ>*M)LD+?:0#3_ !+:O+#(Z$C
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MF?\ CU8>J:?=7\8#0M]WTKF=7\+7;*0+=_RHV(>YUEQ\7M,B/^OQ_P "J/\
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MM*-@_+4LSQA<%QFLI1=P(4TW34Y2W%3QBW!VJO2HTFM]AS**9!+"93^\%+E
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M1N/%?C0,<6$O_?5-- ?1D7CS3R<+M_.K<'B>VN!D8_.OFRP\5>-&89L).O\
M>KJ]#\3>+& W64GYT[H#VJY\1V]NI8XX'K7/:Q\2[*SR&8<>]8VEW.K:C;,;
MN!@=O>N9\6:%J\X;R+1FIV3 Z"X^,NGH^T2*/^!59TWXMV$S\.OYUXOJGAGQ
M6L_[O2I#S6CX8\/^*#< 3:;(!FC0#V:X^)EF8R0XZ>M<EXL^,=MIT9=IAT_O
M5>T'P1<7D'^E6Y&1W%3ZM\$=*UB+9/&O([K19 >8W/[1-LMZ(UN@!GINKL?
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MXC\U5&0,Y?XG0L/"UZ^>D9KY^_9DN9)?BM?QER0+X?R%?07Q8N%C\'WY+?\
M+(XKYH_91U$R_&+449N/[0'\EKIYO=,SZ\DRK9S3H95D.*=*JNA*U!:HR2$X
M[UFV YD?SL@\>E2XR,&E.#SWI*CF1:5A/+3^[2@ =!111S7&%(44]12T55V
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M445HE8 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'^Z:6B@".BG[%]*-B^E #
M**?L7THV+Z4 ,J2D"J.<4M)JX!1114\K ****.5@%%%%6 4444 %%%% !111
M0 4444 %%%% !1114-6 *:_0&G4C]/QI , R<4RY_=C-2+U'UJ.]!*8'I51V
M(8Z([XNM1ES&<FI+4?N]IJ'476*-F/89K2+$9OB[Q'%HFC/?%U^7UKYL^+?C
MV?QQ>B"UD?\ UH7Y,CO[5VWQG\;7$UM+I%G+^\.<#-<K\ O %[KEVTVN0[AY
MC,./<UM"R14=CHO@[\+-TD6K3PY)Q]^O=K"SBL(@D<2K\N/E%4-#T2RTJQ6"
M!,%:T(Q(:SEJRB20@#<*=;MN%(@W-M-))(D+;1ZUSR5P)Z*1&W*#FEK, HHH
MJX[ %%%%6P"BBBI **,@=31D>HJH[@%(_P!VER#T-1\EN:HA[B,N[O2)'ALF
MI=H]*9<'8FX"@1#=2[9 !W-<;\9]:&B: +DM@E":Z^0@Q-,_\(S7C7[2_B5)
MO#YM;63YE0C&:J-[C6YR/AS2_P#A,-;@U/;NP^<U]%>%]-6RTJWC Z1CBO'/
MV9]%:^T1+FY3)" YQ7N,"B&W5!V'%:3;:+%DD E %/E3>H^E0E6:0-4Z'H&K
M![ *B[4(]J;3S]TX]*94 /3[HI:1/NBEH6X"/]TTD?>E89&*$!'6M %HHHH
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M#BLWL *<H:;3A]RFU #T^Z*6D3[HI:I( HHHJ@"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@!&;;VI>M-?K^%.7H/I0 4TN>PIU1T /!R,TM(
MG3\:4YQQ2LA/8C:%2^[(_.HK\D*%'I2O(P?%+(F]15)7(*]P?*L6E)Z5X7^T
M'(-4=49NC+_.O<->F6VTB1B<8KYR^-'B")KH*6_Y:#O[UI'<#UGX-:6L'AJ.
M0*.W/X5W8=G4 UROP4>*X\%QR >G\JZU$YH;*CL+'%@[C4P!<9-(B<>U/K)E
M#1& <T,@8YIU%*R8 !@8%%%%0 4445<=@"C(Z9HJ-D??G/%,![' S4+W#@XQ
M4XZ8--:-,9Q0 R-M_P![BG,% X-1N"/N\4T"1NK4 2GD=:A\O,F<5-$A49>H
M_M4)D\L=:I6(>XCR&'@#ZUE>*]=MM+L#.]RJGGJ:U-0FCM[.29_X4)ZU\^_&
M[XASWD4NEZ=<[77(ZU0CD?C-XDN?$'BN&&T#2*\^"5Y'>O4O@?\ #Y=*$.KM
M%AGP3D5POP/\ 7WB2*+4-60RL@#9(KZ-T+2[73M-BMXXL%5I/8:W+4D(DDWU
M,HVJ!3*DK.Z+%$>3N-.*@C%"?=%+2;5@   8I-@]32T5( !C@4445HM@"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBD+ =: %H/ S2;QZ&FM*#\M #99F7H*$D9^"#2B(DY-/"JHZ4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#FFP_=I]";N 44458!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I'Z?C110 RG)U_"BB@
M!U(_3\:** &KU'UI]%%  W0_2HZ** %3[PI]%% !37Z_A110 ZBBB@".BBB@
M HHHH)EL.3K^%.HHH)"BBB@<=PHHHK-[EA1110 4444+< HHHK0 HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
:HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>gmab_20250508xex99d1005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1005.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" %3 W4# 2(  A$! Q$!_\0
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M"I'6GT$ \&@".BG,@QQ3:M; *O4?6JM_:O<?=J6Z=XX2\8YJKI5Q<S2'ST(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MCY2:XRA7)XJ13A2:;(!M_"G#[A^M "JX;I2U'"".M24 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444F[ %%%([;14 *3@5'4$CS>:,=*E,JJ/F- #J*KAY6
MF&W[M6U8%?E]*I18KH&.!UJ)SQBF.TWF8[51UKQ#I^BH7OIMH49-:Q5R'J6V
M/)-()!GC-<)JO[3'PFTF9K2^UO;(O4<?XUH^%/C%X$\9*)-"U'S ?I_C56 [
M",DX_6IDZ5!:75M<1AXFR#TI[[@?EZ9J&KLI.Q+13 S8ZTY3D<U)0M%%%)[
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HIKL<X!I,GU-
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MOLR-T&172Z1J<&J*) V5894^U2XZ :%O<%TZ5+34\I1A:<"#TJ6@'(W8TZF
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M.*2)"IS4E #8^].HP!T%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MU752H786^9L=*Z86ZD-F)\=?C/H?PY\'7^LS:W%%-;QY5"^#FOQ*_P""G?\
MP4>\:?&>._\ !FB-<WJVP:%5B?/K[^]>C?\ !2?_ (*"CQ-XKG\">%];\IKV
M1T14DSZUX;^P1^P7\2OC+\2[C7O%7G7MK>WH=%>+C:0*Z.:R,GJ>B_\ !.']
M@E?C)=:?\1O$FC^5/&5/[Z/GGFOV>^"WP0TWX8Z#91603,<"C"CVKF?V4?V:
M]%^$'@U-*;1EBD55 ^7&,5[6I2WC$>WA1@"L)3 6&=\;<'%)<Y&-HJ13&Z9
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MG((X--HIN&#Y%:Q2'RB33-%]VE28.O)ILL1DZ5$\,D8SGBE)7)V)984FY)I
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MD<UY<I:'3&(K2L[%1TJ6) %VL*9% 4.XTLTA7D5B[LV2T$\JV@;S"U03?O9
MZ<C-1RNUV?+#'BIHHQ9VK,YZ#J:<8@QE_J6GV<(-_-M '6OS"_X*G?MO2^$=
M+U3P-X;U?,TP98XO,QG&:^LOVY?VE[+X(>%#JDMW&H\AFY8>]?A]\<_$>J_M
M2_M/Z=]CU*5H;BX?*+(=IR17;2IV,)R.$_9$^"OQ4_:L^+>H)XST(R6TNIMY
M;9+97(]J_>W]A3]DWPQ\*OAI%";413Q[,+Y>.@-><?\ !.O]A+1/@QIFG>*-
M1TZV)N(EF+2;><BOLB[U#1O#EFSPW5M&B_PK(H'\ZTFD]"%)W+<\UU:0".%?
MEC7'X"OG'_@H%\==!\'_  .U!AJ>RZ3=\O\ P$^]=;\6/VO/#?P_LI_-OK0[
M8FZN#VK\=?\ @IM_P4(@\8?VCX;L=4&V3=A8VXKHH4G)ZJQ+DD?#W[67Q;U'
MXR^.P+R<R1IJZY.[/ E']*_2;_@FKXW^ ?PM\*:;KNN>(5@ND*[AY8[ >]?C
M?I7BV[N=:EF:&64R73$'83U:OH;X4>#/B%\1;*+2=&U'4K<-C B9EZUV3BN4
M5[G['?M>?\%4O"FAVKVWPZ\6"9A&%C DQDX]B:_/+XE?MS_MA?&_Q+<>']"T
MY[FT8_NR+MN<Y[;:U_@E_P $@_C#\5;JVOKWQ#J\J[PQ$ETW3\:_1O\ 8_\
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M >7K'_?F7_"H;C]K'XA2' BUGK_SRE_PK>.%35BU.Q_02G[8_P !U?(\1_\
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M'Q.\3Q:?:W#3?Z?#&0AST=17U;_P22_98A&EZ9X_FLAO.SEEY]:Z-H@?H/\
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MCNHOAWXB\LD$+^^W?RQ7Y<?M6_M?_M->-;NZ6'Q;NM'SM7:W_P 57VU\*_\
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M>U>M"/+&[#DU/4OV/?\ @FC^TY\2KRUO_&]S+=Q/*LAW6Q^[G/<U^QG[*?[
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MXML/ VB_VIJ@!49SN..E5_''Q/\ "?@O3KB;5=<BMS'$Q&\^U?F7_P %+O\
M@IY;>%_"EYI'A+Q*+B:/?B.*7GI6%G+5B>Y6_P""J7_!3_PWX%N+WPQI&J)!
M)<%HH]LO<U^7WP(\$?%3]K/X^WCW&M3W=E=3+Y<97(P2:Q]*T[XG?MT^-['6
M=7\-W4Z->!V=_F &:_9+_@FK_P $X/#/POT_3?%LME'%<L%+J8L'C\*N,>6(
MTD>M_P#!.3]B+PM\'/!RP:_X:0SI;J%9TP0017V/9V-O96,=G8PA$084#M3=
M*T2VTR/RXL=,<5;VF/E:R<KCLAL*(G$JY--ODLIDQ<Q!AZ&GE2_)!IC0B;B0
MXK)O4.5%1--@!WVL(51Z5;M593@FIHXEBA*H<TR+ 8Y]:/:!RHJZCI5OJ$;0
M7L0>-NJFO ?VG?V,?AM\90#-X.AF;Y<G;GIBOH625F?9CY?6F3M]FYBYSZ4*
MJ%D?+7PD_8 ^'7@C4HKN#P9#&4QSLKZ6\+>"M&\,P+'IM@L05,84>U:+7<WD
M[L'-%G=LX(FX^M#FV"5B8NB_*:8T8E;*#O3"6DD/IZU/$$B&,CI4\VHQMT_D
MP U'93>;$>>U/F G!1NGO3K:VCA7"$&F R**42DD\58" #FER/44=10!#-*J
M#IBEB_>#)HE@#BG0H$7 H 4E(N<56FC,ARIJQ*H8<TW8$3<*F=[: B*VAD7.
M3FJQMY_MF0YQZ5=28*V'./K2.1C>G-9IR'S"L40#S!2#RL[@M,7?,/F6HE:3
MS]A7CUJDI,.9EU"C\@4[@"HTPGW:?PPJN45Q"ZGC%-& >12LN*2G9 *Q!.0*
M9(4"Y<9%.I'0.,&JCHQH:NUHR$&*B6$ALM4P"QC J*61^W-5SI%63)N%3C\*
MC3<YP#3X09(^:55V'(-1=-D (,CE:4*%[8IGFR;\8.*>23UH2 ****=F H0D
M9I#'SRM*'(XI=Y]!42=D"8CQY7 I$4HA+>E.$@_BI)2&B;!SQ41D[AN0Q2P2
MRE,5\7_\%*O&,NC?#378(YRH\EAC-?8UB&%TV1WKX"_X*Q7LMO\ #W7R@)Q$
MU=E)^\0]#^=_XL7=QXY^+>NVGF;_ /B8,,?@*_H0_P""(7@&UT_]G^"26T&X
M1P\X]C7X)?LO^$E^)?[1^OZ??("HUHKR,]EK^F'_ ()?_#NQ\(_!)+2 *,)'
MP![&MZCLB5%'U'9QHMI'&!P$ J+S=MQM!_*IHOD 4]J7[)&S>;D5QR&D.8)*
M!D=J:L"(=^VDF)C_ -6,_2A)&888<5#5RTK#F E.1BG%@J[2*8[>6/W?-5VE
ME+8VFG&.I+W.'^.OPQT;QWX*U:"[TU97ELW"DCOBOYT?^"H?["GB;P#XWUCQ
MSHUJ]NLC,598O3-?TS2Q&ZM9+:0<.I!KYO\ VMOV&?!/QQ\-RV>IF!C(&R&C
MSU_"NB,G'01_*IX!^+'Q:\-6P\*1>*KA%N5\HIZ_YQ7U_P#\$W/V,?%_Q6^)
M?]L:_')=+<SHQWQ]>E?HM:?\$$OA%)KMMJ3VMIF.7<";<_X5]D_LL?\ !/SP
M'\!WM[K21 &CP?DC(Z?A6LJGND?:.O\ V+O@)I_P<\&C2!I@B(A51\N.E>Y7
MJ8@"H, "EL["&UCQ&PP*D<+*-I-<DYIEA9?+#DFB5]YPM,#A!L!IZ*!S4EH$
M;;P?6I00PJ)P,9I48]:33&/*<\4;#ZBG Y&:*:T"XW8?44A0@9I](Y(&!WH
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MK>3(=N1(F1U^E?T#>-?V?/!GC!Q+J2#.0?\ 5@U:\*?!/P=X2=)-/497&/D
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M4 %%%% !1110 4444 %%%% ",NX4A3 SFG44 1U&95W[0HJ?:OI44@B!XZT
M-E@+#@U"^GR/R&/YU/&^/]93B^WYATIW8$,,9M>&Y^M2>2LGS #)I25E4\\X
MJI"UTMV01\M3S:@6TC,?!IU/^5A1L7TI@-5L<&GTQ@ >* S#C- #Z*13D<TM
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%!X&: $9=PQ35S'QBD5B7P33V
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M-FAGYXIP((I%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %0FV)DWY_6IJ*EW BF@,F,&E\G]WLJ2BE=@10VYCZFGM&I&,"
MG44@$1=HZTM%%7'8!&7=2>7[TZBF @&!BEHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ H/(Q110 T1X;-.HHH 0* <TI&1BBB@!@C.<YIC6Q,F_/ZU-10!'
M)#O  ].U.C38N*=10!'+#OZ4^-=B[:6B@ P!T%%%% !1110 4444 %%%% !1
M110 4444FDP"D9=U+14 -\OWH\OWIU%5%@07?[M,]:\R_:%\&KXM^%FO6?D@
MF:P=1Q]*]/==Q^<UG^(+"UU#1[C3W7(EC*D5M%V,S^6?]N;]GK4_@-\:-?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%3+8 HHHI+< HHHJ
MP"F/]XT44 )1110 Z/O3J** &R=J<O0?2BB@ IC=3]:** ')T_&EHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>gmab_20250508xex99d1006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  V % # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z2EIK4
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D6Z'ZT]$$:A5 "@8  P ***0#J*** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>gmab_20250508xex99d1007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  H (H# 2(  A$! Q$!_\0
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M/:SH$T5S<S-EHK2ZA*RQRD'EX6P&&>2K$<,#CG8/B)H'B'4+?[3X/:;Q5-&
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E&.()\D=Y"568@XP#)&\;$>L1/5C7HIHHK2?1D1ZCJ***S+/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>gmab_20250508xex99d1008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  J ,P# 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z**0G%
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M ,O)?B3%2LTM"#P9X\N/$6M7NC3Z<4NM,MH'O;R$_P"C+<2#<85R=VY1@D$
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J@HHHH 3 I:** $P*6BB@!*6BB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>gmab_20250508xex99d1009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  O *,# 2(  A$! Q$!_\0
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MUO7=S'96TMQ,XCBB0N[L<  #))KA=%AEGNK07A!>>:34KL'/!7&P<]E)0?\
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&BEHI ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>gmab_20250508xex99d1010.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  X '0# 2(  A$! Q$!_\0
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M<TY)RO$WBFEJ>,^&I-0U4^%O!UW:SK?^'+SS=1N3;LL(@MPRVS*Y&UC+F)@
M20!)G!%>R@ BC;S2YXJ93YM@C&PM%%%26%%%% !1110 4444 -/2O+O@MX7G
ML]+U^XUG3O)O9O$NH74"7,)W1()3'$R%L\%%!##C#8'%%%:)M0:1FU>2/4Z*
:**S- HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>gmab_20250508xex99d1011.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1011.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $I!#8# 2(  A$! Q$!_\0
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MZ"P,&TKMXQ[5[!'BW&T>E2T@"Z8+P*B@)-#EI&]C4L"*HYJ0)%3(SFBG;U'
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M-M)+J)U,B#.]2/YUZC+>&Q0A4SCVKC_ /@./PND<=K!L"8 XKM5CA>/;,.:
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MBGE%"DY_6EE4(@(%1;))(R5/;TH ="1*Y7(ZTV1RDPC%,L[:=9B2>]321[9
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M]<Y&*C<L6R!48M;@G(JQ$4A7$HR: (O,?'(J2(KG=D4LLL#C""JYAF8Y4\4
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MM(";QW\1_&GQ\^)SZ4VE7,UM/G]YU')^M?1?[.W['7ASPGI;W>MK#;,\#/\
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MP!"R>]=1^U)^TQX<\!>!+^QG=%F4<,7P>AK\</VH?VF=6^)7B:6VT766 %Z
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M7X3>'_A_X8M;&+18HIHE^9@O-.^@%SX3?!S1OACI9L-,V;0@7Y5Q786H$,N
M>E.MF$D)9?2HD;=(0*0%V3$@)KEO'GA>+Q!:^1,O\..E=1&I5,FHV$=P=A4&
M@#XK^(_[&6C:]\0(M>GM$PCDEBE=%KD7A[X!:,D]E?1QLL&<#CM7MGQA^)OA
M?P/HES<7EE#OC'WF/_UZ_.K]KC]IZW^(\LVDZ!>B-D;9^Z;WH \_^-OC;Q7\
M8_BP/#D5G+-:W&[+YR.H_P :^I?V&/V$O#WA4KK&HVB0M)F4[H^YYKFOV,_V
M;;CQ/=6GC'4;,S[<9=U]>?Z5]I_$#Q?X=^#_ (>C5;*&(I: 'M_#0!PWQI^(
M%A\,O!,VBZ=>+B/. I]J^-;O5]:^,FOH8[=YE%V,G.> U7OCK^T(GQ-\:3>$
M=,O</+G 1O?%>Q_L,?L^7FC#[7K]NT^_<X,J^N2*; ]U_9T^$.G:'X/M=0=5
M6?NN.>@KUY+N6#$;#CI5#P]I(TBW6"--J+T4=*OWKK,<H,?2D Z^EQ;>9%RW
MI4&G2W$D1\Y2#BBW;8_[TY'H:N2RPI;/<(@ 09- '->-_%,?A.S-[--Y8P3D
MFO&M;_; TG3O$,.EMKR*9)-N-]9/[=_QXL?"?@IQ%*L;)&W(-?F'J'Q1\4^/
MOB7I]QINOSJAN<X1N.AH _;+X>_$73O&5M"\5^LA<#H:ZF;$3X6OEW]BJP\0
M0Z=I\^HW\L@9%)WU]03 DY- "L^\8S0!C@4R!69L9[U*T149- #:*1&WG I&
MD"G;0 ZBE0;^E(>#B@!Z1HZ$L:I^0);DQMTJRP8< XIH&QMY% $@TZUB&-XJ
MM=7%AI -Q=7"HOJ:+J21CO5C@=:\@_:Q^)R^#/!)NEGV$(QSG% '2^+/VA_
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MV[[_ )E?BOCGX:1OXE\4>=*N2]YDY_WJ]L\0?L[>-/B#X%N/'UQ>W$J( 2Q
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MMQX9T/6VMOM,[QJL;^Q_PH Z+]K?_@J]K>@WEYI'A/6GN# Q51%+7YN_%O\
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M\>: (H9$C^^<4K%"<J<U%?VK@_*31;QM&,L?SH >1*3G;4FV,H 3S3DG3;C
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M*W_!0WXY6M[XK&E:=?;A-<;,9ZUQW[(GP/GU3QLOB:2RR)W5MV*\1\2ZC?\
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M0-&NA=2:#:D#L8E-.Z _(7X4?LZ_M*?$"3?XB\*\2,2W[QCU_P" U]&? O\
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MHHIIV ****L HHHH ****T6P!11168!1110 57N0D ,QJQ4&MPC^S6;=S]:
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M-"&G>5=AI>P@<'^5 'M'[:O[7FI3W36GA/4L[W5/O^IQVKSO]F;X:>.?B/\
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M@>E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(PR,4M
M% #-C>E*JD')IU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4$EK*&\T5/3VE+1^6: .3\:^"M/\:6TD&HVWFAHRN,>U?+'Q6_X)O?#
M/Q3K<NMOX0#3/GY\#_"OM"V3R<D?6FO>O(_E%>/I0!^?,/\ P2W\ 7<H,_@\
M$!O[H_PKN?!'_!,[X3:-,LS># ",9.!_A7V:]P;491<_05!#K5P\_EF,X^E
M'E/P^_9,^%OA1$,7AL(5Z=/\*]*B\+Z/HM@L&D6OEE1Q6K+.9.U,C&]\$4 0
M:7%=>7NG;.!47B72[;6[3[+)'NP,5HL_E#8!UJ)5,+^8.M 'P?\ MG?L*:C\
M1[FYU;0=)_T@%C&_EYP:^$M7_P""<W[8-KKMR-)NV2 2GRE^QMP/^^J_>+[3
MO7:R9SUR*C^PV^=_EKD_[- 'Y$? ?_@F)\1K^\M[OXD::;A@1O)@(S^>:^Z?
M@9^PE\(_ L$$LWA,)(%!<\#G\J^CQ<"W^5(Q^5*UP9Q@C% &)HGP^\,>'(!#
MH]AY:CH,UK(DR#:IX P*<&93BI(WW#F@#D_BAX4N/$?AV6SC3);VK\X_VV?^
M">'C[XK:@9M$T\L/.5C^X)XR*_4AKAB=F.*CDN5@X* Y]15(#\@?@C_P2CU^
MPUV,^*-!,D8QN!@Q7W#\%/\ @GW\'_"]O')J'@\;T4'/'7\J^G/+ 'VA8QGV
M%3VLS3QD.N.*&V!R7A?X3_#GPQ$EMH^CB,ITY'^%;VMZ=;MH%U9VD>&>$A:D
M:P6*X,H'6I223DTU8#X'_:P_9!\<_$N6Z6UMRZ/G:/*)KR_X7?\ !*V)[57\
M2^&_,? Y\K%?J3'$DQVLH/U%/ED6SC(11QZ"AOL!^4?[4W_!-RQ\->$$F\(>
M'O(G\@DL(\\Y/M7RE+K_ ,3O@-.-,GU0PQH<,NTCI^-?NQX_T6/QI:FRNXP%
M Q\PK\J_^"A/P3TU?%D]M&(_F=^ *$P/E_XA_M9W/C&S73M3U7S=B[2-U>F?
M#3]K#X.Z!X#:RE4#4L+L?SAZ'/&*\ A_99O-2U69M.TIYBTA^XN:[?X6?\$[
M-7\7>+;:._\ #DRQO]YGCX'(I@=5=^(_B%^T5??8_"NI%XS+M5=I;C/UKZ0^
M'G_!.C4O%/P\%UK.B^;=-CY_*]J]Y_8K_P"";7AWX3QVU^MM"K,H<_+WK[2\
M,^&+7PUIHTZ%5P/04 ?D5JG_  2?\6S:K%/8:(0BW"L?W!Z;@:^LO"'[+ME\
M)_A!"&TOR[V+J^W'05]I-<-:'$<6<]\5Q?Q_M5F\ RSQJ"_S?*.O2E>S _)K
M]K+Q]-H>MJ-9N,[)QCG&,&N-N?CO;Z_X831/#MWMN1G^+/7%5O\ @HEIGB6]
M\2^59:3/(&N@/D7WJM^Q9^S#J_C'QG"^J:+*B/LR9$XZTP/>?V-/@WXS\=SV
MNI:]F;:P8GRS7W+\8/@]GX,6FG6-KMF2%L_+6Y^S=^SU8?#33$BAA1<1@<"O
M7]4T*#6].72Y=NU1C!I-@?A?^U79^,?AUXRC5+GRREP<?*1V/O7-Z#\;_C?X
MCA31_#/B,JZ#:!L)_K7ZB?M,_P#!.CPS\7?$8O[J* YF+$E?8UA?"+_@DKX'
M\&ZM_:<:V@+.#P*3>@'QE\$/V9/VF?B1XKLO$&MZ@T\*N&D/V=NGYU^GG[.?
MP.N/!NCV)U"UQ*L8\P[<<UWOPU^$NF_#'3/[.LDC(  ^45UT&HR+A-F,>U2!
MS>I?"7P#J%S]MU720\H_BR/\*O:-X.\):2W_ !);$1D>];,EJMXNYSU]:ABL
M%L&W)@]^* )8D*GR1T]*+B%8!E!S2[B!YN.12QO]L_UG;UH 2."!%^T.OXU#
M>2M=_);GCH13IIF8_9<'%26EI':\@B@"C;^$M$CG^W26O[T]6JW)'"I_=C J
M2XD.W IMK")$);CZT .2:U0#:N&^M0S%KAP.QZT+9H9C4WE" X!% &7XA\$>
M%==M!'KMB)5(Y!(_PK#M_@E\*4CS#H( 'N/\*ZZ[07D?E-3+?2XXX2F1TH Y
MS3OA+\-5E(MM& .?4?X5NP:-:Z)";?3(MB>E.ALA82F6/GG-6A(9T(;O0!#I
MDA,I$A[U//#E_, X%,AM4C?=GK27-VZ*8QG% $4TZD[3]*L"V22VWQK\WK5:
MTM_M+$R<<]ZG^U/:_NDS@>E #;2.>(D3G-*R;FXH-T\WW@:?&!U- #0LB<*:
M00RNW/\ *GW$I4_+2173 ]#^- #EB>-<&HB65OF-/GNW+8 I!\_7O0 J%<<T
M[*>WY4GE@#@TQC@9H DVJ>13&C)[4@E(I?./O0 T1L#DTZCS2>.:* "BBB@!
M0I/(%&UO2G*<@4M $=%!ZFB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *38N<XYI:* $958884T6\2G<%YI]% !@=,4  <BBB@ )SR:" >
MM%%   !T%+DXQFDHH 0J#R12@ =!110 $ G)%%%% #4&Z3%,O[&:4AH^W-*[
MM'EE'-8?BGQE/HMK*[L5VQD]?:@#1O\ Q1I^AVG^F <=<FJ6F?$+1]6.+4 #
M/]ZOE7XM?M-7@UB;28[MCCL&KT']E+6I?&=GY]R2?E)^:@#Z#6]BN( ZCK3$
MR1BEBL8;>T&UA3K= PW>E #HPT/SMTJ.XF6:3'O4L[JZ;,U'';IMWDCB@"GJ
MVEF:$>0N#CL*_.S]N3X8ZS=^-)-4?<8D=BWRU^CQN7)V*"<>E?)W[96GQRV-
M[/)C(!ZT ?,W['VE?#^3Q2]MXCTB.;9<88,:_03X7?"OX0W&GKJ.G>&(5<8V
ML#7YL?LWR-_PL&[0\ 7I_I7Z9? :VSX/64#H%_E0!WMIHVFV2!-/MP@48 %1
M2P2)+N)XJ2"[,9P33Y)#*N: " 02*=R9.*Y?X@>';G6]->T7)0Y^7%=)#N0_
MC5KR8I8_G8?C0!\9_%;]BRV\=ZJEU-HPDQ,&.4]Z].^!O[+/AOP$89UT)4=,
M9.VO>TMH(?NN*C:X8-M7/X4 +%9VMG'LAB"\8JNF]9R0>]78%\X$R<<=Z2:V
MA0;E89H 9]FM+D;IHP3V)IJVR0-E%P*9YC(V%J4NS*,B@!&^;[W-)Y:?W:6B
M@!02!@4A);K110 8&,4+\GW>*** $VC.['-.W-ZTE%  1GK0I*\*<444 &3G
M-!)/4T44 %+N;UI**  _-UH QP*** %!(Z&FE5;J*6B@ 4!#E.*" QR1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1R %CU[U*/,0Y4<U,DR;<S-AO2@!DD\=C&'=1TKXB_;3^,.G6NKSZ&2FZ0L
M,U]C>*]6@T^W\RYDVKC@U^:7[:GBG2;SXGB&*Z!+2OQ0!%^RYX/F\1^,IKBW
M4_O+K(P/I7Z0?!S1GT;PD+:4'.%Z_2OB[_@GQX>@OO$:R2KPTP(XK[STRU2Q
MMOL\72@ ))8A6[U/';NR9)--$:@YJ19648H 01^4<D4LN2G!I&8MUI,G&,T
M%O*L&=XS]:D-Q&1D*.:B*ANM&Q: )//4# Q4,R22\*QIVU?2E!QR* (X86B/
MSG./6IVN(W78H'%,//6D" '(H 6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>gmab_20250508xex99d1012.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1012.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" $> F$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]_****QY7
M<!&&1BF$8X-24C $9Q4N(#*-X48HIC@YSBFH@/'S=*C-XA?R1C-&YATJ.06T
M)\UW -:*($K3K!PQIDFHQA>HK+UCQ+I%K [7%VJD*<9KR7Q7\6KZ._DM=+D+
MXZ!6K>,+@>MZIXPLM-R'QT[FN5UOXP:3HV;B8)CKR:\JG\4^-M8F4M8R$$\G
M=5V]\+ZGK-@!=VAR1SFMHQ40._TCX^:#JTBI$(_F..&KLM)\1V]]&LT>,,/6
MOG&3P3K>C?O;&P8[.1BEMOB)XZT%S'=6<B1KT):G:+ ^HHF$X\Q:E' Q7EOP
MR^+-OJ=JL5_=@2,!A2:](M[QYX%F3D,,@UE*+N!8,?S[LU*6" 9J%')^\*EP
M'%9.]P$,@88'\Z(T*THC -*6 ZFLI( R,XI:0 'YA2TX*P!1115@%%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HI&) XH4Y&34\R 6D;H: 3GYJ;(6(^7\*$P$JGK=\EA8/
M<,P&/6K D,0)E.*\Q^+_ ,0(8-,FTVQG_?<X&:N.X'+?%7Q@=3N!#;MG+A?E
M^M;/PW^'CW/EZRZ=<<FN.^"&B:CXIOI)/$461YK%>_<XKW[1M)BTVP6"V3 '
MM6O,D!:L+9+5 A4=,=*M,0JY%0PG9Q+4AW/P.E2VF[@+$2XW>U#?.=@%.A3:
M*>$4'-8SE[P#8XBB[2:C>TW'(XJ<D#J:1G Z528%*]B5[5K9QG<,8->-_&[P
M.([-KBVB"EE))48KVQD1CEJY?XCZ=:W=CLF'&VMH6 XKX0O)IM@D,LA)P.IK
MU6SOUEB48[5XMINLQ:9XABL4?"D]*]DT6:TGLXFC.24%5-*X%Y<-A@*=),(^
M *:Q"KD4R']Z<-6+5]0)T;<N:6HURK8 J2I **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG4B=*6D 4444 %%%% !1110 4444 %%%% !113&8YZT /HIJ$GK3J "BBB@
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ME(.:U 7>?04*^3@TVE3[PH ?1110 4444 %%%%)[ %%%%1=@%%%%:( HHHH
M**0 @Y)I: "BBBH;=P"BBBFF 44C D<&E'3FJ ****F0!1116=W< HHHK17
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M/I=HK.5R, U1L=031;=[,?*7!45>^&WA"?6/$C7-T"\;,, BO032CJ-;&_\
M!_X>#7?#\EYJL.QUA!PX^E<Y\6=/MO"]N[V[C(!Z5[]::1;:%H\T4%N(QY>,
M"OGC]H:62XMY4C8C@UP2;G)C/0OV>=6_M#0UD9L_(*]?MI \0QZ5X3^S''-'
MX>568_<'6O:XKI;6%6D/:I<6P3LSS_XJSF&&5FX49R37F?@OQCING:C*3?("
M'/&:[;X]>)+:V\-W<RX# <'-?*GPZ;7O'WB>XMM+OI!MN2,)SWKT:2M307N>
ML^(/BQXO@\3 V%C.]OS^\4\=:]:^"_Q'OM<VK=%@>X)KG8O"^F^'OAU)+JEF
MKW"X_>..>AK ^ _BB"?4Y8HB!B=P,'W-<U>-P/IRRN/M$(?-35G>'7:>P63-
M:->7423 ****M; %%%%, HHHK&0!102 ,FF,<FJBFT ^HY3O^4]**S-;\16V
MD6S32X^7U-:Q38&A#;Q1DLI&:9]H?S?+ XKD]%^*.GZG.T497AB.#7464ZW4
M0N5'%$H6W MF,$9I%DPVVD%PI&!351M^^HY0)Z1AE>*%8-2U0#53/)I0H'2E
MHI-V ****A/4 HHHK0 HHHI/8 HHHJ "BBBK6P!110>!FF TN>PHWGT%,+ '
M%*"",B@!RODX-.J.@''(J6K@244@8-2TTK %%%%, HIC-G@4E)JX$E%1T5/(
M@)**CHJP)**CIR=: '44446 *1^GXTM(PR,4 "?=%+0!@8HH **** "BBB@"
M"X#.OK535Y/)T:7)YVUH@JW&*RO%BF+1IY<\!:N-KV,SYQ^-T;:MYL3C(&17
MKGP$M5L/!( XP%_E7E7BITUO4)K9!DAR.*]>^'L?]E>"6![!?Y&NF2M%%1W,
M+XR>*38P[%DQD8ZUS/P]\*PZGKT6ME<GUQ[UG_%Z[EUN<Q0R'A@./K7I'P;\
M/&+0HY73)XY-.=DB3T:V*I;1IGH@'Z4R8X^9>M!!C4 GM2-E%\P]*Y4K 1B1
MW0^9Z5YS\=]=.D>&WG9\ ;N?PKT2203(60=!VKPW]KC6"G@>2")\,-_(^@KI
MHI.0WL>2^'?$3^)M0B,;[P9.3FOI#X;^'+>STR&\C'SD<\5\O_LH>'+K7+9+
MF1F?:,\U]>>"X1:6<=NZ_=K>I-)%K8V[I#/ILHE&"4KPOXM>'8[T2@IGKVKW
MK4RHT^5QQA*\;\;:E!+<RQ,JG!KDAJQ,VO@5X?2QT, )C""O13!%(@27@>]<
MO\*&C?1]J*!\HZ5M>)-3&D0>:YQQFK2<I6%='@_[0VN:?^_T?[0,OD;:Y']D
M3P+96_B::[E4 /<,0<5SGQJU2ZU?XD(D=PVPLWR@^XKU_P#9Z\/-;-',J[2>
M<BO1M:G9B3UT.W^+^CQQ^"+E;<9],#V->"_ :*\M-;FS&0/M+_\ H1KZ0^(T
M0_X1">*09/O]#7DGP7\.K>:K,T4>/W[G@>YKE>J+/??!DLITA"PQ6W69X>A^
MR6"P$<BM.O,K;@%%%%*+N@"BBBJ **1W"#)H1PXR*S 'Z?C3*69P@YIJL&&:
MTB@%;H?I7F/Q>U&\@TR?R5)_&O1+[4H[-26QT[UY3\2O%MG<K)8;5);-=5*%
MV!YI\,]>U635G66-@///?WKZ2\(S23:$KMU]*\,^'&@+-?-*L> 9">/K7NGA
M<>18+ :*T +]NKD_,O>K0P$QFD7:O\--W[CM%<H$D8 Z4ZFHI09/I3!<J7V4
M 2T4 @C(HJ9 %%%!( R:R3LP"B@'(R*"0!DULM4 44 YY%%, HIOF#.*4D#K
M2L@%HI P)Q2TP"ANA^E!..332XQ0!$W4_6DR1T-*/F; KG_$_C:W\.,5F"\>
MM2G=E:6.C'UHKCO"/Q8L/%.I-I\&S<K8.#76/<JC[#BM4AZ$H..12[V]:3/&
M32JI;I4O<E[AO;UH+$\$TC?+UI0I(R*6EQ"44V:01#FF1W(=MO%:6NB_=):*
M1G"]:4'(S4M$O<**CFG6%MIIR.'%9.5A#J <<BE"D]*1_D&334DP%WMZT;V]
M:1?G&10!DXJ@%WMZT;V]:'&P;C4<<PD; H E5SGFG4U5SS3J5[@%%%%, HHH
MH @GDPO[NN=\?75W'X:NG"_P>M;\"$MR<UD?$D*G@^\.!D)5P:3(2N?*\6OW
M;>([E >DY[U[;X=U6\_X025SZ#O[&OGK3;PR>+;Q"#Q<GM7NF@ZO&/!$EMQD
M@?RKU(QO!: CFM$@.OZI(DPSB4_SKW#P-9"QTA8E&!Q7E/PAT4WNKRN5)!F)
M_6O:]*M?LEL(L8KDKNSL(=.SG%3QH)(<-220@\FD$VSY,5QH"#4!'9VDK ]$
M)_2OES]I#Q NK0SZ6DF<9XKZ<\0 RZ7<R*>D+?RKXU\;7#ZU\1[G2=Y;&.,^
MI-=V%6K&]CO/V,/"XM]('F1X_=^E?25GID%M$& YQZ5YI^SAX3.AZ7M9,?N^
MXKU,L"-E9UI>_8I;%37)0FB7)4\^7Q7SGXIO=2FUNX2-,C?QS7O_ (EN_)TZ
M>,]TQ7BTT45SKDQP#F2KHPU)DSO/A U\NDCS$Q\HIGQT\0_V7HX=9,'RCWK;
M\%&+3?#DDQ51M2O'?VA_&RZG926D;X*H0,5M3CSU/0R;LCR?:NO>/8)7YRQ_
MG7U-\+_#UOIMA!(BXS&#G%?-7PVT22\\16]V5)P:^M/"-L$TN%=N,1#/Y5O6
MDE!CA*QR7Q8UF:/2)K:-O7C-<E^S?'=3:A*9%ZS/_,U?^).H"XU=]-W<G/%;
M?P+\/C2Y3*R?>9C^=<DIV@;)W/3K1-B $5<J!5Q@^]3*VX5YU9W8Q:***E %
M%%(S;:IL!) &&*;@H.AIZK@YS22?ZL_2IW A:02G;FC.P;345NI$Q.<\T^](
M2%I<]!6T.P'#?&/Q0OA^R\P2[?DKR*\OY]:?[6GS#US6O^U?XBV:=LBD.=@Z
M&J/PRTEM0\(B]?DC')^E>E2ARQU Z/X3VLS389/XC7K^CVQ2($BO//A;:I#<
M$%1]XUZA;86 $"N>M*P$JJ#UI?+4'=38Y,TZ0_)FN)NP#968G"]*1847YVZT
MD<H[\_6GR@NF10G= .# K\M1;I-W2DC;R>":>9EZE1^5-JX#T)(YI>#Q3%DW
M(6IBS_,1[UFXV E)"BFDECS29W<T]5QR:J+ %&!@TN1ZTC' )J)I-M4!(0F<
MDTN5<8J$ON'%+"2O?-.S >P*TT/(>M.9P1R*:L@!_P :0$@R1S3'VJ<&I <C
M-03H2X.>]3)@. 5>:PO%OABTUBTED=<L1QQ6Z#O7;3'Q&"&&1[U-/<#QSPYX
M>OO"^ORWBP[5,F0:]1T.Y:^M_M,IZ"H]:TJ#4X_+2)5/J!BN.USXFV_@4-ID
MC*3TYYKL4;K0#T2.[B<["_3K4RN3]WI7CVC_ !Q@O+HKD?>]*ZC1_B]:7,ZV
MNY<M2J4W% =WC/+&FF38<9_6J]MJB7<:NI!R,\5+Y9D&[-86U 68I)$S'G -
M><Z_X_33-7:V$^,>]>A3CRK67)_Y9M_*OF+XFZI.GC"5%F;'H#[UU48W=@/>
M?!WB5]?7<DF[CUK1\5:XFB:5]JE?;UYKSCX!ZRT<(69R<J>M=+\;HY;KP87A
M8@G=]T^PI58-.PKB>&OB%8:TP/VK.3ZUVUO*DUJLL1SD5\O?#&:[L+J..:Y?
ME\?,U?2WA8^9HL+L<Y'>N.I!IBYBZLDB]14JL)>]-9-W2B.+RVR6'YTH1"[*
MUUK.GV3^5/-@^E0/K,=SQ:/N/:O._BIX@?3=4+K.0 QZ-3?A1X_36-4-J9 ^
MU\<UUQIOEN',>I6D^^+;,>34H6&,YSUJHJ&=PZG%6&MVV@Y/YUA-607)A(AX
M!IU5D^5MI-61T%91N-.X444C-MK48M%-\SVHH C#QG_5\UB>.H9;KPY<P@9W
M)6G9(P?D_G4'B9PNE3#;GY?2M*;U(6Y\M+X7BT[Q!<W,\> TQ/2M^RUB0+]A
MA;*MVS6%\>/&P\&B:X*!<Y.=M9'PJ\7_ /"5:C"^<[O:O9@O<$>]_!G3&MKC
MS9$QN.:]-&5&1TKF/!.DBRM8Y5 Y0'BNI7#)LKS,0_?;*8BR@C&:&4$9%0R
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M?H0TN.9UW <8KU;X4?"V\M+KS]51I 6S\ZUWEE\,M,TV93$HX_V:Z"WL8[%
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M*G[0'AK4=/,MP\S[22>:^NIK6)HRC=/6N#^)_P -],\36IC*;B5Z;:Z(32V
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MJY!XVT*6/"WF:'3: V86())[&G'!.<"LRT\2:5*V%N*MIJEE)]V8&IE&S M
MHO1:;GG%,697'[OFA=Q?D4<H$R@@<TM .1FBI ****ER ****GF ****I.X!
M2,,C%+15  &!BBBB@ HHHH **** (\ =!33)AL5+L6D,2DYH&-ZTA0$YJ38M
M&Q?2@+C.#3#&2>*FV+1L6A@G8C6,X('I55[,F?>PR#ZU?  X%-=%(SBIL[CN
M<SXL\'QZZI"1*#["N+F^&%]H]R;_ ,V0+Z;J]7" =":CNK.&[C\N5>*VA/E!
M,\*\6V6H7=R(XI9!EL<$UF3?![6]?@ 2ZG&?^FAKW6;P5H\[AWCY!STJU;:!
M8VH B7&/:NF.*C$GJ>6?#WX.R^'41+]#(PXS(<FO4M.T:&TM5$<*J0.PJRMG
M""&Q5D* NVN;$UO:K0"H76.0(R9/KBIUQC@4K6ZLV33P@ Q7GTX.,[L=]")D
MW'.XBA(1GCFI=B^E* !T%=CE="*S.JN5"\FE:)FP<U*T"EMU." =:XU!\]P&
M;,18I($X-2D \&D"@=*[$]+ 1B!A)NS^M/= 1G%.HJ)JX$,K#;M Z4ZWZ?A3
MC&IZBE50HP*SLP&7&=O%0I SMNJRRANM"J%Z5I%,!KOY*#V%(L^_H*>R*XP:
M18D7H*;3; :T18"GHNU<&EH^E9M.X!14;%__ -=.5ACDT<K =12;U]:;YGS?
MTI\C ?13&GC7@FC>3R#3]F^H#Z*B<G&<TB,2>M/V0$U(_2F[V]:0MN[T>S8#
M)9"5\L5'#9!'WRKNSZU+NA#?,>:620,/D-6HM"N9>I:#IE\Q5["(D]R@K)G^
M'^G*"1I\7/\ L"NB=_+;>_2HI=9T]1B22MDI+8.8XFZ^%$$UQYT=JH^@I&^$
M\DJX"GIZUV$FLV/WA)Q31XJTJV!\V;'XUIS32N@35SSS4O@3=W0.W</^!5CR
M?LY:ANR)9!S_ 'Z]0N_B9X8M@1)=?J*H/\6_"1/_ !_=^Q%.-2JRKQ.(M_@%
MJ5LH/GR_]]TZY^#>IK"R+<R\C^_7<#XK>$]N6O1CZBJ]U\6O Z ^;?#\Q5JK
M-/45T>2:C\!]=-TTJWT^">TAI+;X)Z]"03?3_P#?TUZ3<_&7X<J2'U#'XBJ$
M_P ;OAK&W.I?RK5-2Z$6N<O!\+=9ME!-Y/\ ]_#4%]X.U:U!)NYN/]LUUB_'
M'X:RG:-2S^7^-0:A\3_AY=PLT=]D_A5<B;"QP=UIVIPDYO)>/]LU-;:I?6$?
MS7<AQ_M&E\3>._"GS&WN?Y5DQ>)M&OEV139)H=$1MP?$Z72CEIF./6KVD_'Z
M,7BP/(/Q%8^C>%QKA8Q1[LCCBN/\0?#KQ=;Z]NL;3Y.W7UK&4.4#Z:\!?$&'
MQ"J[2IR.U=E"ZS1[@!7B'[/VB>([/ U2''7UKV.R%RA"L.*Y9I 7U7:*6FL2
M *3>WK6+5RUL/HI%)(YI:AQ=AA1114\K ****M1L 44458!1110 4444 %%%
M% !1110 4444 %%%% !2-]TTM% $=%.9.X%)L;TH 2BEV-Z4;&]*S>X"5)2*
MN.2*6@ HHHH **** "BBB@ HHHJH@%%%%4 4444 %%%% !1110 5!)=%'V@?
MI4]0LD9?IS2:N C7>T56FU1$."X%2:A"VPF/TKC?$)U5'80M32 ZN/5()#_K
ME'XBIUN[8C)N$_[[%>37%SXH4GRI._H:HW.H^-5!"2_H:U0'L-S<VOWC=1C'
M^V*HR^+;2V/EFZC./]L5XGJNJ_$ JPBF_0UR=ZWQ3FN6*39';@U5DP/I<>,;
M5XRRW$?3^\*Q-;^*=OI*F03)Q]*\6T6U^)C0[99.2/[IIFN^$/B3J4.(N21_
M=-6HQ0'IQ_:#B\P1AUY/]VFZM^T =-MQ.@W9&<"/->,V7PI^)IG5I(^,_P!P
MUVFA?##Q),BIJL&5QS\IK2$:3>H-NQ%KO[8L^GS$+;/Q_P!.Y_PJA8_MQ7$D
MA0VC]?\ GV/^%:>K_ ;[>Q9;+.?]FL^R_9T\B4L]CQG^Y73R8:Q%V37O[9=W
M+:L4LI?PM3_A7&ZW^V)JL;G;8W'7M:M_A7K6@_ ;0VC"7=AGUX%;H_9O\!3J
M#+I@SCG@?X47P]/8-6>":5^V%JNH3BU:QN!GUM6_PKH)/C!J6KQAA!<#<O:)
MA7K-O^SAX"M;CS8M+P1["MRS^#O@^  ?8NGH!2=6BEL%CYLUG7-7O 9 MSS_
M ++5A-?:TKX/VKKZ-7URWPF\'-'M-D?TJK)\&O"+'*V7Z#_"H5>B^@^4^:-*
MMM7U'$9-R,_[U;,?PEU765Q]HN!D=Y6%?1-C\*O#%HV5M"/P%:4?A30K3Y8X
M/IFDZ]%;(.4^8+C]E_5;D>:+ZXY_Z>6_QK)OOV4-89^+ZY_\"6_QKZZ'AZT/
M"Q\>E!\,6#<M%4>W5[DGR+IW[).K^;DW]SU_Y^F_QKJ]&_9%U%XP#?3].]T?
M\:^D8O#NGPG(CJW!96\(PHQ1]::6@TKGSG+^QM=3)AKR3\;D_P"-7-&_90N-
M,NEW3.<?]-R?ZU]!2HFW"T1VRL-Q%1]9G:['9'%^#/A7'X952X#8'=LUMS>%
M+0MYAM(S[[16Q<1RX&RGQ;1'B3K6;JR:NV)V1EZ;;Q:6<) HY[)6K'<!TW;?
MTIK?9,\COZTX-&5P@K"<DV*PX2>8,TM(@('-.5<\GI21:V')T_&EHHH&%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4445+
MBP"BBBERL HHHHY6 4444<K ****.5@%%%%4E8 HHHI@%%%% !1110 4444
M%1&/]YFI::?O_C0 K(&7'M6;?:*EPQ8J*TZ" >HH3L!SP\+1'DH*9+X2A9<;
M%_*NC"*.@H**>U5S <LO@6WEY9%_*G)X LU.?+3\JZ5U"#(JL9&\PKFFI,#-
MM_"-K!TB3\JO6^CVL./W*<?[(JY =PR:<P&,XI<S A:"VC&1 G_?(J+RHISM
M\I1C_9J=^6 J1(T R!0W97 ACMX8EQY:_B*)(89!CRD_ 4EPQ4G%1PR,SD$U
MDY2;%9#UMD0Y6,5()"!C:*DC 9<D4>4GI2O)]0LA@ (R5'--,6>PJ;8OI37
M'2CFGW%8B$ #9Q4BX7L*A=FSUI48FGS3[CLB4G(Z"H9;42-G'?UJ5>E+24IH
M+!&%0!<4_>OI42L2W-2( 1R*7.PLAC@XZ4BIGDU+L7TIK#!Q6L9MBY1# "*K
M27CPOL"G\*LY/K1Y$3_,R\U7,'*-MYVFX8?I2R6X?O3UC5/NBF%B7QZU+8<I
M"UF,\?SHC38=OM5K:,8Q4,G&2/2LI-CL2* U/Z5%;$D<U+5QV&%%%%4 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>gmab_20250508xex99d1013.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1013.jpg
M_]C_X0[ 17AI9@  24DJ  @    3   ! P !    " T   $! P !    WP,
M  (! P #    \@    ,! P !    !P    8! P !    !@    \! @ &
M^    ! ! @ /    _@   !(! P !     0   !4! P !     P   !H!!0 !
M    #0$  !L!!0 !    %0$  !P! P !     0   "@! P !     @   #$!
M @ ?    '0$  #(! @ 4    / $  !(" P "     0 ! !," P !     @
M &F'!  !    4 $  "6(!  !    Z ,  " %   (  @ " !!<'!L90!I4&AO
M;F4@,30@4&QU<P" _ H $"<  (#\"@ 0)P  061O8F4@4&AO=&]S:&]P(#(V
M+C0@*%=I;F1O=W,I #(P,C4Z,#0Z,C@@,#@Z-3(Z,30 ) ":@@4  0    8#
M  "=@@4  0    X#   BB ,  0    (    GB ,  0   'T     D < !
M # R,S(#D ( %    !8#   $D ( %    "H#   0D ( !P   #X#   1D (
M!P   $8#   2D ( !P   $X#   !D0< !     $" P !D@H  0   %8#   "
MD@4  0   %X#   #D@H  0   &8#   $D@H  0   &X#   'D@,  0    4
M   )D@,  0   !     *D@4  0   '8#   4D@, !    'X#  "1D@( !
M #<U- "2D@( !    #<U-   H < !    # Q,# !H ,  0   /__   "H 0
M 0    @-   #H 0  0   -\#   7H@,  0    (    !HP<  0    $    "
MI ,  0         #I ,  0         $I 4  0   (8#   %I ,  0   #8
M   &I ,  0         RI 4 !    (X#   SI ( !@   *X#   TI ( ,0
M +0#  !@I ,  0    (          0   '@    #     @   #(P,C4Z,#,Z
M,#@@,3@Z-3 Z,C  ,C R-3HP,SHP." Q.#HU,#HR,  M,#4Z,#   "TP-3HP
M,   +3 U.C P   C7 $ :3(  '=L  "V7   =^   -P[         0   #D
M   *    X@?@!:T(,P4;    #0   ,51# #G_P< ?9DM /O_!P #     @
M  P    %    07!P;&4 :5!H;VYE(#$T(%!L=7,@8F%C:R!D=6%L('=I9&4@
M8V%M97)A(#4N-VUM(&8O,2XU      \  0 "  (   !.     @ %  ,   "B
M!    P "  (   !7    !  %  ,   "Z!   !0 !  $         !@ %  $
M  #2!   !P %  ,   #:!   #  "  (   !+    #0 %  $   #R!   $  "
M  (   !4    $0 %  $   #Z!   %P "  (   !4    &  %  $    "!0
M'0 "  L    *!0  'P %  $    6!0       "@    !    $0    $   !/
M"   9    $H    !    -0    $   "4$P  9    *?L @"Y#@  %P    $
M   R     0   !0    !    KVH  (F,!@ .$@( "0D   X2 @ )"0  ,C R
M-3HP,SHP.   9T\! #<8      8  P$#  $    &    &@$%  $   !N!0
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M_^T2VE!H;W1O<VAO<" S+C  .$))300$       L' %:  ,;)4<< @   @
M' (W  @R,#(U,#,P.!P"/  +,3@U,#(P+3 U,# X0DE-!"4      !#F&9]D
M:_SA .@_6TNR\ ^(.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0%(            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      !  2     $  0!(     0 !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-!         (  #A"24T$ @       @  .$))
M300P       ! 0 X0DE-!"T       8  0    (X0DE-! @      !     !
M   "0    D      .$))301$       0     @   D    )      #A"24T$
M'@      !      X0DE-!!H      T\    &              /?   -"
M  T 30!I &L 90 @ $L 80!V &$ ;@!A &< :     $
M         0             -"    ]\                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   ]\     4F=H=&QO;F<   T(    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   /?     %)G:'1L;VYG   -"     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M%       !     ,X0DE-! P     "58    !    H    #    '@  !:
M"3H &  !_]C_[0 ,061O8F5?0TT  ?_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( #
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M    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ U     0 X0DE-! 8
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M!^8  0 !        86-S<$%04$P     05!03
M /;6  $     TRUA<'!L[/VCCCB%1\-MM+U/>MH8+P
M                       *9&5S8P   /P    P8W!R=    2P   !0=W1P
M=    7P    4<EA96@   9     49UA96@   :0    48EA96@   ;@    4
M<E120P   <P    @8VAA9    >P    L8E120P   <P    @9U120P   <P
M   @;6QU8P         !    #&5N55,    4    ' !$ &D <P!P &P 80!Y
M "  4  S;6QU8P         !    #&5N55,    T    ' !# &\ < !Y '(
M:0!G &@ =  @ $$ < !P &P 90 @ $D ;@!C "X +  @ #( ,  R #)865H@
M        ]M4  0    #3+%A96B        "#WP  /;____^[6%E:(
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M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P/_P  1" /?#0@# 1$
M A$! Q$!_]T ! &A_\0 P@ !  $$ P$! 0            H'" D+! 4& P(!
M 0$  P$! 0$              @,$!0$&!Q    8" @$# P,# @4!! $5  $"
M P0%!@<1"!(A$PDQ% I!(A51,B-A%G&!0B07,Y&A4D,E&+%R-,'18E,F)Y*B
MPAGQ@I.C1"A($0$  @( ! ((!0,# P,# P4  0(1 R$Q$@1!4?!A<8&1H2(3
ML<'1,@7A0A3Q4B/2,Q5BDJ)R0U."LL(&XF,D-/_:  P# 0 "$0,1 #\ G\
M
M
M
M
M
M
M
M
M
M              __T)_
M
M
M
M
M
M
M
M
M                                   /_]&?P
M
M
M
M
M
M
M
M
M                                                        #__2
MG\
M
M
M
M
M
M
M
M
M                  __TY_
M
M
M
M
M
M
M
M
M                                       /_]2?P
M
M
M
M
M
M
M
M
M
M#__5G\
M
M
M
M
M
M
M
M
M                      __UI_
M
M
M
M
M
M
M
M
M                                           /_]>?P
M
M
M
M
M
M
M
M
M
M    #__0G\
M
M
M
M
M
M
M
M
M                          __T9_
M
M
M
M
M
M
M
M
M                                               /_]*?P
M
M
M
M
M
M
M
M
M
M        #__3G\
M
M
M
M
M
M
M
M
M                              __U)_
M
M
M
M
M
M
M
M
M                                                   /_]6?P
M
M
M
M
M
M
M
M
M
M            #__6G\
M
M
M
M
M
M
M
M
M                                  __UY_
M
M
M
M
M
M
M
M
M                                                       /_]"?
MP
M
M
M
M
M
M
M
M
M                #__1G\
M
M
M
M
M
M
M
M
M                                      __TI_
M
M
M
M
M
M
M
M
M                                                           /
M_].?P
M
M
M
M
M
M
M
M
M                    #__4G\
M
M
M
M
M
M
M
M
M                                          __U9_
M
M
M
M
M
M
M
M
M
M   /_]:?P
M
M
M
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MMO\ V[1/X_#FJF)CFN(%KP
M
M
M
M
M                '__7G\
M
M
M
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M57=%=U3CL:7$DLK0]'D,.K;<0HE(4:3(QMB8F,PIY<)=\/0
M
M
M
M
M                                      !__]"?P
M
M
M
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M9]WC\?-NM:)XMGBTZV^TV\RM+C3S:'6G$GRE;;B26A:3_H9&1D.QSXHOH
M
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MPF3$E1WFS-*D.-J2I*DF9&1CK1,6C,>+QV ]
M
M
M
M    '__1G\
M
M
M
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MTE:_53AV<"5YJ/ZGZF1'Z%]+VUNK169\L?#@,B O
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M<>G)GP.SKI]O7%/*&KGQ5H$P
M
M
M                                                   !_]*?P
M
M
M
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MW6XTQN5#C=/5MC;7JCFA,89'Q:\
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M3]S9?]MOA*4-\?/XMG9K=32\O[_91/ZO8.R\PU4ZAP&=B63;<O8S3)J5+O\
M):Z3:TU2RYY)(D-+E25?O):(IME[MM.WO:?KX1\W;[?M\1,WC'MQ\TS?I#\=
M_5#X\\ GX#UCUI$Q%N_?BS<PRRQDO7><9K8PVEMQI>39-.Y?>2T;KZH\=!H8
M9-UWVFT>XORTZ]--7[>?FV5I6O[8PO=%J0
M
M
M
M   __].?P
M
M
M
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MBJ,G8CA%U>QK:(M:>7)&R:Z-Z(
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M28
M                                             #\..-M-K==6AMIM
M"G'''%$AMMM!>2UK6K@B(B+DS/Z!RXR+=*[N#U1M\SN==UG9+1L[.<>(SO,6
MC;1PQVXJ5$OVS9GQ$S.6W.?_ )2OW\$9^/!&99O\SM9MT?<KGVP]Q*X:)+B6
M$2+/@2H\V#-CLRX4V(\W)B2XDELGH\J+(9-2'&W$*):%H,R41D9&9&-$3$QF
M.,2\<@>@
M                                                  /_U)_
M
M
M
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MXU=5U59%8@UU= AM$Q$A0849*6VFFD)2AMM"22E)$1$1$-7+A"USP
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MH5:,F2B<<4XADGG%+_:2"0T:3,DN*_:ELEI5SP1%P?!*I^U:5=N,Y2AOB_\
MQA>Q';=W6&^>\4ESK_UBM6H&71M)M2YG_GK9U!(2U85,'(V#9)K&*ZP97_G5
M(>*S2V2VCA,*=;D-[^V[39^Z_")^+RN8SEL-]2ZEUMHG6^&Z@U!AM%K[6NOZ
M.'CF(8?CD-$&HI:F$CQ:88:3RI:UJ-3K[[JE.O.J6ZZM;BU*/J5K6E8K7A$"
MH@D                                     "TSMWWEZJ]%-;S=H]HMS
M8?J^@99>.HJK2Q:D9EF,YHDDFFP;"X1N6=O+4:T$;,&,YX)/W'3;:2I::MF[
M7JC-Y_5[$3*!9WW_ "A^]78>]ML3Z?UQ=/-*/KF1JO)9%=2Y%OO+Z9QQZ*U/
ML+JV3(@8^4J.IIYMJHC+DQ7B,DV;A<&6*>[MLY?2G%8CFCLY1F&<;!R&QS?9
M&99+LS8&4S')=_FVQ,FL\QS"[FD2$%,LKJY=?=><2E*$MF9GQXI+DR21"F8B
MW&>+G]S-X_;/IP>0N2<@R4,N2"-UQM#CB?1;K1'RLV77%>I\'Y*Y/A/*C]"Y
M+G/OT3LQT8C&631MOJFT;,SG'+^KJ6IK4QR)"91-G6%N^S!QNJ@09,FVM[>0
MY[$:MBP62-[W'%'PGA/J?!$?)I(X5[:\5Q,QZ>YH^Y.WC$3[TIKH+^*?VA[$
M4>'[,[I[-/K/KB]CU]X>H\>@IR+>$ZCE.&]_$9%*GDBOQ]]Q@T.)-2ISS1K\
M'HS3J%)+?V_9WB,WX9>U[:9XS.(3C^F?07JGT&UO%UGUCU/08'6^VRJ\R$F"
MLLUR^P;;-+EMEF6SO.;-?6:EJ_R.^""5X-H0V24EOUZ::HQ6/>UTUUUQBJ\@
M6I@
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MKT?Q6-/<6U1/"T<(]<?TRMOKGHB_@G6CZ%0
M
M                 #__U9_
M
M
M
M                #H<HRG&,'QN^S+-,CHL0Q#%JFPO\GRK*+>OH,;QRBJ8R
MIMI=7MY:N-18D2,RA;TB3(=0VVA)J6HDD9CR9B(S/ 0[_E?_ "AL8Q-FTT-\
M5MMCNTMBD_<U6;=KKS'G[K3> ?:/.U"XVGH%B3;.76R7T.26[EQEW'TM(85&
M.Y1+6J%S^X[ZM/IU\?.?T_7\7M<9XH3.Q\[V3NS863;FW=G^8;=VYFTM$[*M
MAY[>2LCR*T=BMDU B,S)AH1$A1&6T,0H49IN/%CH)ADFT)0D<S[TWMFTY:J[
M(QC\'EHMI#@L2&K"2U%CL-K6<M3ANM1T^G@?+9&1)(CY4X?H7U6KR5ZV1QY/
M?NU];-_\-7PI[%^6MZ5M;8&0Y-H_I#A=^=;)SVIHTM;$[#9)5STQ[C$-6OWK
M?L5]9!2F0W:Y&\R^AN0IN"S#EN%-.#MT=M-N-N2G=:+8PV&73KX^.G'0?"V<
M)ZJZ%P35K2X:8=[EL&J9L=DYIQ*<G*D9SL>U)ZYME>\ZXMM$R8MIDC)N.VRR
ME#:=]-5-<?3'O\5*\P6                #R^;YGC.N<,R[86:W$+'L.P3&
M+[,LLO[)Y$:NH\:QBJ=NKVWGR'.$MLQHK#KSJS/@DI,S#D-,YV&W_EG;_L=V
M1[;9C*FMY!OO<>89I$J)TM<^7CF&3)Q(P##D3S227(]/5LQZN$9*X)N*UP22
M(B&>U,QFWBE>L<$K3\0_ISCVP-M=I>_N:5<6Z?U%;L=:-!RW"BR(5%?VM0C)
MMP9%'BR&#<:L4U<JAKXDUB0D_M["T:6@R?291T5S,VGP0B,)ZXU/0
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M+U,B+U,A&UJTCJM.($-_Y(?RM\?J5WNIOC*QNLS^Y2B96V'9_955+CX%4O\
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M:PP6,3T6E\O(T?<K>DS/ U(.5X*-(UZ]%:<9XROIKK5GJ%ZP
M
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M\Q^CJ5V6G7TSXX3@!VD0
M
M  ?_UI_
M
M
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M6&8A2U^.XQC5#5QTQ*ZGHZ.I;:C18S#:4H:99;2E)%P1#=$1$8A!ZL>@
M             C(?E#_(O"ZH='K'JG@\ME[?/>NHR74E<P9-/?[4TC*CMUFZ
M<MF1W&W"-4RNEGCT!*O;,G)SDIMTEPO!=.W9%(QYI5C,Y:WMF#;G54.$X50W
M.0Y3DE]1X?B-'007[B\R+*;9[^*HJ*IJ(Q&\])DREH)IEM!J6I2$I(S,R*%M
MU+XZ8E.T9;;OX@.@%?\ &MT,T[UK?55S]CLQ9N?[QR.H,W8F2[DS=2+'+I,>
M:MME<F-7I3&HZZ2ZRVXY"@QE+;0OE)7:Z=%<*F3@3
M4[VWM?7^BM8Y[N3:N20L0UQK/%+O-<TR2>3RX]1CV/P%V5E*^WBI6\\X3;9D
MU'8;6ZZLTMM(6XI*3C:T4K-K<H&KP^6[Y/LX^5K?T?8!5UUA'6?5$>SH^O\
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M6A<U39DA._7V^NG'&9;ZUZ8X\99Y2(DD24D1)(B(B(N"(B]"(B(7I/Z
M
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M21>A)21$0Z41$<(:')
M
M !__UY_
M
M
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M;$F5]M%)*&U'8RZ]YIWB$\TNSMZ9MU3RAY><1AL:AM5
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M>7GE$E+;2/;C1VV8K##+?<UZZZJ=-7J[46
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M$/3#UZ
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MVE=/UWXV_!;KUQ3C/-GH&U:
M
M        /__0G\
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M3S341O7
M
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M*73E4Y3F*$E/E[A,P6D*(O DENTUZ=<>OBKF<RRRBUX
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MS;;7,L)++9*,D&?FI*54S:>J*UB9F?)3MI'<8Y\/S2N?CJ_$ZSJ_<9S+Y/\
M/45F+1W(4VGZVZ1S#W)%NI9,R)$;:NQ(4<FT(;X=C+BT#BW%^7N-6;))-#UE
M.TM?CMX>J%VG3:G'.(\DP_J;TEZK=&M?'K#JGI3#=.8B^\B5:,X[%DR;O(IS
M9*2W895E5P[)M+20E*C0AZ?+=4A/"$FE!$DMVO5KU1BD?K\6E=.+
M
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MBJ[86I@
M                                                     __1G\
M
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M)?VTQMVQ;_:V78Z3I
M
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M4PB))$E)$E*2(DI(B(B(BX(B(OT&\?T                  0V?R4OF2O\
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M*_Y"]L?;)K^4R6_GK>GV4KP(D%(G275DDB22B21$-E:5I&*PNBL5Y+D1)Z
M
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MB0
M                                                 #__TI_
M
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MQZP:2DW"A13);B$J6VEYUWP<<29&-FFG37,^+M]GIG5KS;G+/0+6L
M
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MMA)0S'C1V&T-,LM(2A"$DE)$1$0[<1%8BM>$0Z3NAZ
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MUK6ME.1_'*^!*1K-&)?(AWLU^[$V]-:AW_5WK]E\=]QW2U2\@W:[;^RZ>?\
MW9E,:4V[35LEOFC:\9+[:;I;:*?IZ=,<+VCT].7IC7KI->,IJ U+0
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M266T),R'6U:::8Q7X^+3$1"]46O0
M
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MO-0C_N[FXE>JWY,APU..+<4H^5'ZF9F9]K3JIIIT4_U:JUBL8A<6+4@
M
M                                           !_].?P
M
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MMI2AM"4H0A"22A"$EXI2E*?0B(O0B(;74?H
M
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MRZ@F(X)M*$LO8:W.)2EN*.Y;8:0U43)&WM=$Q]=_<OT:K1]5_<G@C>U@
M                        #%YW[^8KH3\<55*9W]N2NL]I*B)?H.O^L?M,
MZW;D;[Z#5!:3AU>\A-4Q(\5DU8W\F!"4:5(3(4[XMJHV=QJU\)G,^4/8B90H
MNZ?Y1OR'=F7;C$.L]#CG1W5<\I49FYJFF-E]A+:J?C.0W"E95;,)K:9;R5H>
M2BKJV)T1TN$6"O'R/%;O+S/#A'J3BL1S1TUQ;[*,PO\ /\QOLIV#L#*)+MQD
M^>[(L7LNRV\M9#_NRY\JYO779)O.K4I:WWUJ4?/'D9D0CF+>.5'<VFN,>O\
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MEFTR@EJ(]VGMM6F.$9GSE?B&1H:'H
M
M              XLV;#K8<FPL)4>#!A,.RIDR6\W'BQ8S*#<>?D/NF24(2DC
M-2E&1$7U'DS$1F1&E[S_ ),W4S1:\KUWU.@O]J]NU!2ZP\EI'"@:&QJ\2:F4
M':9RI:7;E+1\.FBA9>8<(C;.:TYR1<KN/Y773Z=$=<^?A'ZEIBG[D+?NAWQ[
M2=],Q1G?:3:Z\@BU<DG\3U?0QETNJ<242U>TBAPQ#RFG7T>ZM/\ )3O=E/()
M*77%);02>=.W=OF;;<S/R>_Y&N*XC'I[UAUY9?;07)+BFU22<\F?/A"5>*O
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M\7W&HQ'_ -S8/LI2N0^M2EK6ZX9F:E'QPG@BZU*5I'36,+.2K@D
M
M                                          __U)_
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MZ1J/]SIER?U&ZE>FD5=FE>FL0NT$T@
M
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M=J)"@PHC1,18D2*P24-M-H2E"$(21)(B(B(B'<B(B,0TN8/0
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MD;&:]?NOI)B 9R'&U^W*ERB0CQV:]-:<><KJ:JT]K-0+E@
M
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M:JM@,)C1H\6'#2AM)$A*2]$_H.U6L5CIKR>O<B0
M
M                               __]6?P
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MG&-?X8RM2_[E+:QR,A2E>I^IF7KZG_Q'5U_]NOLC\%BH F
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M(K,?1JU]$9GF[FC5&JOKEG2%R\
M
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M>(B!55%15P4(9CQX[+:&F66D)2A*22DB(AU(B*QB.36]&/0
M         &NB_)H^4R7VP[$3?C^TSF+S/6OK->F]O^93V;7\7NG?M1*;46'3
M_P"-==.71X:ZDXRFW20G^;3+<>86=?7R!BW;>J>FO*/Q65C$91D:>DSO:F;X
M!H_5N-/Y?M';F:XQJW5^+P)$&$NVS#,;=K'\:J6K"T4U#*,I]Z.TN8^ZAALC
M\W5-),S316N93;6;X<_BVUQ\6'4^BU;5Q:>[WOL%BES3LWM.$DY,C.]FG7J-
M^HJK.2Q'?+'*%<B5!QV$;+*&VEORU,(F3IJW>AKIT1ZU,SF<LLHL>
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MUX)>-A#>,P8!+;0T<E4A]!OJZ-.WU4XXS/G^GIE"9RS!B]X
M
M                                 #A65E74\"7:V]A"JJR PY*G6-E*
M8@P(49HO)V1+F2E);;0DO52UJ(B_4QY:U:QU6G$1YB+W\E7Y$V*Z91::XZ15
M>/[2S"([,KLAW1DZ7EZRQB2T?M^UB$)A:'+V4D^3.09IAMF1%R^?DE/S/?\
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M[1-JDRW2+S?DO&7F_(=,UK4?)G]"+N4I776*4C$0N58$P
M
M                                      ?_UI_
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M*GJCKGKF.$<GT/9:9K3KMZ<(3A1H=
M
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MU]*(B%HAP8C#."]IV6ZI9-MK<_P8^+%)1?=DREI2?!J)"2X-:C)*$-H:,_\
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M4D24I+^A)+T(7(OT
M
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MIV^N-=/?/FV+L!<
M
M          __UY_
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M=.BV$9PI#,C'<;?1_%UQM.D:F7&8OO$7CY.J-)*'G&>,R[%=5*^"+?\ EO\
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MT
M
M    !YC-<TQ+6^'97L+/LDIL.P7!<<N\PS++<CL(U3C^,8MC=:Y<7^07=I,4
MEJ/$AQ679$A]Q1)0VA2E&1$/)F*QF>4#5A?+[\JNP_ER[/3"QZUL*/I1I3,+
M:HZ[8"R5@Q!SHX+[U6?8'-JBXCQ'';FX:(UP84Z.G^'@._8(;^Z7/ES>+W/<
M3LMPY1R]/6LK&&-:70JI#><)Y*B\%*3)5Z+-:6B2VA2E*,B+G@B7Z%^AGSXD
M,=K3;F6C@]!U*Z@=AOD>[-8=UOZ[T#MEEMH\B=DN46"G$8IJ3!XDMN-D6Q,T
MLFS/V(<1M?"&DI6](?<9BQ6W9CK3"]FJLVV16K'LI-K8KX-MAT7Z4Z7^/WK3
MKSK+HVG*)C.%UJ%7>13&F3R78693&TJR3/LQGMES(L;%XO-9F?@RT34:.EJ,
MPRTCL4I%*],+JUBL8A=Z)I                       PJ?+Y\U.D/BPQ6H
MQ-VCD;=[4;)QV3?:GTC733J8::)JQ.HD;!V/DYM/)J:..\W(2QXLN2+"0PN+
M&0A")4N)5LVQ3AXG#Q:S7--B;!VMF&S=W;BR23L;=&U\EE9=GF:W*FCDY!=V
M;Y/R3:880U%AQ&%&4>OA16H\6-%0U'CM(:;2@N=>O7.9RMINZ>#,3\&OP_SO
ME#W/_P"6=R%*C=+-$9?">SE#;"XLG>>PX*V+F/IVHEJ29-T\='L/Y%-;-+WV
MSS<6&I#LHY<1H[>;WS/*/3#RVR;<6SFCQV(D=B)%9:CQHS+4>-'90EIEAAE!
M-LLM-HX)*4I(DI21<$1<$.LK?8               'R??8BL/29+S4>-':<?
MD2'W$M,L,,H-QUYYU9DE*4I(U*49\$1<F'+C(UB_SU?*L[\H/9BOT_J2X>3T
M>ZRYA=5^$3X=HZ_5;_W!7*.FO-VOLP5%&>IXC*Y-7AYDMY1Q5RYQN(_EG(D3
ME[NYKLMBO*%=Y];"C81HM>DT'XL16%H0TIP^4\-)X02DH(U&HR]341<&?IP1
MF7E&EHF&6\YE]-0Z'VGV[[$:AZP:&K/Y_;^Y\JCX]C\9127*[%*]!^]?9SE2
MJU+\B#74\!$NPFRE15&VPPZI*3/Q)=M8F\XA3]F;6C'@VT?QM_'QIKXS^J^%
M=9M/(.U.L6[DFRMB3H#$#(=L;0N(S+>4Y]?--+=-LWS9:C0(:GW?LX+,:(3K
MI,^ZO=2D4C$.E6L5C$+]!-(                     4,["=F= =4-=V>U^
MQVW,&T[@%4AWWL@S>]B5+<V4W'7)3544%PSE6,]U"%?;P(#+TAXR\6FEJ]!5
MMW:M->K;,1!S1#NW7Y>#+5ID.*_'UU:3L&LB+5%H^P'9.WM\.PBTDQ+!3<FQ
MI--8X3%[85LB.CRBR)EY5R4*42GX2222'>7M_EZ5G&N/C^G#P]?M\5U-=9_=
M**SW:[T]W?DGR:/D7;S><O+\8KI3LK%-+X"RYA&B\02J2[(8<A8?!429\ELG
MG(S=G<.2K V$DT_,6V2$#/\ ^3B\YO\ E\N*%IB(PM<Q_!*J02:R#&88=-*C
M^THV"8BI<+A*'9CY$V1$GT\U.>1&7)FM2O[M>KOJ7G,^GS8MUIG#A6V/0,9D
M.>4FO=0PEPE%&<-#"C+@O(W7B02B\_/]W!%Z%^ID1[H[^*QB/3YL]LO*X3>9
MGEV:U>':GQ/)]EYWD3J*B@P;7&.V6?Y1?SY"R)%=6XWC2)$E]]9>J&VT&O\
M:KA)\&0IV=W._'./S^;RE;6E*0^/C\6#M#VQK*_;'R%9GD74;6UFY!G4VD\5
MBTEUV(S#'[" 4M;^7W,QV16X:9)6PAN%,@S[ EE)9FU\!3+2GE=.S9QMPCYS
MZ>OX-U*3%<2F7](_B.^/[X^:2LA]<>O.(5F7P8R69FWLTC-Y[N*X?5':8FRI
M.?Y(EZ7$3)-I#CL&I^TA$ODVHK?/ TTTZZ<8CBLBL1R9)$I))$E)$E)>A$DB
M(B+_ $(A:]?T
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MZ:NE6L5C$+B1-(
M
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MSU[.E9^J(]/<SSOK;EEQ[&-]BXU*F*+VR01K>0XS[#!)3SYN<+-7CQR9_P#
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M--(;:;0A/4U:J::]-70I2M(Q5>2+4P
M
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M7,]YU4Z]R?(K$TI.38V<UU^;->\4I4ZXKP0VV24)W4K%*],+HC"Y 2
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M&%T1$<HPKZ)O0
M
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M=OV^OMM?VZ>^?-T(B(C$+FA>]
M
M                      '_T9_
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MAUM-.FD3A+F&]:
M
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M_M[G)(SG$)"#\XU8X9+43DUUB/UNUTX_Y;>[]5B9V-SP
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M+:1E?VDGP]E[,)B8\J.M31K.MBQ'V739L%I/=V^O'_);W->NN(3$QJ6
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M.>0TW]Q/F..R'C22G'%'ZCH4I6D8I&!6\2
M
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MBM*Y3'CI6:4^I\JYY'T/:=K7MM>/[IYRV4I%(];(Z-:8
M
M                                          /_TI_
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M&:N%2X_CF/U\:KIZBJK8R8<&# @Q$I0VVVTA*$D1?0@B(B,0VQ$1&(>E'KT
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M1+F0958QV28_F\OR*1Y3+*8I)<'(EO+41?M3PDB(75K%8Q#76L5C$+HA)Z
M      HSV"[ ZDZMZ?S?>^\\RJ\"UCKVH=N,ER.V=-+3#23)N-"AQVR4[)F2
MG31'A0HZ%OR'UH98;<=6A"HVM%(ZI&J*^4;OKE7R7]SL][.V4&WH-?U]9$UY
MH# KM^*N1ANJJ-;CK$R6S"6M@K.ZEO/VTY3;KR4*?3&)UUN,RI'#[J\[;]49
M].2.S96D1'FQWD@XQ?Y4^*$I22UGPM:/W\&9J1ZF1^1$7IZ?U,S%5:S'-S=D
MS>[-Y\%_Q'SOE%WQ*RW:%?<0>GNE+2-)V/;Q2DP&ME9<TI,BOU-27+1I2OR3
MX2+MV(XM3$5;:"4T[+8>1=HTV[C9$<JQS_1/3HF;9\&S[UUKK!]28/B^M=;8
MQ489@F%T\*@Q?%Z&&U J:6HKVB9B0H45DB2A"$E^G_$=NM:TK%:QB(=%[02
M
M
M   %'.P6_-5=7-+[%[ ;NRN!A6K=6XW,R?+LBL%I2B-#C&EF-"ALF9&_,F2'
M&84"*WRY(DNM,MD:W$D<+WKKK-[<H(C+4L_(#WJV'\GO=C+>SV:,'6TE[_\
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M5PS642H@.J24Q;*B582F_N'>&6X<:+T-.J*1F>:JULLZ N1
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MX<2+7Q(T"#&8APH4=F+$B1FD,1HL:.V33$=AELB2A"$D24I21$1%P0T+7(
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MJ\:QVG@QT>VQ#K*6F:9CL-(21$E#39$1?0AHB(K&*Q@>K'H
M
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MU@
M
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M2E==>FK;6L5C$*XB;T
M
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M*DJ2DB7)DJ6ZKC]RS,;8K%>3W&%<!Z
M
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MT$A#9H):5*/I]IHZ(^Y?G/)=IT1KGJGFDYC:T
M
M                                      #_U)_
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M5*=%<,@HDF
M
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M))%P1<#7$1$8A=RY.Q'H
M
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MVC-[\N&&[M:_3-I\4_@=AJ
M
M                        !__5G\
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M6?,26
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M(,AE*R,R4DR/@75TZZ3F(,0R0BQZ
M
M                         *6[EW9JKKWKW(MJ;FSG']?8'B\%Z?;W^16#
M$&,AMHOVQXB'#)<B0XHR0S'92IQ:C)*4F9B&S9357KV3B! @^6OYS;CY (\K
M0?7I6::VZVQ)LK_<LM,B129;N5,5PV"CVWV;B%QZ-:2-Q$1*_-XE\/I+P\1\
MQWW\ELWVC7JC%/Q1O>NN,Y1XVYZL88@U]>S%KZ<ENL.(;4\HGHQN$HR3'9,S
M)1&?!K49F?\ U#WM:1:<V<S9_(;IF8CE[_U<ZCQ_>?9G9F']>="87<[*V)ET
MANOQ[#<>AIEE&;4ZCSN,@DLDE,6+'2HW'YDTT,,M^:G%D1<EUL5B(BO.5M8M
MNYSR;#[X>_@KT5\?F 8MLG;6,8UM/N#:0(UGD^P+6*U<UFO)LF$2'<6UHW.;
M(HS$;S=:7/-LI$CR4:C0WX,M[-6J(CJMS:]>J*1QYI (O6@      H[OW?6K
MNLFH\UWAN7)8^*:[P&J<MK^U=3[S_M)43;,.MA),ER93RS)#$=KE:U'P1?45
M;]^OM]4[=LXB/3@-7IWG[RY9V^[-;([#Y'8+>7EMF[#P=AN&53!H]?T3BJ[%
MJZOA&?N-J;A$P3AKY<4Y[CCCKKKCCBOSSNM_<][W5ML\IGU\(\/DLG?6E>CE
MZ>UC;S_.V+E]]IA25R$M*7)D.>I>?DE)+61&9J,C,S(R+G^XS'0U:;5K&?'F
MY'<=Q,\(].7K99?A-^(/87R9;RJ-C9PU)INHVGLEKI&>WSK#S<78]W5R"F%@
M= X1)]PG#2A4YQM9&AM2/4C42D];M.TG;;CRCG/Z*NWT?=MU6Y-HO1T=1C--
M58]C]=$J*.DKXE74U<%I+$.OKX+)1XD2,TGT2A"$DDB_]OJ/H8B(C$.O$1$8
MAVH]>@
M
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MT]=N4-A\+G3
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M7]\Y]\*_\BMHX9]/>HB6O,86E!O0K:0L^%$<NQ>D.?H9^9*7ZF?ZGR.1WO\
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M3>KD^GK]#(:*[]-IQ%HSY<I61,3QB5])&1D1D9&1D1D9'R1D?J1D9"UZ_H
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MD+4:UI@TM&RQ&9(S,S,FVBY/U%T1$1B(PD]6/0
M
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M3D=K7KKJI%*^#MZZ1KI%:KCQ8F
M
M                              __UY_
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M1UC:O!*'9LI,1)+DRGO$ER9DE;C[R^7'7%K,U'?R;:UK6,5C"KP)
M   X\J5&@Q9,V:^S%APX[TJ7*D.):8C1H[9O/OONK,DI0A)&I2C/@B(S,!JT
M/GU^5 _D.[>3Z#6MV[9=6NN;]OAVJVV'$-5F;Y.EXH^9;1?:;-1O)E.ME$JS
M=,_&$@E))I<EY)<Z\3OVY\(Y*]^S[5>F.?\ HP*QC?D/$ZLU.(<\O;]2]4+_
M +$>'/)JY(U>1$?UX/C@N>EV^BM*VM//@X>;;+<4G;\;SXG4=TNP<3MIM5HW
M>O'5_,(:ZJJ<)WV]C[LJVFK>!C[Z4&GB%1DY#L9ON?L>6MADDNH-\D0M,7MB
MO*'2T:XM]4^#94H0AM"6VTI0VA*4(0A))0A"2\4I2E/H1$7H1$)-S] ,<_R&
M_*/U+^-?5\[.-]9_ =S*9#F%K[3&,R&;C:.Q;IF.IR-7TV-Q34[&B&X26Y-M
M.)F%'-22=?);C2%T;M]-,9MQGPB$;7K7]TX:L;Y#_D9[1_)AN4]N]D,J=7C]
M'(LVM3Z>IGW(. ZLQRRF?<E!J*:.HD2;!24M)FV\PERI*FFDK7[+$=MKSM:3
MW%NK;'RY<ED=WKK'3&/3WK&*IE,MTVC7X$G]Y%Y_N61'X\J)1_W&1D:E<<>G
MJ?TY['^'IS$XB/A^C/W.ZM^GIX<_R>^BU%C/M*2@HZ^RO\AR:;"J<8Q_'X;]
MUD&16MA*1"K:RCIZU#TF1)?=4EMIAMOS4HR+CE2"5Q_Y#&JT17TY**5Z^:6?
M\67XNV[-V9#ANZ/D;J/_  SI*OE5610^ML&R6>T=GL):*QC0]B6%2Z1XW7O>
M3!2HK<G^4,B?CK;KUD3JJM>K9LQ.SA'DNKHUS'UQGRSC]$]S3^E-1=?L$I]8
M:0UKA.J-?4#1M5.'X#C=5B]#$-9^;SZ:ZH::;4\ZLS<>?61N.+-2UJ4I1F>R
M*Q6,0MK6M(Q6(B/4J>/4@            !CB^2[Y,^OWQEZ)L]I;;O(-CG5Q
M#L8>H-0Q+!#.6;0RN-')3,""RVAY<6N86MH[.V=9-F*A:"/S>=89=IW;HU5\
MY\(&K$[4=K-[]X-YYAVG[(Y+_N;8N5OHBU--&;7"QC7>)Q9+CN/81A=0MQPH
M5=!97_C;-2W'G%N2I;DB6\Y(5R;:[7V?<O/&7/[S9RQZ_P N:U^SL4'_ (S2
M;SDA2S6H^/)QWR\O3U(S,R,_1)'_ &_7DRYT8Q5SIV3-F7[X9?B>S_Y3=^P*
MRYKKS%.I&KK-J?V V9#.37OVKT=29%=J#!K%2>'+FSX\IKK9&W A&<A:R>=A
M-2*M5+[]F(X1'.?T:^VTS?,SPAM*=*Z5U;UVU;A6EM+873:_UEKVDB8_BF*T
M3!LPJZOB(\?-UQPU.R)#RO)Z5+D+6\^ZI;KSBW%J4?7K6*1TUY.K6L5C$*HB
M3T                                                       !T&
M5Y5C6"XQD6:YE>U.+XCB-';9-E&2WT^-54F/X]10'+2YNK>SFJ0S'BQ8S3C[
M[SJTH0A*E*,B(S'DS%8S/*!JNOG%^9W*OEBW%#P37Z9V+](-*Y583M58M)]Z
M+:[:S&*S)I&]T9M&<0VXPI41]]BFJUI)<&,^][BON)+Z4<7N-M^YG$1PCEZ8
MYS^'#S4;;S&,,+;4E#$(X[1\()LTH(S0DB_8220DC/T(B+@B^A<<^G/ KIJX
ML=[3+CL1D*;6;OMF:8Y/^XIQM*64\\>9J<,N?UX1]%GPDC-9I2K1CR8;Q?;C
M$<F8?XU?@;[A?*O2PMC8@BET#U07<*JY6]]DQ)[UAL,ZJP3%R)&G,/A)-^W;
MB.I6TJ<Z[%K3DMNQ43528TIEFVFK9?\ ;R];H=OVUOW6X-J'I_5V)Z/U-K'3
M&!PCK<'U)K[#M:8=7*>=D*@8O@V/1\9H(1OOFIQ?M18K2/-:C4?'*C,S,QT:
MUZ:Q6/!T>2HP]                    'Y4I*$J6M24I21J4I1DE*4D7)FH
MS]"(@&.;M)\M_P <G3FNR!W>7;C3=1DN.&IB;K;%\MKL_P!J+L5->Y'K"USA
M"K"V9<=,TI)R3%:91Y$IUQ">5%5?=KISGX<4JTM;DC!YE^9>W,:R:-J?H?:/
MOHL;*/A5UG6VD-0K&K;?6U4VN1TE+3DJ*XZCVWGH;%@[X'RW[Q^C@S?Y=YC,
M5B/;*5JUKXL+N^/R*/F!["3;MA'9&DZX8?>Q%0SPOKKKK&<?=K633X*76[$R
M=%OE45]:3Y.1'O&U)5ZM^/H2:^O?LSF<>STRA]S73GZ?-A\V=E.R-U96]G.Y
M]G[-W[F,F.VP]EFY<^R#.[PX\?DV6'9>22I+[C;?)^V@WR2DOHDA#[<YS;CG
MS1OW6N,8B/E^KQ4&N:;6EJKB06G35XN-I@Q841"?^I)R&V^?7]"_]XT:-&O9
MG/ACR9]G=1..GT^;VE1#=BNI*?$;=BI41>VQ,,X"#5]3-222I)G_ ,1LKIT5
M\ODS6W6F<P[ZSAU31D\S'J2+Q-1^]+A2";]"\22EY[RY/U]/7Z?H*.YFE>GH
MGSY>YY6+6SS= ;F')2V];OT+*B-1FF02([9\&7)>+"S4?Z?IQ_J,O7ZTOMSZ
MW$?O]?16GW6UQ)9&EPX$>F58R7E3&E()M+<=DUFHE$L_H1<<?08>]MLGIBDS
MX_D?;F?-7#$^M_:C957%O=:]-^UF?8].3Y5-YB&@-LY'4VB7$D:7JVTKJQR.
MX@SYX4EW]/7]!S;:>XV<HF?BT4U1'/\ HKAA?QI?*EF4]BMQCXZ>W#,B49?;
M2,JU7D>!59D?/!RK3,4P8Z"_7]Z_0OKQR/=?\;MVS,[:S/NG\X67UQ*YF+\"
MWS=W;"9"^BSL1E236V5CO/0,":DC+GA3#F1>Z@_IZ*(C&W7_ !,UC]OX?HK^
MS'K5"UK^.[\T6;9-&QFYZSZ]U16R>3?S/9VY=?V>-P4(2:C3);P"=<V"_+Z$
M3,%7)\?\KK_QEIF(I&/A^B=-6,KI;C\3[Y4E-H_C=J=&G5.D?NMKSC<\5$8S
M(OVMD>&K]/KZI_\ 8+*_QEXC$X]/<LZ(=,Y^);\KA,I2G;O1=U9&2B26>;G-
M"%?ZJ>P;G_V$+([';'+'I[D+ZJWPYE5^)5\JAFI,[>'1Z A1FI2T9=N6<KD_
MT0E.%MD7'^OU_P!./7W_  MOJ]/<K_QJ^G^C\9#^(]\H#$-4FIWCTRR":V1K
M3!>R?;-<:EEZFAAY_$_;_<?ZK4DO0@_PMWJ]/<?XU?3_ $407^,!\SM>\^TC
M#NN%HRV9DTY7;GKX[$DR/]JT_P C'9<3_IY((Q'_ !-_E\X>?X]?3#RF4?CP
M?-)BS"HQ=6<+S1IA"7G)>%[QU7*-TR+R]M#.06\!U1E^A);/^GU'M>WW4SFO
MX?J]_P >JRBTZ._)-J3(YM#F?Q[=R"D54EV/(?QG0>PLTH%N-'XJ5!R+$(<Z
M!(:/T\7&)*DG^AF/)ZHYUGX/?\>/3_1YO,]8=DL>JI%GL+J5V?UK70$&])ML
MJT)M&AK6DEZ\S9=G5H0E)<>I^7!<^OZ"G9QYQR1MHF/VK8Y6:8^Y(.//K:J.
M?*BD1KPOX^0LR,O0X[ZTN)4?]/#G^O J^CU(_:N[F!4:XO5,DF)7PW'#-2&D
M299(\OU-*N2\B_XD?'_,,5GEA5LUWC'#+V-IHZB_CD6%2J0:EI4^:8TF&X7N
M-D1M-^#;B'"YY5X^:3YX/CC@Q"_#EP4Q%E![K%F3E/,OUO+\<T*-,UEL_4U>
M)\H\C\C+T_0^!#,I1U0II9XP3<]$^!&>B28ZR>:D1VGHTB.^TX1MNQI+"FW&
MS)2?(E-J)7H7J/8Q,XEHI>:LL?4CYM?E3Z?VL*9@7:G,MJ8@PY"^[U3V4N[C
M=F$SX5<VXTU4PI>7R5WE/'X<+]E'<PU?M02E+2A*2TQW&[5CHM\>,+Z;.KW)
M)W6K\RS6<HJVB[H=0L]P&P:BQH]OL'K_ 'E=G^+R;0U^W(F)P7,G*JP@1/\
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M-MEXH;9BPT(;2DB]")*2(A?$1')+$1R=F/0
M
M                                  !^'76V6W'GG$-,M(6ZZZZM+;;3
M;:?);CBU<$E*2(S,S/@B 1!/F)_( 9QFXR/JKT-V!5(RBL<>J=M=BH3"+*DP
MZ2E_[27B^!3/%YN;*02E'/L8[2T1S03;"W'?>2UR^[[N8_X]4^V2<PAFY/D4
M2UO;/);W*;/,,KN%J<R++,CL7[61=7#SJW9$J1=VIE(<4^I1K2I1DHC(CXY+
M@^3^Z9ZE<STVCUJ3W6;3XKT3&Z.)(MK"[<575E5%-4^TMIDEQ"&VH$9Y2G"2
MHS)/+:>#,^3^OI[73X_BQ][&8QZ>"7K\0?XV",Y@8AV=^12GEL5]A'CWN&]8
ME/N(:=BNI*33VNR)K:N20I/MOIJV%<+29)DJX4M@NIH[*+8MLX1Y>,^T[;M(
MB.JZ;GBV*8S@^/4^)8;04^+8OC]?%JJ3'Z"OBU5155T%A,:)"@P(:4-MMMMI
M2A*4I+@B(=2M8K'36,0Z$1CA#T ]        $5G\@KY5)NI*RQZ):,LVV<]S
MW$E2=UYE"D-JD89B=RHFZ[#:MYDU&U/M&42%35_M<88]LDGR\?' _F._MJC_
M !M7C^Z?RC\Q!FMGF*N,]%\?%3Z'&R6RTCW'EJ(E\'XD1\^AER?/H7/U/@8-
M-8F*VLIVVB:84?BXSDF?9!18-B%'+R?+,PLHM%A^-US:I$V[M[B2F#%@J:+A
MP_)PTGSP7''Z\CKTV5QBLN!-=EMF&S5^";XLE_&SUE<=V"M,[L-N=NIR3:LD
MEFXUCS;+:WJC"H)FE!DB&EX_?)9&?O>7J7]B=W;:9UUZK?NEW>WTQJIZYYLY
M0TM
M
M         __0G\
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M6MYJL2E)FPJT<\I[R3<+W6F75,%S;UKLOUVXX;=>OHCUL_X]6
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M$(2AI"$)T:]==5>FKJTI6E>FJY<6)@
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M*VI5I739R&BN<G4PLHZK+[9+$(B6B(J0HFY@T:=,U^J_-KB9QQ2N!I
M          %GO>7O-U\^/3K]D_8GL7E2:3&*<RJ\8QBM5#DYQL_-Y<9R11Z[
MUS0RWF/Y"WG>TX;;7N(;9:0[*DNLQ6'GFXWO%(S(U27?7MSMWY)>UV?]L]UL
MJKG;\XM%J_73=G*LJ'4&K:5]QS%<&I):_ EOM^ZY,LY[<=DI<YZ3)2PTE\D(
MYFV\S>+3XK:6KB8\5J=K*2EM#+3I$9/$DG7UH<)E:T>2OV?M/U)!FE?B?'T,
MS-22/V,(7B>:[KX]_C_WC\G'9&@Z[Z>BN4$&(E%WN#:TNO5)QC4N F^4>=<V
ML1"TG(M)*3-JKKB6A4EXT\N,-)<>;3VO5:*PHQ,6Z6U=Z,]%^O?QZ: QCKSU
MUQ-%#C%,DI^19#.]F7F&Q,ND,(:M\WSF[0A"IEC+-"2,_%+3#26XT9IF,RTR
MCH:]===>FJR(B%X@L>NMMKFHH(#]K>VM;2U<5"G)5E;3HM= C-H0:UN/S)BD
M-H222,S-2B(B(S_0!'1[N_D[?'[U;EY-@VGI60=N-PT*I<%6.ZJ^W@Z[K[A@
MVTMQ[[:UP10C94:U$MVF8L5(-"DK0D_'FG9MBL?3QE=&F>=IPB)=N/R _DZ[
M@65O&K]V3^K6MK$Y$>!K3KLM[&+&- ;G>XP=[M7S+(7Y9M&EJ0N%,BQW"Y\8
MZ$J4D99V;;?NG'L75UZXX1B6,'"^M.2["H<ZW:] R"VHL:M6/]_[1R";*L51
M[R_C6%W7,WN463BR586C5=:2(L=UW[B4F))6GW"86:&)F)GR>;K=,0\=!_V=
M:/,5-%9S3EJDH/\ D)[##$149+G@MTG5*2X2?H9&XGZ&1E^HR[>XKKYQ/I[V
M:TQ+W%KDMG;YK0:HZH8/F^V-ILR(ST<]0XGDF6Y?96\1@GYK%=3TK3SZ_ME$
ML_-#!^))-9GQP(Z>[^],]/5'M_+BJGA/%DNZU_CY?,OWSL6,IVCB1]9,!L7U
MRW\L[0VT^MRV2P3YQ)!5NKH+4R\.224^;35I"@,.)))E(X\3&N*=Q>>'+SG,
M)XKXI!?6K\-7J=A\J-==M.S.XNQ4Z--B248G@=;6:/P-^&TT12JF[^V>NKJ6
ME:_I)AVL!PD_1)'ZE?7MYG_N3GV?US\L&(\$D[J;\;W1SHY0,T'5[K7K/5_M
MMK:?R2)2_P ]GMHAQY4@RN]B90N;>3N%K4:"EV#A((_%'BDB25]==*\H%[A$
M1$1$1$1%P1%Z$1%]"(A,?T
M
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MM_S;.7@UZ].N/JQQ]R;4.TN
M
M                             !__T9_
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M3\9#%IF>96;2$?<3'R;0A"4I2TPRAN.PAMEI"$Z_:Z,1%8Q"]0'H
M                                               "C'83L+IGJKI[
M.-]]@-@X_K#4^NZARXRC+LDE_;PXS?D3$&M@1FR6_-L)TA34.MK833LJ9)<:
MC1F77W6VU1M:*QU6&N;^9W\BK.?DJQ&[ZN=7L0RG2'4:V?A.9YD^7/P&-N[L
M;@N-SX5+95^/29<.BH&Y;9NO0&)\I^<3;!OOLLJ?A'S>Y[F;1%8X0IOMB$:>
M+!C5\=$./^U"$MH_8CP]&T^)?4SY,_Z\\G^HII,V5_<B?-P99(82ZXMPFR;2
MIQQ9I\D(2DR6A*_3T49E^WC]?0B,U$1V1&$+6B<)ROXS'PHQ)47&ODG[<8#+
M.V5*B6W4;7V8Q&2*)4I:<=:WMD6/R4'Y2I1NM*Q=3Q))IMO^292OWH$E&K1J
MS]=O<MTZX_=*<X1$1<%Z$7H1%]"(;&@                 4VVQN74>A\*M
M-D;NV?K_ %#K^D)@[?-MEY?081BU<<I],6(W+O<CD1HR%O.K0TR@W/):U)0@
MC49$<;6K6,VG BI]U/R[NINKI]K@W2'5&7=MLP@R5PWMCW[TG4^AXO,5U"I5
M1;64:3D5R]&E);2Y&*C@QGV_);%D9&A1Y+]Y&/\ CC/M]/T3B(S]4HE_>?Y?
M._OR+0[&C[$;Y=QO4UDXR\KKEH:!,UQJA"6/MW4(R-Q<N3<W9?<,-R&FKVTG
MH8>\G6":+Q93@G9N[B9ZYX1X>'I[5N=45Q7FQB5-.T@TQ\?J8L)*_P!C;\&-
M%8DN.%^Q*7)CI&\KDR5^[S\?IY?])%96D1*B]L<G;HJ$LN-O3$H-7E[C).RV
MG%.O'QRCR69$@T\F9ER2?0_UXYLF&3;>9G'DX,O*\;QPWFW)L;[EUW_/'0I3
MLMYU2R]A#T%OETT&?D25$WZ?KQR7-%KS637,SS9(>K_Q-_)?WH*JO-&]2,WB
MX%9?QS[&TMM/1=3ZY_BK-9MLW%-,S-V'(N(J4(6XY_#19:TI)'[>7&R7/5]W
M=RB?R6Q2)_<D3=;_ ,/'+[8XMEW)[>PJ: 25I?U]ULQU^>Z:32?LF6Q]DLH;
M;XY/W&2QMU/_ ,+OZGKKVMO[IP]^W5G,ZT_C;?%%UQ<KK27HN;O_ "NN4MQO
M)>P^12-@(=6M)H_RX;';@XZHDI,B02ZA7CXI,OW<F=U>WI7UO8I6)S$,W&%8
M%@VML>K<2UYAN+8+BU/%:@U..8?056-T=9#803;,6#54[3+#3:4D1)0A!$1$
M0NB(CDF]8/0                          ' LZJKNH;U=<5L"VKY+:FI$
M&SAQY\.0TLO%;;T64E:%I,O0R4DR,)B)YC =W+_&L^,KMM;RLUQ_7]_U7V?*
M4IR3FO6NPK\,KK19^2_&ZUS8QIN.N)6XHW'W8M=&D.G_ 'R#$(UTKQK$(6UU
MM'%% [Z_C]=^.@]E'RO4=%E'??0,A?$F^U1@T]W<&'2%FDBCY3IJLD64UZ+P
M:U(LJ1V8RE+2URT0O)I+D;3->,US'JACW=O/AQA@\SE[6-YC46RQW)4GDZY,
MN!>83:5MC37N-6<1U+,F#91)K#:?/D^?%+BE)(N%D@S(CJMNU9BV.7L9M=)I
M:<>GM=.QU W9F>-6F6Z_Q>=EU/04S>2Y4Q3QGIC^-8\[;Q*!F]O/:0;<:$NP
MGPX*)#SB4'(D,,$?NO-I5@[C^1K%NFO''&<>$<(SS\YQ[>#3]6/4M5DHM<<D
MRF4N2:Z;!E.1Y<(R.,_&D,GXJ;=1R7'J?Z_H.AKV:^YU1:N.'L_JHO&8Q;DR
MC_"IVGZK]1_D.U7V4[J?[G>UOK^FR^1CEC08VYF;>,[%MZ]%1CN3W&/127*>
MC0FW93Z'(;3K[,A+#B&U>)FFK-:;,VY0J[6M:[HM/'TX-F?U'^8CXU.\=NC&
M.MW;;6>6YP[(5%B:YR1ZWUELBT>;CKER/]OX'LR+46EHVRVVM;[]9%D--D7*
MUIY+G57=KMPB7<Q.,LEJ5)4DE),E)41*2I)D:5),N2,C+ZD8L>/Z
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MC$>.E#*=>O335'TQQGG/C/IX1RCP%YXM
M
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M)0A*2(B(B'T41%8Q'"(7.R'H
M
M                              #_TI_
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MS+8N1,M'][E.:WJ$)=ERGW5NN)0?#+"5$S&:980AM.VE(I&(:ZUBD8A><)I
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M5U=%CP8$&.S$A0HC*&(L6+';)IB/'8:(DH0A)$E*4EP1$-S:Y0
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M.J..(GVK(K$<F5!*4I224I)*4D1)2DB)*2+T(B(OH0M>OZ
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MNM>/.5\5K7E#,.RPS';2U'9:8:01)0TRVAIM"2]")*$$1$7_  (6)/J
M
M
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M8_W4M9>KC[RB-QYU9FI2C,U*,_4?3ZM==6N-=>4+57A8
M
M                                                    /__3G\
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M4A/N/.?M0A+;#*6H[332-E:Q2,0WQPX+JQ(
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MJD999);JS-QYPTFMQ9FM:E*,S/7%8K&*QA'.53!Z
M
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M$8]/-(3^-#\<+L1W&L*;:O;.7DG7_KP;D&WC4$B-'C;7V7'6\EW^/A0EDO\
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M4]
M
M           '_]2?P
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M=;'J<=Q3%*F%24E5 BH\&F8L" A#9?U4KCE1F:E&9F9C1$1'"&SD]X/0
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M.B/6Z&JG17$\V5(6+
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M&.X_2PT0*JHJ*N"E#+###+:&VVVTD24D1$0V1$1&(:HB(C$/6#UZ
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M!)')L)BT-H)V7->=>7P7DL^ K6*QB&[$>"X 2
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MQ,
M
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MT8GKM\$R9MMMIM#32$---(2VVVVE*&VVT)\4(0A/!$1$7!$7H1#J\FM^P
M        8H/EL^1FFZ"Z").*DS?=B]PKG87I'%&GX:E5EH^PEJUV3D4=]7)5
M="T\F6I'CS*D>S%(T)<<>9Q][W/^/JGI_=/+]4JUSQ\&LSV'F5S9Y-DMY=W=
MED=W=W%M;6F16\MVQM+ZWMYJIMK=V<V89/.R'WE*6MQTC4KR,S,S/@OD*]KO
MOMF]^/+S]_AXL7>;JUZ8CU_DMXO\G>(D+<<1[#+CSTCDDJ0PTWXI(TH4HN#X
M-9)X_4R+ZF0[>O5]NGKX.7BUYS"49^-%\3$[L/M:-\AN^<70[I+6UY-K.O\
MB^1UKZ4Y;F50M+G_ )%A(F-^V[%K'R2W&=02N91.&EQEV(DG-?::+WOU[.4.
MKVU9KF9\6PF'5:@
M
M                         ?_5G\
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MX\12)F-X-$/S345#;IF1,QUFX_XH5(==]MHF^EKU12,SQE?376C,P+E@
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M'I8]6Q,F-0FJ]R[R"P_=+M;-]IADI=K9R)$R2:27(?<7^X6Q$1PA>KH/0
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M#2D_0
M
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MPFB9BP8$-@B2AM"2)*2(OH-<1%8Q#KQ$1PAZL>@
M
M                                                 /_6G\
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MC4E*W'E183#;<:,3BR990:UFKIZ]==<8AT]>K7JC%(B%^PL6
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M; D-,LOO1IK.KS)-]-:?2Q(0BU3#5"4\V;'W"7_)L6ZZ]$3-XGCCGS^"J?\
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MBG1C4N
M
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M*?J9FI79U4Z*8GF[';:?L:NB>,^+(:+%X
M
M                                            #__7G\
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M,;;\O#UM':Z.G-Y\4]DB(BX+T(O0B+Z$0Z#<
M
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MBEPUR0DSK*UM2C2EJ/XJ<)*#<4LT),NMJTQ3ZK<;?A[%M:5K'K9CQ>F
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M1>#SJ_)*R1X(4@C02U=[^,[::4^_LYVY>QLKKBOM2DQUDP
M
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M0[,:E6Z]$5XWXRA:V4D BX]"]"+T(B_07H@
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MF!0XYCE#4Q4PJNFI*:L;:CQ8L=E"&F6&6TH0DB2E)$1$-41$1B%[TH
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M)21$1#IQ$1&(:N3LQZ
M
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MUK22V:J ;KB&&R\?,S4XHN5#I=KVT:(S/&T\_P"C5$8AEQ&MZ
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M#8Y@]
M
M                  !__]&?P
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M93[".:DD3B'R=1RVXA2FB,4=37,VKF4A,7+
M                !T>2Y/C>%T%QE>89!2XKB^/5\JVOLCR.TA4M%2U<%DY$
MVRM;:R6VQ'8:;2I;CKKB4I21F9D1#R9BL9M.(&MD^>'YG>P';GL5LGKMUB[
M7.*]'<-89Q53^H[N10Q]]6G\8Y$RVQR;-*%;,V?0NNOO06*Q$E4"0VTF0XS(
M\VE(Y<;+]WMO6,]%<8]?/U-5-=.GCS1M8E!'HZ\U1$K::-)H3XK,W'.5<DMU
MU7*E'P?'*E&9_I_0K:Z(B6#N+],8\_Z/3M18AP&7/%2I'EY-D9D24N>/'[U<
M\F1_\!=6L5Y./LF>KBZM,E<=:&'?-*&W%*:)!EP:CXY)PS,OZGP)*;?M=1?O
MI4LE^7AXH43:N/1MLD^:E.&GGCT(S,_I^G/)D1^*9K:?VL[/X^GQ$G\F>_I6
MT]S0[!'4+KQD%3:9@PNO>^QW9GS$E-A1ZJA6KJ29.O:0V4[)%LK6Z45<>*EM
MM5@B7%]BLVG'@ZW:=O/3%K\&TH99:CLM1V&T-,,-H99:;224---))#;:$E]"
M21$1$-#IOH          ,0'RR?,EUR^*K7]<G-2D['[#;#IK>3IK0V-R&$W%
M^_%;7%B9/G%DM7C28VB;X1W[%Q#C[O#R8,:4N/()FK;MC7'#C*%]E:?N:OSM
M1V0W/W=[ 9UVG[&Y0WEFS]@3U3'J^$;J,2P:CBRS/'=<:^Q^:[)<@T-6P2(T
M&,[(=>69+DRWI$Q]^4]BC5%[3LOQF5?^12TXCT^:W;(GOX\^7I9QC9::4X^\
MY[W!*27LD2T&HU*7RI*4(\U%X\'QZ#5]R*5X-%)SS22OB#_&]W)\@%5B?8#M
ME8Y'H#J'9M-W&-X]7M)A;MWU5'X2:J;3M6C3C..8](7P^BXEL/2IL<O^PC--
M28]JU7%+[IB;<O3DLF8KR;&+0N@]/=8=2X5HS0NO\>UEJK7M0S28KB&-0DQ(
M$&*VHW7Y,ET_)Z7,E/+<DSI\MQR3*D..2)#KKSBUJUUK%8Q"N9SS5?'KP
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M\#BO:A>:]7WM$?3..J/]L_G"F],PCS3&G29C3D+6RO\ ^>25&3D933A((V_
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M00(U71X[CE! ;JZ6DIZV&E#3$:+&:;989;224(222(B(;HB(C$#T@]
M
M
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MZE8B(Q"\<6/0
M
M                          ?_TI_
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MZ&V?O6%I/?6<BVR&^L%_OE3YTA3DB5(</E:U']"X(M$1$<G7B(B,0N,'KT
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MX<=F+$C-(8C1H[2&6&&6D^#;3+39$E*4D1$22+@B&Q-]P
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M<8]7S56I,6B?++PO0+MEE_03NIH+MMA=8J_EZ@S Y5YC3<M,=66X-?U;^)[
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M./ON..N+6KHQ$5C$+9G*J@]
M
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MZ';4B9Z_)/>';;0
M
M                              '_TY_
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M]ALFU3K.61$Y*E.F1K?DO&IQU9J<6HUJ49Z8K%8Q#;6L5C$*X#UZ
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M7.F/J4](?<<>=6IQ:E'UJ4K2O37E#K1$1&(5F$GH
M
M                                                     Q=_*/\
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MQ6XL*)':223<62"Y<=69>3CJS-2C^I_3CK5K6E>FO"&B(B(Q"I0D]
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MD/V,Y39<NR9"R4Z^\XI2UJ,S4I1^H[.K5732-=.4.O6L5C$*T"Q(
M
M
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M^Y5C#TNY44)7W;'F[&\6VU$;2D?O4XGQZ.O?>;Q79B(GVH=5>4)<HUO0
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M.6VM8K&(:X%Z9-N95UEV4W\W+,^S*XM,KSO+KN>Y.N<HR_(+!5OD-[>RI?\
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M6B8C18L9DDH;;;0DD(0DB(B(B(N!M=!RP
M                        1U/R:N\&(=7?CBV#HYF[6QNON?66FE]9T$5"
M7)$C$CE05;FR&::E)]N%&HI2ZY2T>3AR)\8DH-'NN-4=Q>*TZ?&7L3CBUL]
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MZ&O7&N,0VZZ1KKB%\@FF
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M:(DBSJ:66])CH=-IPFU.M))1H41&?B?%U-NN_"DY17)BP
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M50HU=6U\=J)!@PF6X\2)&803;+$=AHB2E*2(B(B(=*(B(Q#2YH]
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M=$ZXG_$N5/6Y$6I"C/AC_I/@SGV6K-IW6X^$-G:Z\1-I3.QTFP
M
M
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M606_\TN0?^6PNK:6LS<DS9CZER)<EY:G'7%J6M1J,S'=K6*QB&_&%>A(
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MU;"Q6$W&EVDKQ(DI791S8L#21%P;Q_M27!#=VVS[FJ/..$NE2\;(S#*X-"8
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MZ:XO$3/*,ME.E*4)2A"4H0A))2E)$E*4I+A*4I+T(B+Z$.LU/T
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MO_QU+"1#1+L9)$2GY<@TF]*DN<K==4I:S-2C,;HC$8;JUBL8A5\>O0
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M;(K%>2_$6/0
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M+*^+D@
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M<S#C$27'Y4Q;SKKO_49\^A<$6K72*5BL-M:Q6,0N<$T@
M
M
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MQBA@QZVHI:6JC)AP($&%%2AMMMMM"4I2A)$1$1$1$1$+XB(C$+WMAZ
M   #"W\V7Q3W?RLZ.U-K;#=B8IJC,M7[63G4?,<HH;"];D8Y)QB;376,1VZP
MR<1]W(<@/K4KE)$QSQY<$>'ONUOW-:_;F(F)\<\O<KV:Z[(Q9:[T7_&:Z*]:
ML91+W[CD#L]LV:R:+*SR1JTJ\)K36EUEYFBQR+)2I?FE:%&_)6;A*27B24\D
M?NGLZTKC;/5*BG9Z:SU6C+.!UTZG]=.I.-W^(=;]38OJ+&<IOUY1D%-BK<YN
M':7ZXB(*K20F<\^KW/9;;;_:HBX21<#33537GHC&6JM:UC%8PN&%CT
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M2_<N',6TTZJ!7<_QU4TM"31&:0:B]U;JE;=6N-=<>*J9S/!DJ%CP
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MVS)G-641X\1*'3(K>-&9984[:NN)[?:[^B_1;E/X^G#X/:VC]K8]CJ)@
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M+R,4QG:-;33;<V8\9]^3_%LR/8;1YO>"5(-4Z[J7G$?.,#)P+0
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M28#^/MS%(+R-"8Y+^B0[:O3G')JTYQB4X4:EP
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M/"(;-(=!O
M
M                           !_]>?P
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MUR]M;,<$\$:T
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MKHW!_<2F,;ME<6,=E1>+TRI?E1T&:/-TO-'EIT=YHW\*3B?*4LY9-AJ
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M7GQF/E_JEA#8Z0
M
M                                /__0G\
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M2<C_ ,C8H6ESU,G&XS*T\?KN[:G.\NOV],5ZI3%AK:
M                 1I?EF_)+ZT=#UY-I+K:G'>U7;N JRI9^,TEVE_46FKZ
M.I<#_P#.[EU*X:Y,Z+*2OW\8IW?NB]AYF?+J7%1U/8]_=1K^G7QGY1^J-K5I
M&;(#?<?OIV]^03-&MA]N=O6.PG:R383<+UU5QVZ#4VMDV3Y+?@X;A4(R80IM
M"6F$SY1OSGD-M_=RGU)4:^5:ENZV1?=.>GE[^>.#+M[F+1$:LQYY_I*SN,@D
MO$MU*32V1D:$G[2>$D24^+:C\4D2>/4N"X+@_7CGHUOJUZ^FD3GW,WW-O5SX
M>]ZO'\?N<ZR;'L%U_B>2YYG^8V**G%<!P:DLLLSK);1WC[6%1XM5(<D/&YZF
M3A-&@B(SYX(QFG[TVS,QZN?I[%M9F\X25^AWXK'=K?65TF3]W;2/U0T=[C4V
MVPVCR7'\RWYE5>IMF0Q71FZ14VBI&WVG'FUR)SSTF,Z@TJKE\I<3IUZ+WG-N
M$-5=48XIV/3#X]^H7Q^X#_X^ZJZ6Q?6L.8S%3DN3M,NW&P,XE1/-35AF^=W"
MGK.R<2MUY;2)$DVF/<6B.VTV?@-E-5-?[8616M>4+SQ8D  ")=^4_P#(3::=
MT5A?0W5%\B!L7M%!L[G;MC6VBF+C$]#44MF([4.1XCB7FSRR<IR$2G"-EZ#"
MLXSB3)\C3B[O?6F-?//DE68CC+7ZV/-8S%K6$I9CQHGL1D)21)-Q!)1RDBXX
M-9&G_0_$U>G/ QUZ;>#'MG,\%=^DW5;)N]/:W1?5#%KAFEMML9.]76%R\RIX
MJ3&:2"]?Y=;(0GU-V/719+S!?M)2TDGW$&?)IU]=ZUKSEYJC,MOWUTT#K3JU
MH_677S3]#'QO7.J<3K,2QFL80A*SBU[7#]A/=27+TN6\;DJ9(<,UNO.+<6I2
ME&9]:E(UUBE?!JB,*TB;T     81/G ^8*@^*#05%98KCM3L3LON.1;4ND<
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M92HS;5]GV<V[:4JF6D];:5.+X2VRVEJ-&;9BL,LM].E8I&(;ZUBL8A=V))
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M$./.S'*.,W9U'!.$2"R"L@FZ:7#92M"%*&V>XMJC&)]W^J[7VNVG"R[#JO\
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MJF9,MH_]/VC36_<3''$>YIGNM7A$^GO6X;+_ ")OF(SZ>NRK^SU%KN"^@_\
MZ#P#56NJJ%"]$\&B5:Q+"89^GIYR#_7^H]FG<VXQ;X?Z/;=UIQ$1$_+]5&W/
MG;^8PD>#?>78<B.?[E248AK)HR61^J/<35^?']/'C_7]![&CNK1PM/S_ $1_
MRM?E/R_5P#^<CY@Y#GO.=V]G*4?!$10L>B1S+^I-PX+:>?\ @0G7LMUXSMVS
M7WX_&'D]S3/*?3WNXC?//\QM,\A;/=+,I1I]2CV6'X1:Q5$1?]2Y=:;BO_TC
M$_\ !F/_ +\_^Z/^E.O=:8_=$_+]7>*_(6^9%]7[NX[\11%RM):MU>RR@_\
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MZI)^I$LD&DS)1$9FE1%93N=&R,UO'X?B\F)CFN.%[P
M
M                                            '__1G\
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MO_$EZ:XQD^:=C>^&6TC-A;8+:1M!Z2G2?\J:)^PJ"O\ :MQ$9<;-)/O1I-1
M9DMN&M+1RFC)*5_O^A[*,TZI\/T<_7'U6E.B&Y<
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M&G13MZ5XSQ::Z:52!4I2A*4(2E"$))*$)(DI2E)<)2E)>A$1>A$0O6OT
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M3\$J;(QP_JV)7XE??G=G9W079/KCO[8F5;9RGK#FV&V6!9]G-Y)O\KDZMV?
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M\V9I6A:3)25),R,C(R/@:.?&!]@
M
M                      ?_TI_                            (IGY
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M,\?\<U_S^ZNELF25.^VR2G$L)<5IT:NF.NW/\'6[31.JLS;G*28-+6
M              _AF22-2C(DD1F9F?!$1>IF9F U^7Y#?SIV6_+?87Q[]3;2
M?1:<QV_FXIV!W-63U,S-NV=',7 OM5X@4<T.QL=C2V5-6=F3A*LUI]EE)UA.
M*LN9?NHW7G73]M>?K9]^SIQ6/%$OJG(=6I+++*/ B/E1$9J4K@_4R+U,_$OK
MP?H7'/\ :(XES\VF>/)PIGW]S-BUM'639]O;3685-754-VRMK6T?<),*OKZV
M+YON/O*,B:0EL_4^%%R9$*JUFF9GC['L6BMHSXMC5^.3\--CT2U+([.=DL<2
MSVRW731DP\?M66USM*:TDI;FPL56RI!''N[)9(E7A<F;)(CPR\%,/&YO[?3B
M?NVCC/+U.CJU],=4\Y2=;&Q@5$&9:6LV)6UM?%D39\^=(:B0X4.*RJ1)E2I+
MYI0VVVA*EK6HR)*2,S/@AJF8B,RN0>_FI_)<B36\JZG_ !IYG&LTSF[+%]F]
MNL?<*555GBIR#=8SH^2XW[4YUQ/+:\ICK5'0VOSJW'G5-RX^*V^=UNC5^WQG
MS]BF=]8G@@_0F8E:X]'2Y_EY>DRYCJW'')$B2KS=>>D.F:UK6?JI:N3,_0SX
M))%.FJFJOT1C+%W5ZWZ<Y\?R?-M49J5_(39:H4+VU^[*6:$HCMEZFOS7_=Y?
M_@\D7H1F1FDC3>(G"F--92?_ (>_QPL^[SX_AW9?M#9VFG.KUS,9N,7UZU62
MX>S-U4#;GN,VRW9Q-G34=@GQ4Q*6E<B4R:E,M--.,2ERBMMF)CA#5K[28GC/
M!L4-2:CUQHC7&):DU)B%+@FO,&IH=%C&+T$-J#75M?":)IM*6FB+R<5QY.NK
MY6M1FI1F9F8T1&(Q#=$16,0J,/7J S^3C\P2=OY';_&3U@S"')U_BUK&=[=[
M$QJ<<I=UEE#:&['T'6RR03*6:Q]AN;D#[#CAKF)8@&IHXL]EW%W$VV_128Q'
M-Y:\4C,H>5DMAJ$TVA)I0PTU'C-^7*4>*?V(,C,S(B/R,EJ,SX,B,RX(4W[?
M[<1$XGT]CD[=L3;BY>O<!RK;.PM;Z@PF)]QF>V,WQK ,2ARG6F/N<ERRX9I*
MKW%K,_!HG7B,W3X-)>I\$?KYCPAY68OR;?7XXNA6JOCLZNX#H#6]36%;5];%
MM=EYC%@-1+#8&Q9T1O\ W+E%DX1J<43KJ";C-N.K]F.VTR2U);28Z&ND:ZX\
M74UTC77"_,6+                               6O=JNZG57I%@+FR^U
M6\L"TQBJFY:JP\JMB/(LH?@)0N7783AE8F1<7LQM+B%*AU$&2^25$KV^/45[
M-VO5'5LG'X_ ]:''W6_,,R*7/N,*^/3K;'*$@W(\/>'98Y<;[QLC=CKL<:TY
MC$AMXFG.&WH4JVN4++U*36$9&V>..]F]IK2LQ_KCV>OAE&-E,_5E$;[+]C>Q
MG<W;$C>?:?;F1[LV9+C0X3=IE*8E;18[4Q34N/1X9@]*TQ3U,)I:UO(BUT-M
M"GE.2'".0\\X[JUZ+W^J_CZ>3V>XUQY^['ZJ/_>>!*4Z24K)*R-*VG&T)1Y>
M?[$^)<\J4I1\<^IF?IR/=W16(S'$C;79/TQR<=W(6VOMH#$-V>_,63+$&##=
MF6<IYY1):B5]8R1O/.N&?[?!!EZ<$9J,B/G6YO4HKXR_Q9^Q?:R'B6YN]5W=
M]8=&SWX-S7Z1AQB_\]YS1NM?<(+("ED;&*,OH6WPF<W(L$FEQMR#%_8ZJ[5H
MM>.JW"/F\Q#8)=>.N.DNJ.I\6TAU\UUCFL-98?#1%J,;QN$W%;<>]M+<JWMY
MA\OS[&4:2=FV,QQR1(=,W'G%K4:CW4I6D=-7JMHD     "%+^5=\D5<>.4WQ
MEZBNON\DR5=!L7L[/K9[9,X]AT%W^7P36D]MA*UG+M);<>[D(-;*F6(L7GW6
MYBDIP=Y>9C[=?>C:<0A#27$L0FXZ>28C0T-H,UDIU?"?%ME""]5<<&2>"/@N
M",R].<>KQ8[[(G$1EW6D-/Y[V.W/K#0^L:YVWSS;F;X_@F-16$FOVI5[8-PW
M[:8MLEJ:A0&EKFSY/@:&&65K<X(B\M'3,\(>1&9Q#<.=-.K> ]+^LVH>M6MH
M;47&]7XE IG)*&T-/7=\XC[O),DG);X2<BPG+?E/&DB(U+/@B+T'0UTBE8K#
M=$8C"YT3>@   +=.UO:S1O2O1>;]B>Q&:1<(UG@D%I^QG+9>G6MM93I"8-+C
M6-4L,E2)]E82G&HT.(P@U*6HC5XMI6M,-FRNNO59Y:T5C,M3#\F_R![.^4#M
MUEO9G/8$S%,:B1(^%:2U8Y-9L8.M-7U$A<BMK'9+33:95A/DN2+.WEF2B7*>
M4EKQC,Q6VN7.S[MIO+)L[FE_II$\/3S6"R3;B(\G%\J2DR)))(B+@B0G^\S4
M?H1?51__ %S._7,>]Q]EKVXY>>G/-HC(6XIPW93R&V&6R4OWI"UDW&:]LO[C
M4I1$@O!7K]#)7B2M<6K%>*.N)GFVN'X_GQG5?QV]&\1E9=0KB=ENQ5=1;8WW
M8VD%J/?T$JUK2E8?J)2EM-R&8V,07_8?BO+<+^4>LI"%)1(2VW[2L1'5YOH-
M%.BD+)_RY99-_']I6"A]#4FQ[48BF.E:S2A9Q\$OWEK4DN3,D>BO0CX'-_EO
MVZH_]7Y-FF<6EK\LTG3F9J%M.&ZZ=0A!K4@CX<-!>9GR?U4G@O\ VBFW;7M3
MJX>GN6;HS$0VA7X\>"8#A'Q(=4GL$?A3CS6AR?-\RLXC3;;TW.KC,9[.1,SW
M$$1K=A+83 Y5ZDEA*?T'3[2G1IB)YLE8PS7C2]
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M$E_T^//!_D<3OG'A$,VV8Z^",?=NOIEFW(,S2A)K(S]2)2G$I(O^)D9<_P#
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MP^!D,14&UB8]5Q(D&,1K:6I"9,MJ1)21GXOEY*YMIHUTMU1S>XB.3-"+@
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M$Q9OL'X?MY;<<6V9HY29IY29IX,^EKOUZZW\X7*M"8
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M:3$^QZ]")
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M>1Y;"2;B)F2?;K0<9IQ1HKB6LU(5-]M<-IT_WW^#H=GVMJ_\NWW1^J8B-;I
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M>Q!R8U[=U(USBU=&8@4ZY)<M_<DE^:ADUL%+-IUU*XTT5I.9XRT,[8O
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MGCS%U*LJ2(ZY[TMNOO'YR)ILMFF.F5$)9D;R2.[7BL17S8XF)G$>"7R+7H
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M'P7]OB2S_P#A_IZ^I<C=I[_IST1%O=G\WOV[^3@R^OV=39CC9QYWW"D*<?\
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M=_XH\HD_<$U>X7>1F3/]&GTG&6Y_I_A3R)SW=H_L^$_T65WZ[<I_#]5RM?\
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M0
M                                   '_]2?P
M      P#_,7\^O7+XN:*PUKC3<#>G<.\IUKQ/3%';15U6#/SF6U5>4;LLH3I
MR*NO)#J9+->PVJ;-22$(*,R]]ZU3MV]$3%>,_+WIUK$\;<(:R'=>_P#;G;7?
M6Q>R78#)7LMW#M/('+_)KAQO[2%'\&&J^KQ^HK$*4F)6UL)EB! B(_:TPTVV
M1K-)J/F6U[+S-K3&98NYIUQ]/IR4PO)'@C[9L_<?=4K@^4$I7*R2?!%QZ$1E
MZ?Z'_P U:S2>/BYU:_;F<SS>?5#;CJCNS5>,5*E$_P K2MHU>7[$&TGE:U+4
M7"/%/U]/J9"R;Q$9>33KG-93KOQNOA$J\AH<8^0CN9KB4J6_9?S'6?4><5:F
M(C=>RI3L'<V58M9M^2W)"E)=QMN2GQ)M"+%#:O<A/(O[;7U_\EN7AZV_MNVG
M7F=F)SR3E4(0VA+;:4H;0E*$(0DDH0A)>*4I2GT(B+T(B&YM?H
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M^J<RZ-=5*\H2"HL2)!81&A18\.,V1);CQ66X[#:2+@B0TT1)(N"(O0AH6.0
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MEA8=BSC+:I.%ZWHWGI)P([SR35/F^Y[\SQ;)?MM(2R5FO5%.,\9:]>OHYL_
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M8CQHS#9NOOOO.&24(0DC4I2C(B(C,_0!K"/R%?D&UWW^[_T#&DLP3GV@.L&
M3-;X9?USJ)6(YALFYR!^QV?FN(2TI(Y$%W[>IJFI:34Q*37HDQ5.1GFW7.5W
M5_N7C'*%=ZS,Q:/!@"RJ8\\PXF2E3)LDMPUK+Q\E$L_'_F?F9<?T(A?IY*.X
MUSMCZ?G[DN/\,77.-VW8?O5MF6^\K+<*UEJ7!J5@GB2W_M_8>36]Q?+?8/\
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MI!F7D:%I-23]2/T41*(R'0[:)C12)\FKDO,%X
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M)I>G[8YN:OK%=2&/N4Q4(3^Y2I"8KAMMEZ&I1R27SZ_T\?T$YV:?")^$//\
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M>2I@M>
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MJ3JZJ=7P:>?U,R,OT/T&VLYK$MO+@N;'H
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M<H.HH^Q>HLDO8-%,]DF[&ZQC&;>;95_@M]AJ0S/B,NL.K2R\AMWE!48C9/\
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M/]!9K_P=V>%8QZJI5_E,>G]751L:R(G?\,V9+<4?!G(ES6GTG_T&CASR]?\
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M^*T*0?"DF13K:MZ]5)B8GQCC#QW@D               _]:?P
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MTZ^3267K2WFJ\I$^>^2$G)GS779#RB\G7%J]1TJ4KKKTTC$--:Q6,0K8)O0
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MPV!:0F6K>6V?'[(;'LHCPF"]$-(3Y&M?DM6FM<0[6JGVZ8GGXLE8DL
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MY-X-E+V-EL1[8NS)KI1TQWW2SC.%SIT1M[CS<AUSD:(2C,T1T<\#73MM.O\
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MT92D-O25MMOV+S7W;[<=!L0XO6[?MXTQF>-I;].F-<<>,LZ8TKP    !"O\
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M:C4.+N.+8C7CKG_:V&Q[V$2E(=F3")10C<3Y,L'X%[9J<(_GN\W6[FT17./
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ML"BI-"_[R,TD2C,DJZ^G5;9NK6>,9S\$-'.6UQ'T#4
M                                            #BS84.RARZZQB1;"
MOL(K\*? FL-2H<V'*:-B5$EQ7R4AQIQ"E(<;6DTJ29D9&1A,1,8D6HY_T%Z2
M;2=:?SWJAH#(I+)/I3+D:LQ")-4F1X^Z3TVNBLNN?V)\?<6KQ]?'CR5S1;M>
MWO\ NI'PQ^ MUO\ X6OBWR5I;-ETSU<RVOS\BHY&88N9^?'D9*QFSB&1^GH9
M'Z>O'')\U_X/:?[/G/ZO<K:+K\<7XL[9E]F)JG.,?-TE$AZGV7?NNQ35]3BE
M???(3_P-!D?!<D? K_\ '=OX9CWO>KU0MTRG\5[H!91U_P"U-C]B<8GN22<]
M^PN]99)"8C>VLEL1HAXQ#>2LUFVHG%RUD24FGP,U$I,9_C-/A:??B?R>Q?$3
M&(4"O/Q*M#2WDKH.W6TJILE*4:+366%W"S(^/%)/5TRM/T]?51'^G''KS'_Q
MFK_=\H0MBRC^<?B+5\UQG_9?=2;[!-<OHRC4,=OR?\N$MM(K+EWQ022Y-9J,
MS,^/$O'E4Z]G?5&-%HX\\Q^DPJ^U&<\%*YOXC&VV2\Z+N/K>,\A/"#E:PR(B
M>_HEQ34Y?A^OJE*OK] ^SWG^ZO\ \OU/M5\H^"A&;_BK]^*"22<!VYUNR]DF
ME+*Q=L\PI)QF:N#95%M*M*$N*(N3,GE((C+]W/)%&='=3PV8GRQ,_F\^U'E'
MP4<D_C-?)W#/_M\<U=;/&?\ D<:VG01X3IEZ>?M2I3:S_P#P>4%Q_P QGMVG
M<SRK\X_5[]FGE'P_H\?EGP-?+GKR-]MC/7T[YY32G#GX3NC 7F5);/Q2A<-^
MX0KR]5>"."/Z\EP9<TV['=,_72?=A7L[?..G'I[E#C^+3YN:EQR/'ZE[R=::
MY2ZC_=V/OQ7DGSR37V5HXE1>A_VF?_UA#_"O_LM\(5?X]O3_ $>%E?%Q\P";
M)4F1TEWZW)4X2_=9JI%DW[A*_P BR>ANK+Z\'R9^OZ?00MV4^.N\^X_QK*LM
M_'Y\R,W&JS$KSJIV2<Q.GLKB\JZ+^%R)=?5W>10X,"_N:ZMAOK2W*FL5=8S+
M?0R3CR(D5"U*2PT2,6_L-]J],:[XYXQX\,^'CB/@]_QK3'/T^#Q,OXX/E2:\
MV?\ ZCGM-8H]>748-GC*FB4?!);\F5DYS^O''''Z\C%7^.W:\YT[)SY5S^1/
M:VCQB?3V._POI'\RNN;ZEO<3ZK]S:"53V<.XI[*CI<W@V5/;54I$VNM:V16D
MA^+)CO$AV.^@TK2M)*0HE)Y*_7V6^+1--6RLQQB>G&)>1HO'+T^2[JS/\BG'
MJ:RR*8?R,P<>JX,F?;.V.3;KES84.*R;\B4I#LM"TMM():W'"5PE)>2C(BY&
MW[?\E$9FVV(CUV6TU[/[K3\6,VGQ3MQ@V656PG< W?AN5U5M"R"@RV'C.4T-
M[37U+,1/K+BIM(RVY$>7$D(:>COL.)6TXE*T*)1$99M>C7KM%\6B8XYX9S[4
MHT>4KL*;;GS$=@862:[P_/\ OKN./?8Y:Q\FPN%E.\\QBVN&STIH;QJ\QI,^
M24BK=*8W#GD\PIA1/H:>Y)Y*5="FS9MS2+;;>K.>'Z%]-L8F9X^M9?MC4W:+
MKQ=P\>W_ (!D.JKNRJ&<@@8SL?%+/%[VPH9$M^O8N(U/>(8?<B+D1I#")'MF
MVIQIU"5&IM9)KOKT:YQ>MZSZXB&._9=7&/3Y/!1-DS3AO,EC>O;!+Z"2;DV(
MXQ-;\",C6POS+A2N>?V\_0OIZ#RLZJQ_Q9CSSC\F>>PV5\(GT]CPC>:32LC:
MK8T)J2M9FMJ151E,MFD_V_;RG"4HR]3_ +4_TY"=F/%Y_@[/+\?T>\L<PV(N
MJ4U(Q]VTKC;);TDL0L9B64<?M4S8)CF2.2\N%(47/ZGZ$(7W6KC'5[GL=ALG
MRCT]CP%7DF3RYJFJ^LE-QSY0N/*Q^2EU9*(R-+#KJ.4G_J7_ +A#_(GSOZ>]
M[_X[9ZOG^BZC167['U3D<786+8[4E;UB9?V4?.].8MM:@D*F0GH+OW6.YW7V
M=8]XH=6;1R8B_;=]MYOP=:;<1;7O/M3U1&R?=$_BE7L-E9S&/AG\87%9_P#(
M3VZR>IL<.1K/0B*Z[JYE/9O0NF'62ILEQ;",<-]RKL*?$&9\)_P6LV)<%]J0
MPOAQEQMQ*5E;_P"3S&+5O_[*K)[7?,8Q7_VQ_P!*SF3FNP::4VY8ZFPR/[Y*
M4T<W!WZ\G5I,C?4VR^A*5'^Y/)$7!>GH7(C_ )5-G*+1CSC'YFKL]E,\OG^C
MK9NU,IK#5.<U=BI*7R1(>P&&J*H^.4DEQ#9'QZ__ !$? NCN=4<^KY+Z]IQS
M;$^GL>KUOV:D8W=,66<=6-";'QY!2#D8WEE;E=/6V/N1'8S?WKV"6E+:H]I;
MJ)""CV;?+C:"7YM&XTY=_GZJ_MB??_25L=MJCG$*=;EV7@6R<EDY3C_7;!].
MPEG&]C&-;.9C+Q2#]O":BO''7GMO=VBC><:5)<]^P<X<=<)'@U[33=.SO9MR
MC'I[2>UTSX?A^C@8%N''**XI).3:3P#-:6MM($V;36D?(ZJ->0($I#\BGN;+
M&9U;8HCS$)-F2J!+8D$@U&R^RYXN)RVW;;3$\\>W\I0OVU*XZ(]/<KAN3LGI
MG.H%"QB75W1>DXU65@<U>LO_ "_>/Y$4_P"W^V;OG=LY9DKB#B>RY]NJ 4<U
M>\[[_N^+/M+[-EOVUZ?9U?G,H3ISRB(^*CNQ-I:9S>#BT2JT-AFLGZ/':JDM
M['#_ />TU&;64 E%,S3(V,ZMK@V+.<:B5):J#@UR?%/V\!@O+RE7?>O.,<O/
MCZ^,_AP]2K9KV5QT1^*FF06VMYK4&)68;,>2ILVER32R7D[XI)*F6F6O-')\
M^AJ/_E^L_P#*MYSZ>].EME(QB?FR%]).P'Q[Z=PV\H^R?0:Z[)YW.NV7Z[(+
M7>N0:JI,<I&8QH9@5]+BE;[\B0^\MU<J5.GO(-"(Z&(\92)#DJ_5W\:XG-9M
M,_\ JF/U6_>X1U5G/P76,Y]\)6S\^O\ (=C=7NTW6W&7:=J175FD-WZSV14P
M[2(U&AE"C0-JT,.>AJ2E,F8])?O92DOJ]MIA+"TE'NC^1US/UQ:L>JV?QP\^
MY29XQ:&.;LK0=,F,T>/K?LS;-EKB<B38P5[+Q+!\=SF@*3:/_:8]/=P_(;2#
M9G'@IA^=LV4'[A]3_P#]'1$(;]RJW>[)M_Q3./7F)^5IS[>'L0F_'AE:W_M[
M!6T./Q[:';D;ODEVW?BE+6@OIY);<61&?ZD2C_XB/^9W/G'S_5Y]R?6ZER#@
MDY1MSF&4$EPOVU,F&ITTI/\ <9I6X7T]../]193N]TYZI^<_JLUU^[G/AYO9
M4F$:=L7V?<R5Z*X^?@3#L%A]QHD?0W3]TO3U_3D_]!9_E;/]WS_JL_QZLNW7
MO0_PO7>I-EV&]NS786AVS18'7S\!QJJTE0PZR?L,\<LI-K2T#=18Y&WDD5JR
M;@1XRKRRPQ#R%H\Y+!2'W:R^G<4M6>J\Y]/7/Y/?\>C%3?X#K=+BWFH-PE+S
MBG'7Y,6M01H3Z(3'AH>+U(S^IK/G_3]:?\G;Y_C^KS_'KZ?Z*;3<1Q.O0^N*
MMU];BB;0S):CL&?*N>6VC<3ZER7]J_\ V>@C;NMD<_S_ %>3HK5P&JFH:4Y.
M2_["XR_:<BMNQR(TF1<FZVISZ^GZ*,1_R[>G^KR==8C/%[-C$L>NUQ'&"CNN
MK;,T%$EN?=$KT_8:/(R+G_\ !Y^@1WNVO[<>_/ZJK4G^R)='8Z[<::D_;R$M
MJ6YZ13F2"\"2?H;[S[7Z\_\ 3S^O/Z"=?Y#;'.(GX_J1&R(QQ^;SDG!Y2R2Y
M_)MH-MLR4PT_]RS]/7Q7PD^?Z_M'L]UKW?\ ?K'#EB/CSE*+;:\H_%T4;&_%
MUQ).R&N#/W)"XQK27!\%[7)GZ_7]"#K[3_;\H>_<W>7XO[.IYL!"'8\QQ3))
M6HW7C:8?Y49<?L22S(O^ =?:?[?E!]S=Y?BZ-JLR9]U$J._72R/R)!G+;6ZD
MO^HG$KX^OI]2_J'7VG^WY0?<W>7XO45U;<<FB6=;"6O@E+4MHB</U^I$9\\?
M_=".X[?7^VO/U1^KV+[I\/Q=FW&E5DEHGFXLE)&HT.0/M&%I^AF:UJ2?D1\E
MQ]./7^HT4W4ORK7X/>K;Y3\WM(M4>5LG"@P(S<\R_P <N0_%</R-)\)3XGR9
M^GTX(:(K3&;UCW0=6WRGYJ>V>$[!-Z7!E1*[PB$?M*L5NQ$K4?)$EM)O)_\
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M?#U>IKUS>8X\W3R3QQ+*';#'HCY$2O-Q\VI,EWGCUY5(49<?\3YY_P!!SO\
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MMXZ9MC/&9Y%XU1"<^/H&4     ?_UY_                     "-=^0/\
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M>5\A2G9LLEK=8<O)B6UN-I03,:+Y/>[IIKQ/5;X)Z]%:3U3QE)R%J\
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MBE?7E9J,U*49F9FKGU^JOW&I2J8KY,E[=3IK":R;JDK>]LX_BY[OGQY&1_\
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M$"'5U==&9AP*ZOC,PX,*)';)J/&BQ8Y)0VVA)$E*$I(B(B(B&CEPA:YP
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M4+=^8RHU^_56$5,R/,<Q/ X=U-C.&A1$<:Q1'>0KDEMH^IJ[.XO]41B)]?\
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M7Q?':Z+4T=#1U,5,*MJZNMA)0TRPRTA*&VVTD1$1$1"Z(B(Q#=$1'"'IQZ
M              ,%OR!?CU] ._V:Y#N.[I<VT1O[)$$]>;9T??LX\]E=E'B*
M8@SLYPRU8F4UBLE&A4F4W$CSI!)2ER;P1<8MW8Z-LS;&)EY,1/-'XR3\-W>\
M:>E.)?(EA61U9NK44G,]"WM%:QT+X+T;J,DLFG5$7IZK1_:1_P#5PFNG8SKF
M>F8XHQKA=QU+_$!T%AEP=_W9[$9EV48C*;_C->Z[KYVFL(<(E.$__N:QBS9M
MO-2M*FC;1"DP/;4E7FM]*R)NZO:Q'[Y3C@SCZ]^#KXFM842\=Q3HQI/[%QDV
M').1UEQFEVM'G[A*_P!Q9A,G3R6E7[D+3()2#_L-/!"[[&K&)A[,S/-K[_F<
MZ69+\9G??-,(HZ:WKNN.V7%;&T-D$Y+[V/,4%FKQM\!B6KOD29-!*-R(;#CB
MWU1RC2'5&;Z.?F.[[*-/<3B.'./3U/&,%?\ M?)/*QG6J(*B41)<>?1RZ_(X
M,F/!/[B41$1^I<$1_N,N2YLI-J0.FNH&/,14?;RXL]2E<-'%6;SJ?W>)J<)"
M?3GCT,_K^@G]RSR;8>=D//5B%+:4OVT-^XLEFEQ"4)/Q)1HY\B(S/CDRX(^"
M,^3+FO;U;,>I"9F7G;39YU,;V5,1V7%MFXN22B;<:0WR9I\'"Y-7')FE!&?T
M+ZF1"W7XO8MCFRF?'C\)GR _*=C-CM#4M9B>I=)QY4NKB;3W#/N**JS"P8(D
M2FL(IJ>%-EV"(ZC\'9?M-Q?<\VD/J=:>0WT-5;[.-(X>MY:.N8GR2H^@OXA_
M7C16>P]F=T=J1^U\NK4B73ZMK<9FXCK!BT)];BI.1N29;TVY:X]GVXJT16OV
MK2\B0ASQ1KIHQ.;SE.(PENZYUEKG4&(T^ :IP3$M<8/C\5N#1XEA&/U>,8[5
M1&BX;CP:BG:98;27)^B4#1$16,0]>Y'H    U_7RV_C_ 'R"9-WFW5NOIKJK
M'MQZ@[!9U>;58]C9>*8YD.!Y9F"VK_/*C*ZG8<ZK9-J5D,RWGUKM8N2A,=SP
M?-E:4(/A]UV&RVZ;TC,3Q\$;1E:YK_\ %C^6[9$RE=V#=];]+4=H["9R!=YL
MFPS/*J"N5(+^1>CT.'U,ZLER4M<^RR5FE"E>AOMD9F?FOL-\1RQ[_P!%=M,7
MYIC7QB_!]TM^+YH\OU?0VNQNPEQ0)I,O[!;'D(LLPGL2")VU@8I6-<0:& ^[
MR:F(#1/.-DAN3)D>VDRZFCMJ:>.<SYIUUUKR9CAI3      !TF1XUCN84=GC
M&6T--D^-W<-^ON:#(:R%<TMK DMFU(A6578H<8?:6DS2MMQ!I,CX,AY:M;1T
MVC,##KV4_'P^)CLO32HEGU-PC3F2+BV#-9G775H]+9!32K)27'K-%5AY,T<Y
M]*DD;9V]1+2GE1$DB6HCRW[+M[1B*]/L],(S6L\X1MNV'X=NV\=;DWG23M?7
MYTRNQ\F->=@Z2)C%O#JS:22EHV1B#+\:?)\D^),NTD)LTGR;G*?W9I[+93CK
MMGY*[::SRX+U^BGXDG5^DUC2WWR%V&7[>W38.3WKO"L'V/8X_J['6#D^-9$A
M3L=C0+&8^EM/FZ]]TA'*B223\3-6C3VTQ7_DGB1IKXLV/5OX./B[Z>98C/-+
M]5,.:S2.N.[79/GUA?[0M:9^*XIR/+HG,_E6"(3Z349>_%0APRX)2CX+C175
M2LYA.M*UY,L;;;;2$MM(0VV@B2AMM*4(0DOH24IX(B_X"Q-^P
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M6"2U(PRIBP+&[LZQY!_V+F\Q7"/R)1MGZ(-'*NMV>K&=D^PI2*)G0WK
M
M                       'FKW"\.RE:7,FQ/&LB<0R4="[VBJ[=:8Y+-PF
M$JL&G#)!*4I7B7IR9GQR9B,TI;]T1/N'A7^O>@Y)FJ3H_4$A1\\F_K3#'3/G
MZ\FY",1^SJ_VQ\('QC=<^O<*0F7#T3IJ)*2?DF3&UAA#$A*B]24EYJ"2B/\
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ME/-(=/S<)IRWF%XE)=::2E)(92MS72D1]4\U]8PD1"Q(
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MHVHS3+1$V541A<O('H@;_E=Z,VMD?<GJ;L>!S?8#E.EI6I,3H(D]1V5=LO\
M\C/S)'M5;G@GQLF;."@GFU*Y^W4ESP\6_/C_ ,G/3LIGQB56VO5$(M_>'J=N
M?IAL_%]3[YK:/'-CW."56;S</KIY2;3&JJV><;KH>1,>*"9E+2VIPD(4M)I/
MR)9D8RXFD]%XF)<Z^N]/)[_XI.\%3\?'?W2':/)V,HL->XDG+\6VE0X:EF3?
M7F#9QCKM/,;BUSS["):H<HHM@B.XZA"G&$'Y$9),>UW3HV5OC,>.$]-XI;JE
M-M[-_EI_'K@^MY[_ %;A[.[%[;MZ&=_M6F7@%_KW"<>R4VVT0VL_OLZ17R28
M;4XIQPJ>'--?M*;-;1+0X?6CO-=_V1+HUM%HS#7D;HW/LW?>YMA]@=NY??7F
MW-H9?/R[),LB29%6\U:6$@D1H%4N,M"V(4-OPC08[;Q-QV&VV4<>*?.6ZD7K
M7'KY^Y[CC,LS?P8=ROECV)WQZ\=?>NG8+>VR=>%G6,WV\L+S;)Y^P]>8EU]H
ML@CEL*\N5YJY);IVBANKC1ELO-.O3'(L1CW);T9E>*E=U=D=$S^7AG/AR_)9
MF);4@=9  ?Q2B21J4?"4D:C,_H1$7)F UHWSX?.3L7O9LC8_3GKKD#.,]*,!
MRN1C&4WM.Y&?M^QV28E;)-W()=NV3J6\:B644G:6%&<(I:4(G2EK-R.Q#XF_
MNIWWZ*_L_'U_H7K,0C=ME75L3Q:0A#+)(:1XI,O;21>+:#Y4?/H7!'Q_I]"(
MBO[:U*5G'CCY9<_=-NJ/)W%1+K(%C5VEM5Q;N'6V,"S>HYI.'!NF8<I,HZJQ
M6PI#B8\CP)#JFU>7CSP0CLB]XQ&/>HS*]'OI\F?:?Y#;'":W=-QC^(ZCUE45
M='K3K[IV':8/I3#XM/$.NA6$;#RE2$/V*8ZE1T3GEFMEC_MXR8\<S:.NT;[S
M_P DQCPB.4+/O=?/P\EB$=LV63]DS:;\/$TH,T)2A)>"&OJ9\$DB(N/3^A%]
M3\KKQ.;,U]F<Q&85GHJVO_\ &653%1/.1)>@HK5F:#4Q':6HY"G>#Y(U&?Z<
M_I_KQ?5FM/&%J]ZV7\F^I*?<-M!$G]W/+:WB-SV^3+UX\>/^?^@DV]MLK$<8
M].*=O^%=D-8O7W?S$FHI_P I#V!IN_?GJ\/-4";3W\"-#49_N_:MEQ9<?M+G
M^OTT]O/&8=37>+<DXX:5@     \-LC9VM].89=[%VUGV&:QP#&HQ3,AS;/\
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MB5-/5P(;*8\:)!KX*$-MH0A*4D24_0AKB(K&(X0F]$/0
M                             60_(%WJU)\>_73*-[[4L(YR&6WZ;7V)
M$Z2;//<\DQ%N4F,U;)&2E>XM)+D+3Z-M$I:C21<EG[CN*=O3JMSGA$><ITKU
M3ZFJ>["]F-B=BMT; ["[:LGK;-]FW-CD4U:'73BQ6I<A2(>/UOOJ4MJ/":\8
M[+9GR24_N,S]3XU>WW;=GWK3$YXSS_13NV5IP6T6*;J0X4>'&DV+MF;<:NK8
M2?NI4RQEJ_PU\5I/^1;AJ\>"))_3U_3GIZ=E-59B(G+';9%\1#86_CG_  M0
MNH.NX/<SLMB2'>V&UJE3^'T=VPEU>D-;VK:7HU5"@R4F;-U9I\'K"6HS=0R3
M4=OV2^X)Z[33J_Y;1QGDTZM?3&9\4JD:%P   #S>9974X)B&5YQ?K=:HL-QN
M]RNZ<82VIYNIQVK=M[);*7EMH-1,LK-)*6DN?JHB]1&UHI6;SRB,_ :EKN'V
M3L.S783L=OB[<81:;)V)=Y)71HK;S4&%5*?6W75T%$IUYU+3+#2&FTK<69))
M)&LSY,?$]QKV=WW/W*XC,Y\?''M6YB.#&G;I?E(2S&\SGVSC%=&1QY*3(L"*
M.M/A_P#%ZDGTY^ICLQ:O;:ZQLC,^KTCS0K,1S;>_XJ^OL3K%\?'5;4358U66
M51J;&;G)4,K-:9>3Y/!3?7-@KU]#><?\C+Q2?_QH2YYD.UIC&J/7Q>3SX,@P
MM>
M
M                                              /_T9_
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MZ6FFF&FV66VV666T----(2VTTTVGP;;;;1P24I(B(B(N"+T(:E[Z
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M4N*=^Q70.1Z^))<0DG7(,E*?(VE*/?ICII%?)7C$82+Q:
M             .._%BRO$I,:/()"B4@GV6W?!1'R2D^X1\&7Z&0\F(GF.0/0
M
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MM1:"/':N V\@D.E X^^D+2Z2FEDQ^Q25GQ+HBUXQRCFNT:\SF6RA&IL
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M
M
M                                            /__2G\
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M2X(MM*Q2N(:XB(C$+DQ)Z
M       #YO,M2&76'D)=9?;6RZVLN4.-.)-#B%%_0R,R,.8A]=W?Q$M ;KS3
M-=H=2NQN9]:<CS3(+K*I^N<DQ6DV#J"%8VSAS'*O#H=9_$V='#7)4ZYP<F>E
M@EFW'80TE#:<-^RK,YI/NG^BNU(M&&(5W\/[Y,8]XBOA]BNFLO%W)B2D9 ]=
M;?K[],%MPR2XG'&,6<96LT*Y]D[/CR(R]S@^2IGL]N>&/C_1"FJU<Y9/^J?X
M>&I,'SZAS/N!VCLNPF+52HL^9IW ]=2M68Q=63$A+JX5_F#U]96,FO6V2V7&
MX<:#(42N2D(+R0J[7V?3.;6^"5=6+3/@F":OU1K/2>$4>MM0X#B.M,!QJ*4.
MBP_!\?J\9QZL8\C6LHE53M,LI4M9J6XLD>2U&:E&:C,QNB,<(6J@    @+?E
MIZ<N:3N/U9[%7+"Y.!Y?H:TT]6RG4/.5U-E^&9U-R192?,R:2])9R%E3)>IJ
M2RX?T0?'!_EJ3.RMO4ALFN(BT3*)VN!!M(]@4]E7OQ%O).1[S9^J2)1))!H/
ME7KZF2S+Z?\ /E1$QPEQMVK,YA3J%-.CE26T,QI:#+A1F@W74D?_ *:5<D1H
M^I^I%QZ>IEZ<W:K]$^UFZ9SBOB[&/ M\MN*#%\,QRZRK.,JM8M#BV&XA22+[
M)LHR"S>3'J::EJ:XERI#[[JB;9;:9,UJ/Q3R9D0Z>KCRGFZ6G3>8S*4!\9GX
ML?8_L9)K=C_(;-R#K-IF-,IKB!I;'GJ>1N/:5?,@_?O1\CM&77V\2AH]QEEU
MI]EZS</[IE4>O-+,ES=71:W&W"&V=43ZD]CK#U-Z[=--756FNL^J,5U+KZI\
M72J,;A&B5;3RC-Q'+K);J4;DVTL'6VFD/3Y\AY]PD();ADE/&JM*TC%5M:Q6
M,0@-_EO9#BK'R9==X;6-QJ_(*KK) <R7*2=))9)6VN>694%;-2OT2NL]F:M*
MS,DFB01'P9%YX>YV5KMQ/DQ=YKFWU1",+F=8T=D2HJVGT.L?=-K:6E?++G'M
MF?\ IP7*3(S+@Q")RY<TF+8EX X9/*4VHDM+3Y&APU$GD^/$S2DU)\OVF9?0
M^ Z\-5]M==8B<\73R6OL2\5+_P 2C+A)*(TMJ-1())*5P9<EP?K_ $,:=7<=
M/&?3YL-K7MQAW&N-<9'OG:NN=#ZZ9.=G^V]A8EK7&X:&U2#_ )O+KZ/1UDAU
M;9+2TPV\^VM]_C]C?D9_T5#O=E=O3%8SS_+UMW\?U=5IGU-V#UUTIC'6[0NF
M^O\ A;UA)Q33&M,,UGC\NV<CO6TZLPV@8HHT^V>B(::<E/I9]Z2XVVE*G%*4
M22(^!JUTC7KBD>$.PK*)@ P.?,;\%NJ?E4D81M"IV//T-V4UI12\9QW9,+'(
MF5T&58H[+.SC8KGV-.OPW9+460M]5?*8F(7&^YD&;;Y*0E&'N^RCN)ZZSBWX
MH;*=<1QY(8?9;\<[YA.O[DBVK],8)V<Q:JK),Z9D'77/(EG.3$AGZ)D8/GR*
M*]DS5M_N*-5UTPOVFE*U&:?+F6[/N-4<:Y]<<?Z_)GMHV3RF/FM,Z_\ Q#_*
MYV1S->'8'TJV]@*VB0JVRC>E6_J'$Z2,X]]L4I4_-VHRI!-J,UN,P(\E_P 2
MY)KDT$OW33;G%*S,^S$?/"JW;[?:RVZB_$.^0K-\XIXO8?L3UZU)KYDO>N,C
MU9*RO:>9.);3Y(KZ^ANJK'(I*6?*#D*G))!*\O!SU2.AK[?=,_7$0LIV]X_=
MA+W^-OX5ND?QB,2[[2>'VN7[DNJS^)R/>VSYT;)-BSJUQY4I^HIW8[$:!3PE
MN*_R1ZF%']]*&?NE/J9;4G7336G'G+337%.3+<+4P
M           :[+Y)\>G];OEE^032LBQG8'K;N%K>MVR])QO'*C(964MJCPMN
M5-0;5H]#7$1-V%CL8[2? D?=,L-N.I;FD3M?*_/_ .9U_9[_ &TS-:[(XXB)
MSQBT1ZOJB,SSCU\ILYT1C^Q-8XE^MG$TM"G(OW*TG_<EU:C;)+G/KZJ22R_T
M/^OH/>SO3[6*^G!FG,3S3Q?PXMOMY/T/WOIF7;'*M=3]AIU_#JUNFLZW%MDX
ME E5RF$&?*&G)U=8GQXD7F2S+GUX^I_BKQ.NU/*8GXQ_1*DS,<4O@=9,
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M8LA,9AMQTJ2M*5I,E)6DE)47T-*BY(R&E4_0
M
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MX3KXMAJ-R8
M
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M6["D.8]1+;-UMZ]?CK)FTLT.*)M'_9Q5>T3[TO5JU8^JSVFJM)RE,C0M
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M$1<\?H0]B(CD.6/0
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M.?7:9%J\I?ZD<KQX,R))$9D-5=6NG*/?/%LIJUZ_V1A?(+%@
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M2ELDD72U6ZJ\?!1:,2S?BQ$
M
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M9S1:D
M
M                                                  /_U)_
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MRU(8CD:D\DAM*>3X\CV]M6:Z8SSGB[NBG1KB&5(7K@
M
M     '%FPHEE#E5]A&8F09L=Z),B26TO1Y,:0V;3S#S2R,E)4DS)1&7J03&8
MQ(L[ZZ_'=T>ZE9'>9AUQZOZBU+EV1S+:;;95C.,,?[D=.[F_R%C"BWMBI^5%
MA*=X4B!%=;C-$24--(0E*2KKJUTG-8>8B.4+SA8]
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M!.-N-N(,R-*B,C(R/@:53[@
M
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MAJ5XMM(2A/D9GP7J9F.FO=B
M
M
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MEN'7QDQ(R#\"27HA"2]$D7]"(=.(Q&(?01PX.Q'H
M
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M6;8.+3[;C\EQRVQY*VU$XXN=%5()U<".YU>TW16?M6\>1KVUOP3RQTEP
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M0M^P6VUUM-_IBL\_#V*K1QRE."Y$
M
M                               !1WL#O+ NM>F=B;QV99M5>&ZXQBSR
M2S6MUMI^>Y"C*7!I:[W?14J:_P"W%C)/T-Q:?(R22E%#9>NNDWMRA[6)M.(:
MOOY)^ZV6=\.Q>5]CL[H(F-(ETE1A.'XO 7*<KL=QB@)UJN904QUY7W#RE.3)
M2R<4E4AYWP\&B;0GY'N=UNYW_=G'APAHM7HB(8F+N6PZN3.<6:6F34OW"-M!
M>1<))"E+)7!E_<K]OZ<<^HZ6JW32/9##LIU-@E^)!U]/ ^B>R]_6N,_Q=YO[
M<%FU57<K[E$Z[PO7L1-3".-'=_8B$W:2+1II:22IQU#W*?;0RM?4[3C6;O==
M.F)2NQK6     "Q#Y(N[.(]!>INR=^Y!(A.Y%7UKM'K3'9+S"7\IV%;,J9Q^
MN9CNJ)2VFE\RIBD)5X,-K4:3]".CN-T:-<V\?#VO8C+5$[=V]D>S\USO8F73
M%RLRV/F%OEEY8/+<-]^5>+.=8I5Y&K@DOK62$D9DE/!$?!$.#3MYV6ZY\?3R
M5;=DQ&%N=E8&;!G!2Z[)<43,!OP(_N)1H-*VD)(S-2C/@R(B%]]<5B,LE8S:
M(EM(_P ?3HK7=,/CYUE8Y!B[%3NG>]<SM39]K,@''R%QK(#5,Q.AGNR6TOH:
MB5ZV5)C\^!+<6OCR4HSZG:Z^C7U3SENCDSG#4]
M
M
M                        !__6G\
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M56)9JQ<D
M
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M(X;5C09AA&05648U=07R\FI=9=TKKT=]M1?13;AD.A6U;1FLY@>T'H
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MO(3B%^<28@TR:Z>T@S-B;"D)=A3XCG#D>2TZRXE+C:DEU*6B]8M"B8PK2)
M
M
M (C/Y1_8R&SBNB>J=!F-@S:9$[D.R=BXC5S(QPK"GA.PX&"MY"PT_P"ZE29*
M9\EA#C''!)6DS)7IROY/;BD:XGCS:.WKF9E!]V'?+D38E<:EM-HBF4Q"?WI;
MEH4E!.%Z_57//_M_Y\#5KO-IM.,)[)B9QY+]_AJZ"87\D/=W'=*YZ_*C:GPB
M@D[,V:S"DNPYF1U-!*9*/C4>1'2HT?>27&4/JY09->?@M*O$RZW;5C9LC5/K
M9L3$-IYKG76%:DP7%=:ZYQRLQ+!\*I*_'L9QVGC-Q*^JJ:R.F+$BL,M$1?M0
MDN3^IGZGZCNUK%8Z:\D7M1Z     #7K_ )'O>*C[)]JX&A,0R)5YJWKA%FTS
MI5$PWJ.UVG8NDC+YJO:><CR%0FT-P&I#?!EXN)\?0U*^?[_?&SN*TKRK/QY)
M<J\?%%9R\WY5@\;!I+VE>XRA)E^TR2E*VS,^/0R1YF9_J:O].>EVVN)UQ,^G
M!BV4M:<Q*0;^.9\6=AW,[2P>R6V\0=L.L.@;!=G#:MXIJH]@;-;(E5=*AM7"
M7XL,TE(E<.$?)MI)"T&[X3C779>,QPA[JU6B<V;+N/'CQ([$2(PS&BQF6H\:
M-':0S'CQV4$VRPPRV1)0A"2)*4I(B(B(B+@:VI]@
M
M
M                           ?_]>?P
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M+40X]?55,&+6UL"(TAB+#@PF$QHL6.RT1)0A"$I2E*2(B(N"'O)TW8
M
M
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M0-EU,%*_:K[& <5*)4Q!^+\(E,NI<<*/[6CMKS&R(IX\_3U(Q;J;18=4
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M:"L(T=+2/>L'UJZVB_3;$^*B\>+9"#:K
M
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M\HM7D22):5+DNJ1X&DO!*$H+DD\GHI7IK$-<1B%\8D]
M
M
M                               ?_]"?P
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MIZ3(4MUQ7*EJ4HS,:XB*QB%\5BO)6,>O0
M
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M+=934E/60TH9CQ8L=IMB.PTA*&T)2E)$1$0[,1$1B%$SGC+OAZ
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MSW#H(@
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MV=PMQV'D6>-1%I(VVV$$AF!(2XKW%*>Y01$A2M^K%OJCDTZ*YGK3R1>U
M
M
M                                             #__T9_
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M$1<$0U+G[
M
M                                        !!J_+4[KW-KG?7WXZ<'S
M";78O+JF][=CZRGF1BBWAN6QPM/X/D2ZZ0<KQ8.%8WDNKEL(:<)ZIEI4M2&E
M-\3^5WS%JZ8GASG\DZ<.*&OC.$9KLW9F%Z>U?C$G+-E[*S2CP36^(U2669^1
M93DMHW55L0I#RV6VXY./^X_(>6TTA/)O+0VI2BYNO-K16O'*R6UO^(SXPM8_
M%QU;J-3XTS!N]NYN=;F7879K9*?F9UL=< FWXD&=);:>31T_N/0J.&:$);:-
MQ]392I4IQSZ7MM$:*8\9YJ9G,LIPT/             !2C>>N8FVM0[$U_(I
ML4O)>1XC>PJ"+FV+8QFF-Q,K.M<5BMQ88SF<.PJY90K H\I#<V$\UY-EYMK3
MRDZ]VN-NJU)B)S'#,1,9\.$YA['-JP_DNQ7?&T-J;?N.VV&KPWMO@<[[39L>
M/AN+837YNZGS8C;"A0<,@P*Z0BP)MITK*'&]J:M2WG7"E.F3WPUNX[G1WLSO
MX6F>/#&?7B,1Q\9\5]*]7[6,7KIV+[)?'7V UUV8ZYY3+PG.J+E4)UU4B3C.
M>XQ*E-.7>N]ATS#K16-+:>VC[B,M:7&S;:D,.1Y;3#S?TNC=%JQLCQ3MJ\FW
M+^,3O[KKY*NG&JNT&"*KZVWR&J:I-K8-#GMSY&M-MTD9MG-\)F*(_=)MF0HI
M-<Z^AMR1 >BRC;2E])#JTO%ZYAFO6:3B60(31
M                          '\4HDI-2CX2DC49G]"(BY,P&O<^7C\DV1V
MXUSOKIWU=U=(PW3-K96FO,XWODN25]G=;.Q>#;'"M*_",9KF%18%;:'&6W]W
M(GR'WHCR%>S$-?KR>Y[BV[7.NL8B?'S617'%_/Q/^@,[9/8*X[]9%:*3B6AJ
MZ\P7!H,%Q+96VQ<QHU5=@])41<_;P*>3))3!<DIR0RL_#P(EY_X_M^K=]V>5
M/QDO/!L)1WE8
M               "'1^61O3(*_%NL76NILG&J;,?]\;8RFI9=<0FP>Q*;74>
M+O34$OQ4EDY-D;/+?)*-7"O7@N'_ "^R<TU1RY_E'YO+1F,H/.PIZYMBS%B%
M_P!NAEAOV3,DI97&92RXWRGGGD_W?\C_ .?+U\X:NVKTU21_Q..G51O'MOM#
MMMER5R*KJM60J+ 82VWD-.[$V!$E0E6Q/$7MK.NK69:%,F9GYRVW/VFV@SZO
M8ZHV;ON3_9^,LN<VF6Q6';>@   /D^^Q%8>DR7FH\:.TX_(D/N(988890;CK
MSSKADE*$I(U*4HR(B+DP&NQ^?GY0XW=#<"M,Z>RQ^;ULT^_.JXSU?)6S2['V
M'$FJ8M\Q<=8<6F;"C>*8M6A;:4'X./EY)=0L^7??&_9,5_;'+Y\6???IQ'FB
MY74A3$@B6DU^YY&KV^5K;?01FE1FOQ(TFDC5R9EP9J+CZ&?C/.)AFG^%;X:L
MU^4W9B\XV(5[B74S6&1P4YSES;#D1_8MQ%64QW7^)2UF7D9H)LYTIHS)E#B.
M/W++BS5J^Y/J>TT]<^IM"=?8#B&K,(Q77& 4-?B^%831U^.8QCU3';B5U/35
M;!1H4&'&9)*$(0DB(DI(B_H0Z$1%8Q#=$1$8A[ >O0
M
M
M                              !__]*?P
M                                           *$;5ZN];=YH6C<FA=
M0[/4XM+BW\XUYBN1S%*3]#.=9Q7'O]>/<XYX/ZD0KMJUV_=6)>36)YQE87L+
MX*/B6V==5U[E'2+4+<JND%(.-C<6ZQ"KL#)2%$S:56+S(D=YK]O!MJ;\5$H_
M(C].(?XVG.8C'OEYTU\H7_Z,ZVZ!ZR8L[A/7O3VO=-XI(D)F2Z/7N+U>-0IT
MU$=$4IU@FN;0J0_[;:$&\\I2S))$:CX(64UTIPI&'L1$<HPK8)O0
M
M
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ME8M7E+),36<2K<)/
M    $8/\B+YIJCI!JO(.GF@)L^R[B;RP29#DW]0XZS#Z]:SRE*J2=L";/B.M
M2/\ <4UA4MO&(L0^8[K:K&4XTAB(Q88>Z[F*?\-?W3S]7]4JQGBUTNM-.[!W
M5F>$:.TQA=QG^RLWM:['<5QJ@;5)F6MQ/<2AQV4^LTMI98(EO/OOJ2VPTA:W
M5H0D513JKB(6-L7\._QX1?C0Z28%H"PM8^0[)M)<O8>XLAA>7\?8;'R6*PFU
MA57/B2H=<RPQ7QG?;;-U#).J0E2S26SM],:*8\9XRJF<RREB]X
M                                                      UOGS^[
MYMMQ_)[MS%YCCLK&M(4=7J'&H3LG[EJL5%Q>!DF3.1^?1HI%C,?<4VGZ']>5
M&:C^1_D=\V[Z\6SB,1'JQ''XR]F8B(A',V,ZS6NW$TD^U[#RUQC\B+QE/_X_
M!)?KRDS,_P"G \U1G$^2Z-D:J\6R#_%^ZK+Z[_&9BF>6K$N-E/9G*+7;]RQ+
M;2DD5IN+H<6=BK)*34T_"81)3Y<\&X?!^OBGZ'L-?3IZI_N9JQQFWFD9C<D
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M)Y-R5,>\Y$EY9FI;BC4I2C,S/I4K%*],-D1$1B%=A)Z
M
M
M                                 #__TY_
M
M
M
M                       (IOY?&]K/77QK8'IBH^V(^S'9/7N(9(J2T2S+
M"]=Q9>UYI0U^1>+YV]51I]2,E,F\CDE*3SC[VW_'%?/\OZX2KS0Q_AT^/B^^
M53NGB.@7I=G0Z!P.H1L?L3F%.TXW90-<4DUMB%B=+/<)*&;3)9JVJR(ZKE49
MA4F63;WV1LN<[3VE=MHCP_+X)S.(;;K7V 87JG!L1UIKG&:?#,"P/':C$L.Q
M3'X3-=2X]CE#!16U%1608Y$AIEAAM#;:4EZ$0[=:Q2L5KPB%3V D
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MFPMI!1,CMG3([5LE.JCL-,L^ZAQR4RGK::=,=4^*%ISP2K!>@
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MA8=BL59^2:N"XXOP<>3[K[AJ>43:5I9:WZ=7VXX\Y;8C$,S0N>@
M
M
M                                          /_U)_
M
M
M
M                               (_7Y%7Q;[N^47J%@6'=<KK$XFX-'[
M15M7'\8S.<JFJL_KEXI-Q^VQ2%?*:>9AV#AOL/07):41UK;-IY^.APWD9.ZT
MVVQ$UC.,\.7/R]?MX)5G"C7XRWQ/[P^-+K[OS(^T^*5V'=A^P>R:5=ICM=E-
M'EB:/66MJM^'A4.9/QAZ36HDOV-K?3%)A2G4_;.1$N*2ZVIM$NVUS2LS:,26
MG*34-*(                   "$K\KO63JU\<G>>#V'V'HFIVQU,[NQ\UDY
MSJ2SRG)<%HH/8VN95/?9@9SC$>9/IX5JN6U>(C0X[AF^S,;0V4?Q0CYW^1KK
M[/=&^]>K7;.8S,<?;'Q;-=YOKZ8X3",)\DOQM[:Z]0L5[64'7G/=<]8]VMR<
MOQZBR.7!R&XPBODV[L.*S.N*>/"*0PMDF'6+ ZZ(U(8=CS$QFH\R(;O.T]U.
MN8MMUWUUV1FDVQQB)GQS[,<(S$Q/*89M^9G,3Z<'6?#-\J6:_$YVRI\_)RYR
M+J_MZ13XMV&U_!G+7'L,<<E\0=DT<+R6RY?8VIZ1,C<\'(8=D0%.,_>$^WW>
MVM>/^6)X<ICQ](4UMX2VY&O=@87M?!</V9KG)*G,<"S[&Z;+\.RJAF-3Z;(<
M;R" BSI[>MF,&:7&7V'$.(41_0_ZCJ5M%ZQ:O&)3>P$@
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M:6I&CM-/5]=N2%IQPAL%!TD
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M+%=FVDAA9Q"6VRVTRVIY*3>]XU%ITZ)K/7?FT5I%>*4\-28
M
M
M                                        _]6?P
M
M
M
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M2-;TEO >Y+S8EQ5&27&U$II]E?BXTXE3;B4K2I)=*EZ[*Q:DYB5JHPD
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MW.#<D2I#BWGG%*==<6XI2C[-*12L5KRA7S56$@
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M?;XSQF5\1AFJ%ST
M
M
M         '__UI_
M
M
M
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MQLXL&6T7N;Y?8,(;2],E&VA*4-H0TPRAJ.PVVPTVVGZ/5JKJKTU2F<KU18\
M
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M;(K<T_<39;QI\W7Y#BE*5Z\CL:M--->BD?JC:]KSFRX@6H@
M
M
M                                          /_UY_
M
M
M
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M=-7B\T6@
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MMEEMMEEEM#3332$MM---I\&VVVT<$E*2(B(B+@B]"&Y%]
M
M
M                                           !_]"?P
M
M
M
M
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MUTI%*],"X(2
M
M
M
M                            !__1G\
M
M
M
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MQFJA4F/T-/7LE'@UE14UR&V([#+:4H;::0E*4D1$1$-<1$1B$WI
M
M
M
M
M           ?_]*?P
M
M
M
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M?Y[C]YD='!LVS<A_[IQ%E\K6H>/Q6E<6TA1WD+2M"VTK2I):(O6W*7JYT2
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M
M
M
M
M                     ?_3G\
M
M
M
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M+,3R';CT      !\7Y#$5EV3*?9C1V4*<>??<0RRTV@N5..NN&24I(O4S,^
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M+&<?7+D)@4]0VTPA3S[CLA]9(\G75K=<-3BU*/3$1$8A)48>@
M
M
M
M
M           /_]2?P
M
M
M
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MU# Q^G9<47^62J+ 0@EO.'RIUU?*UJ,U*,U&9GHB(CA"^(B(Q"K8]>@
M
M
M
M
M                   #_]6?P
M
M
M
M                                                "WG='4GJ[V,K
MT5F^.O>F]MQF2<*(YGNN\6R.?7*=(B6]56MC&7*B.^A<.QGFUE^BB$+:M=OW
M1$B.MW<_%0ZF[GD%FG3O.\DZDY\TESWL<?F9#L;4%VXX^J0MV1CMW/.PKG#-
M7MI.OFDPA/TBF9$,NSLZSQUSAZBI]N/A-^5CIGD'VM_U\R#L+KG_ "RX6R.I
MN,WVUXK:$?N=;OJ2)!1D4-:4$E3BY5;]LGGAIY1DLBQW[?;3G&?8KM6)Y,7[
MF?:YC)EU&98_*Q^[B.OU\U&2.NTMS"MVE>VY#L:NS:8>:=;41DM!IY(^2,9^
MG,^QEO3I_:X$=O6MHMA4!<3]Y$3D^.XMWASG_P"4HN4*_P#:7'Z_4:=6[HQ#
M-:+QP\7PO<!JY)F_!MY:^2_Q&MN"1'SQ_:DG3,_]?0:I[R9C$S[/3+/%]U)X
M9X^UX?\ \=MNN-QY%LVS[B^"6AKB1SR7U;Y27_O%-^YY9GT^+5KV;)B,_F_,
M[7$VLGMM+DIM(I^)J6X1-MI;(OJI2C].>?7C^@S7[F,XKZ?-/KZ?!QFL0JFI
MKGN28B?,U$VTF2VELC^A$E7U/^I\%Z<",=Q,^G]3[L>4?!Q#K/L7SBRI+$1@
MUGX/+M"=1X\^GBADEJ+GT/\ L_\ 8+9WS:.#V+=?*.7J>LIX6-^#CRK66Z3:
M%<NM/-O,&I)&I24)+P6?IR9_M/T(_I^M<]Q,<_3YO>FWDZ";G&/5$PHB77)Y
M.F:F%J<2<91)/A1>)&HU'Z*^A?5)EZGP1^T[B+Y]/S0M%O8["L+-MOWU3@&G
M,&SC869W$A;=?AVNL4N\YR2S6RR<AV/58WBS$J:\LFDJ=63;!^*2,U&DRX"U
MIO.(>Q%IC'-FH^/S\;SY$^\4_P#G=HX[==(]05DEQJ7F.\\*NX&R[]QQMQ/M
M8;I^6Y#GN$TI+9O/V[M<R:'"4PZ\M#C96Z^VV;/5'G*[7JF9S9+!ZY_B;?%S
MJC&H+&[*S:O:3.#:B/7.3YWL/)<(HW;)N.2)AT>'ZTE5B(T1;G*VV9DN8Z@O
MVF^OU,]E>SUQ'U9GY+_MT\F9WK-\;O17ITZQ.ZV]7M2:NO6("ZPLNJ<:8L,W
M>@.+\W(LG-;PY5JZA1D1K)<L_+@C5R9$+Z:=6OC6$XB(Y+W!:]
M
M
M
M
M                   '_]:?P
M
M
M
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M)
M
M
M
M                                  #_UY_
M
M
M
M
M
M
M
M
M                                                       /_]"?
MP
M
M
M
M
M
M
M
M
M                #__1G\
M
M
M
M
M
M
M
M
M                                      __TI_
M
M
M
M
M
M
M
M
M                                                           /
M_].?P
M
M
M
M
M
M
M
M
M                    #__4G\
M
M
M
M
M
M
M
M
M                                          __U9_
M
M
M
M
M
M
M
M
M
M   /_]:?P
M
M
M
M
M
M
M
M
M                        #__7G\
M
M
M
M
M
M
M
M
M                                              __T)_
M
M
M
M
M
M
M
M
M
M       /_]&?P
M
M
M
M
M
M
M
M
M                            #__2G\
M
M
M
M
M
M
M
M
M                                                  __TY_
M
M
M
M
M
M
M
M
M
M           /_]2?P
M
M
M
M
M
M
M
M
M                                #__5G\
M
M
M
M
M
M
M
M
M                                                      __UI_
M
M
M
M
M
M
M
M
M
M               /_]>?P
M
M
M
M
M
M
M
M
M                                    #__0G\
M
M
M
M
M
M
M
M
M                                                          __
MT9_
M
M
M
M
M
M
M
M
M                   /_]*?P
M
M
M
M
M
M
M
M
M                                        #__3G\
M
M
M
M
M
M
M
M
M
M  __U)_
M
M
M
M
M
M
M
M
M                       /_]6?P
M
M
M
M
M
M
M
M
M                                            #__6G\
M
M
M
M
M
M
M
M
M
M      __UY_
M
M
M
M
M
M
M
M
M                           /_]"?P
M
M
M
M
M
M
M
M
M                                                #__1G\
M
M
M
M
M
M
M
M
M
M          __TI_
M
M
M
M
M
M
M
M
:                               /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>gmab_20250508xex99d1014.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 gmab_20250508xex99d1014.jpg
M_]C_X  02D9)1@ ! @$!] 'T  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" &F 3X# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M: -".#^*IAP,4P2J1\M-<L.: )-PSBEIJ#C-.H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IK-D[13JB9L-DT 0WBE.GZ
M5D>*_#</B71VL)57#>HK=8I+U%0-]\KVH ^3OC1\$SX8U)+NQA+;9E?Y/KFN
M[^#_ ,7;N&UA\*W+,BIC[W^?:O6_%WA'3]=MI&N;8.=AP?PKYY\8>'+_ ,'Z
M_+JD),<8Z<4 ?2VDWL3Q@P2!LCL:MI,=^>]>3? OXFVFJV>RZEW';@?-7JEE
MFXQ<K]P]* +>/,&X]:$))VFD>958 5)QL#>M #)"?N8ZUQ_Q2\&P^(=.\J0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%%% !1110 4444 %%%% !1110 4V12PP*=2,<#-  @*C!IJ=:<#D9I$!!Y%
M#;G:(B2!7E7QKN8/+ 90>G6O5;E=T1%>1?'F)XHL@=A0!RWB'1;/Q#X&DT^.
MW4LW<?2ODCXM?#S5O .J>?;.\(:X#<#U:OKOP/>K>3)82M@'WKC?VOO >G?8
MQ<18)$2-T]@: ,C]FSQ[+#%;VMS<EF&,Y-?6'AK7(]0MU(;.4_I7YA^ /BY=
M^'?B.-%68JBX_B]Z^[_@3X^@UJTB\RY&3&._M0![%#&QDW]JM55MIXWM1(C
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M>TOX+U \3YXH T5.X9%+5:"24-\PXJP77L: %HJ/<V:<)5'#'F@!U%&>,T4
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M ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7T[I>LKJ%J)D8$'TH ON0>E(GWA3$??VIZ?>% #Z*** "BBB@ HHHH ****
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H ^RP[<58!V]*** %WMZT+&I^8CFBB@"1%'ITI^ .@HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
